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ABSTRACT 
In 1970s, the introduction of presymptomatic central nervous system (CNS) therapy 
changed the prognosis of pediatic Acute Lymphoblastic Leukemia (ALL). Before that 
more than half of complete remissions obtained with systemic chemotherapy 
experienced CNS relapse. The contemporary use of risk-directed treatment has 
improved 5-year event-free survival to rates about 80% for childhood ALL. However, 
still CNS relapse remains an important cause of mortality occurring in about 3-8% of 
ALL patients. Recent clinical trials focus in reducing CNS relapse with the use of 
individualized therapy that can avoid both over- and under-treatment. Moreover, several 
studies aim to minimize secondary negative effects related to use of cranial irradiation, 
a treatment still recommended for ALL children at high risk of CNS relapse (i.e: 
patients with CNS leukemia at diagnosis or T-immuniphenotype with high White Blood 
Cell (WBC) count).   
This project aims to deep insight into the mechanisms used by blast cells to infiltrate the 
CNS. We focused on T-ALL as in this leukemia the phenomenon of CNS disease is 
more recurrent than in B-ALL. To identify conserved molecular mechanisms that could 
be at the basis of CNS infiltration we started the analysis on animal models to move 
subsequently to human patients. To goal in this aim we used a gene expression profiling 
(GEP) approach. 
Chapter 1 reports a study performed on two zebrafish models both developing T-ALL 
but that are genetically different; hMYC-ER line overexpresses human C-MYC, while 
hlk model carries an unknown mutation. We demonstrate for the first time that both 
these zebrafish model can mimic the phenomenon of CNS disease in T-ALL. Moreover, 
we found a different predisposition for hMYC-ER and hlk cancers to infiltrate the CNS. 
A whole transcriptome analysis of hMYC-ER and hlk T-ALL helped us to identify 
different molecular mechanisms that could control motility of blast cells. Particularly, 
we identified on cxcr4/cxcl12 axis, an important mechanisms that could predispose T-
lymphoblasts to infiltrate the CNS environment. In fact, we found a positive correlation 
between cxcr4 expression levels and seriousness of CNS infiltration. 
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The importance of CXCR4/CXCL12 axis in determining extramedullary infiltration is 
still debated, as studies on pediatric ALL patients reveal conflicting results. In Chapter 
2, we investigated the association of CXCR4/CXCR4 expression and CNS infiltration, 
using murine models xenoengrafted with human patients T-ALL cells. Also in this 
animal model we found diverse degree of CNS infiltration on xenografted mice derived 
by different human patients. Preliminary results seem to confirm that higher levels of 
CXCR4 expression favour the migration of T-lmphoblasts towards the CNS 
environment. Further analyses of validation are ongoing on a larger cohort.  
In Chapter 3 we switch to study the phenomenon of CNS infiltration on ALL patients. 
GEP analysis was used to compare patients with (CNS+) or without (CNS-) disease. 
However, this approach on human patients failed to find a strong signature that could 
identify CNS+ and CNS- patients. This result underlines the difficulty to study this 
phenomenon directly on human patients, as a high heterogeneity is present inside both 
T- and B-ALL group. Moreover, we could not find an association between CXCR4 
expression and CNS infiltration in a T-ALL cohort and that stress the idea that blasts 
cells can use different mechanisms to infiltrate the CNS and the high expression of 
CXCR4 might be a predisposing factor that requires interaction with others mechanisms.  
T-test analysis performed on zebrafish gene expression results revealed a significant 
different gene expression profile existing inside the zebrafish group overexpressing hC-
MYC (hMYC-ER). This observation challenges us to clarify the importance and the role 
of C-MYC oncogene in T-ALL leukemogenesis. In Chapter 4 we were able to find a 
strong signature insight the group of patients with high expression of C-MYC that can 
discriminate patients with- and without- C-MYC rearrangements. In both Chapter 4 and 
5 we tested the ability of gene expression profiling approach in identifying signature 
within specific subgroup of T-ALL patients. In fact also in Chapter 5 we showed the 
presence of a gene expression profile that characterize patients carrying MLLT10 
rearrangements inside the HOXA category of pediatric T-ALL.  
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RIASSUNTO 
Fino agli anni ’70, la prognosi dei pazienti con Leucemie Linfoblastiche Acute (LAL) e 
coinvolgimentiìo del SNC era particolarmente infausta. Infatti circa il 70% dei pazienti 
presentava una ricaduta con coinvolgimento del SNC. L’introduzione di terapie mirate 
alla prevenzione/trattamento delle infiltrazioni blastiche nel Sistema Nervoso Centrale 
(SNC) all’inizio degli anni ’80 ha rivoluzionato il decorso clinico dei pazienti con 
ricaduta LAL e coinvolgimento del SNC. Attualmente, le ricadute LAL nel SNC 
rappresentano circa il 3-6% di tutte le ricadute e questo miglioramento si può ricondurre 
all’identificazione precoce dei pazienti ad alto rischio di ricaduta e l’uso di terapie 
specifiche per diverse categorie di rischio, che complessivamente, hanno permesso di 
raggiungere un tasso di guarigione che va oltre l’80%. Tuttavia, le ricadute nel SNC 
continuano ad essere un’importante causa di mortalità soprattutto in età pediatrica. 
Recentemente, numerosi trials clinici stanno cercando di ridurre il tasso di incidenza 
delle ricadute LAL che coinvolgono il SNC, attraverso l’uso di terapie individuali che 
permettano di evitare il sovra- o il sotto-dosaggio di chemioterapico per il paziente. 
Inoltre, molti studi stanno cercando di minimizzare gli effetti negativi dovuti all'uso di 
radioterapia, un trattamento ancora raccomandato nella cura delle LAL pediatriche ad 
alto rischio di ricaduta nel SNC (i.e. pazienti con infiltrazione del SNC già alla diagnosi 
o on  LAL di tipo T associata ad un'alta conta di globuli bianchi). 
In questa tesi, abbiamo impiegato lo studio del profilo di espressione genica al fine di 
individuare i possibili meccanismi molecolari che consentano alle cellule leucemiche di 
infiltrare il SNC, utilizzando 2 differenti modelli animali: zebrafish e topi NSG.  I 
processi biologici identificati sono stati quindi validati in una corte di pazienti pediatrici 
alla diagnosi con leucemia limfobalstica acuta. Ci siamo focalizzati in particolar modo 
sulle LAL di tipo T, poichè in questo tipo di leucemie il coinvolgimento del SNC è più 
ricorrente rispetto alle LAL-B sia alla diagnosi che alla ricaduta.  
Il capitolo 1 riporta uno studio effettuato su due modelli di zebrafish geneticamente 
differenti, in grado di riprodurre la LAL-T. La linea transgenica hMYC-ER sviluppa una 
leucemia LAL-T indotta dalla sovraespressione del gene umano C-MYC, mentre il 
modello zebrafish hkl è stato ottenuto tramite mutagenesi chimica non specifica. In 
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questo studio, abbiamo dimostrato come entrambe queste linee modello riescano a 
riprodurre il fenomeno dell infiltrazione delle cellule blastiche nel SNC con diverso 
grado di invasione a seconda del tipo di modello considerato. L’analisi dell'intero 
trascrittoma delle cellule leucemiche estratte dai due modelli di zebrafish, ci ha 
permesso di identificare diversi meccanismi molecolari che possono regolare la 
migrazione e l’infiltrazione delle cellule tumorali. In particolare, l’attivazione dell’asse 
cxcr4/cxcl12 sembra conferire ai linfoblasti T una maggiore capacità di infiltrazione del 
SNC nel modello hMYC-ER, come dimostrato dalla sua maggiore invasivita nel SNC, 
rivelando una correlazione diretta tra l ‘over-espressione del cxcr4 e il grado di 
invasione.    
Nel capitolo 2, abbiamo studiato l'associazione tra espressione del CXCR4 e 
l’infiltrazione del SNC in topi xenotrapiantati con cellule LAL-T provenienti da pazienti 
pediatrici. Risultati preliminari sembrano confermare la correlazione tra alti livelli di 
espressione del CXCR4 e l’aumentata migrazione dei linfoblasti T nel SNC. 
Attualmente ulteriori analisi sono in corso, con lo scopo di validare la relazione 
“espressione CXCR4-infiltrazione del SNC” in una coorte più ampia. 
 
Nel capitolo 3, considerando i risultati precedentemente ottenuti, abbiamo analizzato il 
profilo di espressione genica di pazienti pediatrici alla diagnosi di leucemia 
limfobalstica acuta con (SNC+) o senza (SNC-)  coinvolgimento del SNC. Questo 
approccio non ha portato all’identificazione di una signature in grado di distinguere i  
due gruppi considerati e questo risultato è in parte dovuto al basso numero di pazienti 
analizzati con SNC+ e all’alta eterogenicità genetica presente all interno della corte 
studiata. La mancanza di una diretta correlazione tra l'espressione del CXCR4 e 
l’infiltrazione nel SNC nei pazienti LAL-T suggerisce che più meccanismi molecolari 
possano cooperare per regolare il movimento delle cellule leucemiche e determinarne la 
capacità di infitrare tessuti extra-midollari. L'alta espressione del CXCR4 potrebbe 
essere un fattore di predisposizione che tuttavia richiede l’interazione con altri 
mecanismi per consentire ai linfoblasti-T di entrare nel SNC. 
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Nel capitolo 4 ci siamo focalizzati sul significato biologico della diversa espressione del 
gene C-MYC in pazienti LAL-T in relazione alla varie aberrazioni genetiche che 
possono modulare l’espressione di questo oncogene. Tramite l’analisi dell’espressione 
genica abbiamo individuato una specifica signature  in grado di distinguere pazienti con 
over espressione e riarrangiamenti citogenetici del gene C-MYC.  
Abbiamo successivamente analizzato il profilo di espressione genica di pazienti  LAL-T 
con riarrangiamenti citogentici HNRNPH1-MLLT10 e DDX3X-MLLT10 per 
determinare se questo sottogruppo di pazienti presentava caratteristiche comuni ad altri 
pazienti con riarrangiamenti del gene MLLT10 all’interno della categoria HOXA.  
Attraverso questo studio abbiamo dimostrato i vantaggi legati all’analisi del profilo di 
espressione genica per l'identificazione di particolari signatures che vadano a 
distinguere dei sottogruppi all'interno di specifiche categorie di pazienti affetti da LAL-
T. Lo studio ha permesso inoltre, attraverso l’utilizzo in due diversi modelli animali, di 
identificare comuni specifici meccanismi molecolari legati all’infiltrazione delle cellule 
blastiche nel sistema nervoso centrale.  
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AIEOP   - Associazione Italiana Ematologia-Oncologia Pediatrica  
ALL   - Acute Lymphoblastic Leukemia  
T-ALL   - T-cell Acute Lymphoblastic Leukemia  
B-ALL   - B-cell Acute Lymphoblastic Leukemia  
AML   - Acute Myeloid Leukemia 
BM   - Bone Marrow 
BBB  -Blood Brain Barrier  
BRB   -Blood Retinal Barrier 
cDNA  - complementary Deoxyribonucleic Acid 
CI-FISH  - interphase fluorescence in situ hybridization 
CNS   - Central Nervous System  
CNS+  - Positive for Central Nervous System infiltration at diagnosis 
CNS-  - Negative for Central Nervous System infiltration at diagnosis 
CSF   - Cerebrospinal fluid 
Ct  - Cycle threshold 
DAVID  - Database for Annotation, Visualization and Integrated Discovery 
DEPC  - Diethylpyrocarbonate 
dpf  - days post-fertilization 
dpi  - days post-injection  
DNA   - Deoxyribonucleic Acid 
EFS  - Event Free Survival  
ENU  - ethylnitrosourea 
FAB  - French–American–British 
FACS  - fluorescence-activated cell sorting 
FCM  - Flow cytometry 
GEP  - Gene Expression Profiling 
HG  - Human Genome 
h  - human 
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hpi  - hours post-injection 
H&E  - Hematoxiyin & Eosin 
IgG  - Immunoglobulin G 
IF  - Immunoflorescent  
IHC  - Immunohistochemistry  
IVT  - In Vitro Transcription 
lfdr  - local false discovery rate 
HSC  - Hematopoietic Stem Cells 
MDS   - Myelodysplastic Syndromes 
MILE  - Microarray Innovations in LEukemia study group  
MNC  - Mononucleated Cells 
MRD  - Minimal Residue Disease 
N.D.  - No Data 
NK  - natural killer cells 
PB  - Peripheral Blood 
PCR  - Polymerase Chain Reaction 
PGR  - Prednisone Good Response 
PPR  - Prednisone Poor Response 
RIN  - Ribonucleic Acid Integrity Number 
RMA  - Robust Multi-array Average 
RNA  - Ribonucleic Acid 
QC  - Quality Control 
qPCR  - quantitative – Polymerase Chain Reaction 
qRT-PCR  - quantitative Reverse Transcriptase – Polymerase Chain Reaction 
ROIs  - Regions of interest  
RT-PCR  - Reverse Transcriptase – Polymerase Chain Reaction 
SAPE  - Streptavidin-phycoerythrin 
SE  - Standard Error 
STRING   - Search Tool for the Retrieval of Interacting Genes/Proteins 
TAE  - Tris-Acetate-EDTA 
TCR  - T-cell Receptor 
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TLP  - Traumatic Lumbar Punction 
vs.   - Versus 
WBC  - White Blood Count 
Zf  - zebrafish 
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Acute Lymphoblastic Leukemia (ALL) is a clonal aggressive malignancy of the bone 
marrow, characterized by abnormal proliferation of lymphoid progenitor cells that 
arrested at premature stage of differentiation, disrupting the normal haematopoiesis and 
infiltrating extramedullary organs. ALL constitutes the most common pediatric cancer, 
representing 80% of all leukemia that occur in children and adolescents [1,2]. This 
malignancy represents a heterogeneous group, characterized by different morphological, 
immunologic and cytogenetic features [3-5]. The malignant clones can originate both 
from the B-cell (85% ALL) and the T-cell lineage (15% ALL) [6-8] and often carry 
specific genetic alterations, such as chromosomal translocation that create specific 
fusion genes, aberrant expression of proto-oncogenes, chromosomal deletion and hypo- 
or hyper-diploidy (figure1). &
!
!
Figure 1: Estimated frequency of genetic abnormalities in ALL. Violet areas refer to T-ALL      
abnormalities; other colours indicate B ALL abnormalities (from Pui et al., 2011 [8]). 
  
The presence of established genetic alterations in blasts cells allowed the identification 
of specific subtypes of disease related to different prognosis [9-12]. For this reason, 
nowadays, genetic aberrations are also used to stratify ALL patients into different risk-
groups, ranging from standard-risk to high-risk. In the last years, multi-agent 
combination chemotherapy and the introduction of a risk-directed treatment allowed 
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ALL patients to receive more appropriate treatment and that resulted in a cure rate of 
more than 85% (5-year event free survival, EFS) in children with ALL [8,13,14]. 
Although the overall EFS have increased significantly over the past decades there are 
still groups of  ALL patients  that experience treatment resistance and relapse [8] and  
remain of major concern [15]. One of these unfavourable events, that position ALL-
patients in  the high-risk strata, is the presence of blast cells in the Central Nervous 
System (CNS) [16].  
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The Central Nervous System (CNS) was recognized as possible site of infiltration by 
leukemic cells in the early decades of childhood ALL therapy [17,18]. The presence of 
CNS infiltration (CNS+) is an event that can be present both at diagnosis (<5%) and 
relapse (!30-40%) in ALL pediatric patients and constitutes one of the main challenge 
in the cure of ALL. The ability to enter in the CNS gives an immediate advantage to 
blast cells:  the CNS acts as a shelter for lymphoblasts preventing their exposure to 
chemotherapeutic compounds and serving as a reservoir for relapse [19,20]. The 
presence of blasts cells in the CNS can be related to pathological symptoms, such as 
symptoms of CNS haemorrhage (i.e. altered mental status, headache, neurological 
deficits, seizure) or spinal cord compression (paresthesias, weakness, back pain, bladder 
dysfunction), but most frequently patients experience asymptomatic CNS infiltration 
[16]. The current methodology for the diagnosis of CNS+ ALL is the cytopathological 
examination of a cytospin smear of cerebrospinal fluid (CSF) taken trough lumbar 
puncture. Nowadays, a patient is considered to have CNS infiltration (CNS+) at 
diagnosis with high risk of relapse, when more than 5 White Blood Cells (WBCs)/µL 
are detected in its CSF. In detail, there is a risk classification for CNS disease in ALL: 
CNS 1, identifies the absence of leukemic cells detectable in the CSF; CNS 2, denotes 
the presence of blast cells in a CSF sample with <5 WBCs/µL; CNS 3, refers to CSF 
samples with leukemic cells and >5 WBCs/µL [21]. A recent study stressed the 
importance to detect Minimal Residue Disease (MRD) in the CSF of CNS+ patients 
during treatment, to better recognise cases at high risk of leukemic relapses [22]. This 
study also proposed to use more sensitive techniques than cytopathological analysis of 
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the CSF, such as flow cytometry (FCM) or PCR-based methods [23,24]. In addition, 
several works showed that applying FCM or PCR methods in CSF analysis, many ALL 
patients at diagnosis resulted to have subclinical disease (CNS 2) in the CNS [23-27], 
an information very important as the presence of small numbers of leukocytes in the 
CSF at diagnosis (CNS 2) is still a controversial risk factor [21,28,29]. These 
considerations suggest that also patients that clinically are considered to be without 
CNS infiltration (CNS-) could partially experience this complication; we can easily 
understand the importance of  introducing more sensitive techniques in the diagnosis of 
CNS disease in ALL  to get deeper insight in the clinical significance of subclinical 
CNS infiltration in patients. 
Molecular mechanisms used by ALL-cells to infiltrate the CNS are not well understood.  
Moreover, also the access way to enter in this environment is unknown and is 
hypothesized to be diverse; blast cells could enter the cerebrospinal fluid (CSF) through 
the choroid plexus, use the brain capillaries to invade the parenchyma, infiltrate the 
leptomeninges through bony lesions of the skull or enter through hemorrhages due to 
natural and iatrogenic processes (i.e: lumbar puncture)[16,30]. To understand the access 
way and the molecular mechanisms used by blasts cells to infiltrate the CNS, the study 
of CNS+ patients is not so easy. In fact, patients’ material is few and it is currently not 
possible to study cells extracted from the CSF, as the sample often contains very few 
cells or no cells at all. Moreover, studying patients does not allow to analyze how CNS 
infiltration occurs at the anatomical level.  
Two studies tried to investigate the molecular mechanisms used by ALL cells to 
infiltrate the CNS in pediatric patients; Cario and colleagues compared the 
transcriptome of children with- and without- CNS infiltration in ALL, they found the 
up-regulation of interleukin-15 (IL-15) as a factor that predicted the ability of blasts to 
infiltrate the CNS [31]. Crazzolara and colleagues focused on the expression of CXCR4 
in ALL pediatric patients, showing that higher levels of this chemokine receptor could 
be predictive of blasts ability to infiltrate extramedullary organs [32]. However, the 
results of these studies still need to be reproduced in validation studies.  
Given the difficulties to study the phenomenon of CNS infiltration in patients, the 
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research of CNS leukemia has two important sources in 1) old histological studies 
performed on brains of CNS+ patients (post mortem) and 2) studies of animal models 
that mimic CNS+ ALL.  
Studies of pathological anatomy on the brain of pediatric patients with acute leukemia 
were performed in the 1970s, when the blasts ability to infiltrate the CNS was just 
discovered and 70% of patients presented intracranial leukemia at time of death. An old 
histological study of intracranial leukemic infiltrates  in the CNS of children with acute 
leukemia revealed the presence of different degrees of CNS infiltration that together 
could indicate the way used by blast-cells to infiltrate the CNS until reaching deeper 
sites: the parenchyma. Particularly, this study described  CNS infiltration as a 
progressive arachnoid disease, identifying 1) an initial infiltration of the walls of 
superficial arachnoid veins and surrounding adventitia, with consequent disruption of 
arachnoid trabeculae and contamination of the CSF when the number of cells increased; 
2) a following involvement of the deep arachnoid tissue in grey and white matter 
regions and 3) in association with perivascular arachnoid leukemia, pia-glial-membrane 
disruption and infiltration of parenchyma (figure 2). 
 
 
Figure 2. Diagram of leptomeninges (modified by Weed, Am. J. Anat., Vol 31). 
 
 In summary the study revealed how leukemia cells do not penetrate capillaries of CNS 
parenchyma, but infiltration of the neural tissue is a consequence of arahnoid leukemia 
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progression following disruption of the pia-glial-membrane [33]. In addition, another 
pathological study revealed how, in pediatric acute leukemia, there is a close relation 
between CNS disease (meningeal level) and the eye involvement at the level of both the 
optic nerve and retina [34]. Fortunately, the level of CNS infiltration that is found 
nowadays in  most ALL patients is very different from that described in  studies of the 
1970s; never the less these “old” study are very informative, giving an overview of how 
blast cells can potentially infiltrate the CNS environment if the disease had develop 
when left untreated.  
 
Another important source to study the phenomenon of the CNS infiltration is the use of 
animal models that can mimic CNS+ ALL disease. These models can be obtained 
through both the creation of transgenic models and xenotransplantations of human cells 
(from stable cell lines or directly from ALL patients) in immuno-suppressed animal 
recipients. In the previous decades, several murine models of ALL developing CNS 
infiltration have been created both for the B- and T- lineages; however, multiple 
incongruent results have been obtained from these studies. Buonamici and colleagues 
created a murine model xenografted with human T-ALL cell lines and found in the 
CCR7 expression a key signal for migration of T-lymphoblasts towards the CNS [35]. 
Holland and colleagues studied the presence of CNS infiltration in a mouse model, 
engrafted with human pre-B pediatric ALL cells, identifying an important role played 
by RAC2, AEP and ICAM1 in the process of CNS invasion [36]. Of note, in the latter 
murine model the CNS infiltration involved also the eye level, underlining the ability of 
this model to mimic infiltration found in patients [33]. Moreover, in another study 
performed in a pre-B ALL murine model, the down-regulation of CXCR4 was found in 
CNS-homing cells [37]. Summarizing, different results have been found in studies 
performed both on CNS+ ALL human patients and animal models and the mechanism/s 
used by ALL cell to infiltrate the CNS is/are still unknown.  
In the absence of a clear understanding of the phatogenesis of CNS disease, the design 
of target therapies remains beyond reach. ALL-patients that present CNS infiltration are 
stratified in a high-risk group and usually receive an intensive treatment consisting in a 
combination of intrathecal chemotherapy followed by cranial irradiation. The main 
! ! $'!
benefit of intrathecal therapy is the avoidance of the blood brain barrier. Nowadays, one 
of the main challenge in the cure of ALL is the reduction of treatment-related late 
negative effects that involve about two third of long-term survivors [38]. This challenge 
mainly concerns ALL pediatric patients that present CNS infiltration, as a lot of 
secondary negative complications are associated to cranial irradiation (i.e: cognitive 
deficits, endocrinopathy, second cancers) [38-42]. In the last decades, many efforts have 
attempted to avoid or reduce the use of prophylactic cranial irradiation [43,44] and two 
clinical trials [30,45] demonstrated that cranial irradiation could be completely omitted 
using intensive triple (methotrezate, hydrocortisone and cytarabine) intrathecal therapy 
[46]. The combination of these drugs is highly effective in the treatment of CNS 
infiltration in pediatric patients. However, as CNS relapse still remains an important 
cause of mortality occuring in 3-6% of ALL patients that relapse [16,47,48], cranial 
irradiation is still recommended for 2-20% of patients at very high risk of CNS relapse 
[16]. Several risk factors have been associated to an increased risk to develop CNS 
relapse in ALL pediatric patients; a) the presence of leukemic cells in the CSF both for 
natural or iatrogenic introduction after traumatic lumbar punctures [29,49,50], b) T-cell 
immunophenotype, especially if accompanied by high leukocyte counts [16,51-53] and 
c) genetic abnormalities, such as t(9;22), t(1;19) and MLL rearrangements [16,54]. 
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T-cell Acute Lymphoblastic Leukemia (T-ALLs) is an aggressive hematologic tumor 
arising from the malignant transformation of hematopoietic progenitors of the T-
lineage. T-ALL constitutes 10-15% of pediatric and 25% of adult ALL cases [55]. 
Clinically, T-ALL patients show an extended infiltration of the bone marrow by 
immature T cell lymphoblasts, often associated to high white cell counts, mediastinal 
masses with pleural effusion and increased risk of leptomeningeal infiltration at 
diagnosis [56]. T-ALL is a genetically heterogeneous disease resulting from a multistep 
oncogenic process in which several genetic alterations contribute to arrest the process of 
thymocyte differentiation at  different stages of T-cell maturation and at the same time 
promote proliferation and survival of T-lymphoblasts. Below follow the main genetic 
alterations that have been associated to the pathogenesis of T-ALL.  
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Constitutive activation of NOTCH1signaling  
The NOTCH signaling pathway plays a central role in T-ALL pathogenesis. NOTCH1, 
whose gene is localized on chromosome 9, is a transmembrane receptor involved in 
normal development of T-cell progenitors and thymocytes differentiation. Physiologic 
activation of NOTCH1 is due to the interaction with a DSL ligand that induces two 
proteolitic cleavages in the receptor. These proteolitic cleavages allow the release of the 
intracellular portion of NOTCH1 protein (ICN1) from the membrane to the cytoplasm 
[57]. Than, ICN1 translocates to the nucleus where it acts as transcription factor of 
specific target genes [58]. Aberrant NOTCH1 signaling in T-ALL was initially related 
to a rare chromosomal translocation [t(7;9)(q34;q34.3)] of NOTCH1 with T-cell 
receptor B (TCRB) described in 1% of T-ALL and resulting in a truncated form of 
constitutively active NOTCH1 [59]. The subsequent identification of NOTCH1 
activating mutations in nearly 60% of T-ALL patients [60] underlines the central role of 
NOTCH1 in oncogenic T-cell transformation. NOTCH1 mutations usually involve the 
heterodimerization domain (HD) or the C-terminal PEST domain [60]: mutations in the 
HD domain are present in !40% of T-ALLs and result in a ligand-independent 
activation of the receptor, while mutations in the PEST domain involve !15% of T-
ALLs and impair ICN1 proteasomal degradation with consequence ICN1 stabilization 
in the nucleus. In both cases, the final effect for these mutations is the constitutive 
activation of the NOTCH1 signaling pathway. Another event that contributes to 
NOTCH1 pathway activation in !15% of T-ALL patients is the presence of inactivating 
mutations in the FBXW7, a gene that encodes for a protein involved in NOTCH1 
degradation [61,62]. In the last years, several studies showed how NOTCH1 pathway 
activation in pediatric T-ALL was associated with improved early therapeutic response 
and increased sensitivity to glucocorticoids. However, different results were obtain in 
terms of clinical outcome; in fact, four studies showed an improved outcome in patient 
that present NOTCH1/FBXW7 mutations [63-66], whereas two other studies failed to 
find this association [67,68]. All together these studies show that the prognostic impact 
of NOTCH1 activation seems to be therapy-related. 
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Deletions of the CDKN2A locus 
More than 70% of T-ALL patients present deletions of the CDKN2A locus [69] 
(chromosomal band 9p21), which contains the p16INK4A and p14ARF tumor 
suppressor genes, which contributes to leukemia progress through loss of cell 
proliferation control [70,71]. The incidence of these deletions has not been investigated 
in large T-ALL cohorts and for the moment their prognostic significance remains 
unknown.   
 
Chromosome  rearrangements in T-ALL 
Among genomic alterations at diagnosis of childhood T-ALL, chromosomal 
translocations that place oncogenic transcription factors (TLX1, TLX3, TAL1, LMO1, 
LMO2, HOXA) under the control of TCR genes (TCRB or TCRA-TCRD) have an 
incidence of 40-50%. In addition, also other non-TCR gene mediated translocations 
could produce fusion products and several genes can be activated or inactivated by the 
presence of somatic copy number variations (amplifications and/or deletions) or specific 
point- or insertion/deletion mutations [72]. 
In the light of these observations, T-ALL is a heterogeneous disease that can present 
multiple genetic aberrations. However, several studied have identified some major 
subtypes that are useful to classify the T-ALL. Particularly, these subtypes are 
associated to specific chromosomal rearrangements, distinct gene expression signatures 
(TAL-like, TLX1/3-like and HOX-like) and different stage of arrest during T cell 
development [7,55,73-75].  
TAL1: Overexpression and aberrant activation of TAL1 is present in about 60% of T-
ALL cases as result of various chromosomal rearrangements [76]. In 20-30% of T-ALL, 
a small intracromosomal rearrangement placed TAL1 under the control of the promoter 
region of SIL, resulting in the SIL-TAL1 fusion product. Moreover, the translocations 
t(1;14)(p32;q11) or the variant t(1;7)(p32;q35) juxtaposes TAL1 under the control of 
TCRA/D enhancers, resulting in its ectopic expression in about 3% of TALL. Late-
cortical T-ALL thymocytes (CD4+, CD8+, CD3+) have been shown to carry the 
activation of the TAL1 transcription factor and this  has been associated to a more 
favourable outcome [70,77-79].  
LMO: Translocations involving the LMO1 [t(11;14)(p15;q11)] and LMO2 
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[t(11;14)(p13;q21)] genes occur only in 9% of pediatric T-ALL cases. However, about 
45% of T-ALL present an aberrant expression of LMO2, suggesting other still unknown 
mechanisms of activation, In most cases, the activation of LMO1 and LMO2 has been  
associated to over-expression of TAL1 [55]. 
TLX1: The aberrant expression of TLX1 is due to a translocation [t(10;14)(q24;q11)] 
that positions TLX1 under  the control of the TCRA/D enhancer [80-82], occurs in 5-
10% of pediatric T-ALL and is usually associated with good prognosis and low risk of 
relapse [55,83]. 
TLX3: The overexpression of TLX3 is present in 20-25% of pediatric ALL and result 
from the t(5;14)(q35;q32) translocation [84]. Both the expression of TLX1 and TLX3, 
have been associated with early- cortical T-ALL [55]. In some studies the aberrant 
expression of TLX3 has been associated to poor prognosis and high incidence of relapse 
[70,79]. 
HOXA: about 3% of T-ALL patients carry translocations of the HOXA cluster of HOX 
genes in TCRB and TCRG loci, with aberrant expression of the HOXA10 and HOXA9 
genes [85]. In addition, over-expression of HOXA genes also characterized T-ALL 
patients that carry other chromosomal translocation generating other chimeric 
transcription factors [86,87]. These translocations include: the PICALM-MLLT10 fusion 
oncogene [t(10;11)(p12;p14)] involving about 5-10% of  T-ALL patients which has 
been  associated with an adverse prognosis [85,88]; the MLL rearrangements (MLL-AF4 
and MLL-ELN) in 5% of  T-ALL, whose prognostic significance remains to be defined  
[89] and the rare deletion del(9)(q34.11q34.13), resulting in the SET-NUP214 fusion 
product [90]. 
 
Next to these rearrangements that characterize the main subgroups, there are also 
translocations involving proto-oncogenes, such as c-MYB and c-MYC. The 
t(6;7)(q23;q34) results in the activation of the c-MYB oncogene through a 
rearrangement with TCRB: this MYB translocation has been  identified in very young 
children (<2 years old) and has been shown to be  characterized by a peculiar gene 
expression profile [91]. Also c-MYC can be activated by translocations with the TCR 
[t(8;14)(q24;q11)] in 1% of T-ALL [92], but usually c-MYC activation is the result of 
different factors. 
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Deregulation of C-MYC expression 
MYC is an important transcription factor controlling several cell functions, such as 
energy metabolism, proliferation and survival [93] and it is also a potent oncogene, 
whose deregulation is present in about 70% of cancers [94-96]. In addition, MYC is a 
complex factor with a dual functional role: while it promotes cell growth and cell cycle 
progression, it can also promote apoptosis through the P53/ARF and BIM pathways. So 
in physiological conditions, the extra cell divisions caused by MYC overexpression is 
balanced by an increased cell-death [97,98].  
In T-ALL, C-MYC plays a critical role in determining tumor growth and maintenance 
and its deregulation at transcriptional level is frequently associated to NOTCH1m , as C-
MYC is a direct target gene of NOTCH1 [99-101]. Notably, most of the genes 
controlled by NOTCH1 that regulate cell growth, proliferation and metabolism are also 
target of MYC [99,102,103]. This NOTCH1-MYC transcriptional regulatory loop 
position the control of  anabolic cell growth  pathways as an  important mechanism in 
mediating T-Cell malignant transformation by NOTCH1. In addition to NOTCH1m, 
there are several other physiologic pathways that regulate MYC at transcriptional and 
posttranscriptional levels [236], so alternative routes can induce MYC activation 
independently from NOTCH1m. One of these alternative mechanisms are FBXW7 
mutations (FBXW7m) that can occur both in  the presence (!20%) or absence (!5%) of 
NOTCH1
m. By preventing degradation of several proteins (among them NOTCH1 and 
MYC), FBXW7m can contemporary induce NOTCH1-dependent MYC transcriptional 
activation and MYC stabilization at the protein level [61,62,104]. Moreover, C-MYC 
expression can  also be modulated  by LEF1 inactivation (!11%) [105] and C-MYC 
rearrangements with TCR or unknown partner genes, even if these genetic alterations 
are rare in T-ALL (!5%) [106]. In addition, another major cause of MYC activation in 
T-ALL is the downregulation of PTEN (consequent to PTEN deletion or mutations), an 
event that causes the release of AKT-induced inhibition of GSK-3", preventing MYC 
phosphorilation and degradation [107] (figure 3). A recent study in a murine model 
showed that activation of Wnt/"-catenin pathway can induce the development of a 
Notch1-independent T-ALL, characterized by high expression of Myc due to Myc 
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rearrangements and loss of Pten activity [108]. Interestingly, several different networks 
converge to induce the up-regulation of MYC, suggesting a critical role of this 
oncogene in T-ALL leukemogenesis [100,107,109,110].  
 
 
Figure 3. MYC transcription and postranscription modulation. Schematic representation of 
a  few regulators/effectors that modulate MYC expression. (modified from [107]). 
 
The oncogenic potential of MYC in leukemic initiation was demonstrated in many 
animals models [111-115], however, several other studies demonstrated that the 
overexpression of MYC by itself is not sufficient to cause T-ALL and additional events 
are required to initiate leukemogenesis [116-118].  
 
Alterations in signal transduction pathway 
In addition to chromosomal rearrangements previously described, genetic aberration can 
interest also genes that have important functions in controlling and regulating pathways 
related to T-cell proliferation that are frequently deregulated in T-ALL.  
Genetic alterations that involve the tumor suppressor PTEN cause the aberrant 
activation of the PI3K-AKT pathway, as PTEN is a critical negative regulator of this 
pathway [119]. Deletion of PTEN is present in 5-10% of T-ALL, but !17% of T-ALL 
lack PTEN protein expression [120].  
About 5-10% of T-ALL carry RAS-activating mutations that result in accumulation of 
Ras in its active conformation [121-123]. In addition, about 3% of T-ALL present 
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mutations or deletions of a negative regulator of the Ras pathway: the NF1 gene [124]. 
Moreover, several studies have described mutations of the oncogene IL7R in 10% of T-
ALL (gain-of-function exon 6 mutations) [125] and recently it has been demonstrated 
that mutations of this oncogene promote tumor formation through constitutive 
activation of the JAK-STAT signaling pathway [126].  
 
In conclusion, T-ALLs constitute a complex and heterogeneous group of disease, 
resulting from numerous combinations of multigenic aberrations and oncogenic 
cooperation [87] that have been extensively characterized. However, the association 
between genetic alterations and  prognostic impact is often not clear. Moreover, 
although current therapies achieve five years-relapsed-free survival rates for about 75% 
in children, still 30% of patients relapse [127,128]. The high number of relapses stresses 
the importance of gaining deeper insights into molecular mechanisms that control 
malignant transformation and drug resistance, to  eventually develop effective targeted 
therapies. However, one of the main obstacle to achieve this aim lies in T-ALL 
heterogeneity: in fact, in each patient multiple genetic alterations can occur and 
cooperate, determining the activation of particular oncogenic processes that determine a 
specific prognostic significance.  
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Microarray technology is a powerful technique that allows the simultaneous analyses of 
the expression of ten of thousands of genes in a sample of interest. In the field of 
leukemia diagnosis and research, microarray gene expression analysis consents to study 
the “whole transcriptome” of cancer cells and help the discovery of genes or gene 
networks that can be related to disease processes. This technology can have multiple 
applications, not only in basic research to investigate molecular mechanisms that 
contribute to disease development, but also to find prognostic marker that can be used in 
the clinic through  the building of a 'prognostic' classifier for patients.  
  
Microarrays technology 
In this project we used the GeneChip Human Genome U133 Plus 2.0 Array and the 
Zebrafish Genome Array (Affymetrix, Santa Clara, CA). This type of microarray 
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platforms can evaluate the expression of coding sequences of genes by assessment of 
the amount of RNA transcription (gene expression profiling, GEP). GeneChips consist 
of a small surface of silicon wafer containing immobilized short (25-30 mer) 
oligonucleotides probes synthesized in situ by photolithographic techniques. The pool 
of transcripts of a sample of interest is labeled with a fluorescent dye and hybridized to 
the microarray. The fluorescent signal bound to the probe is an indicator of the 
expression levels of the corresponding transcript. The use of short oligonucleotides 
probes minimizes the risk of cross-hybridization, consenting high levels of specificity of 
the signal [129,130]. To accurately measure the expression level of a particular 
transcript, a probe set containing 11 probe pairs, is used.  All probe sets are redundant 
and distributed all over the GeneChip.  
Several types of arrays are commercialy available  that are specific for different species 
(Human, Mouse, Zebrafish etc). For human samples, each array contains more than 
54.000 probe sets, which cover more than 47.000 transcripts and variants representing 
approximately 38.500 human genes. Currently, commercial arrays have reached whole 
transcriptome coverage. Often results of mircoarray results are validated using other 
techniqus  such as qRT-PCR.  
 
Several controls are assessed in order to validate the quality of each GeneChip:  
Scale factor: This factor is the mean value of all numbers that are applied by the 
Command Expression Console Software to each signal present on the array to adjust 
them to a target value (default = 100). The Scale Factor is used to assess the 
comparability between GeneChips. We used a maximum of 3-fold difference between 
the highest and lowest Scale Factor.  
Background and Noise: The background represents non-specific binding and auto-
fluorescence of the surface of the array. The noise factor is related to the background 
and represents the variation within the background signal. For the comparison of 
GeneChips with each other, these values should be really similar for each array. The 
mean 10x standard deviation is used. 
Present calls: This control represents the percentage of present probe sets (hybridized 
transcripts) in a GeneChip. Within an experiment we expect that the percentage of 
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present calls remain equal across different GeneChips. The percentage of present calls 
in human tissue should always be higher than 30%. 
Internal probe calls: Oligo B2 spiked controls: bioB, bioC, bioD and CRE were added 
to the hybridization. We used this control to judge the hybridization procedure, meaning 
that the probe sets targeting these Oligo B2 transcripts always should be present.  
Poly-A controls: This control represent RNA from 4 different genes derived from B. 
subtilis (LYS, PHE, THR and DAP) that are not transcribed in human beings. This 
control was used to judge if there was no bias during transcription. We expected that 
both human genes and the Poly-A control were retro transcribed in the same ratio. The 
RNA of the 4 genes had different concentration, whereby DAP represents the highest 
concentration and LYS the lowest.  
Ratio GAPDH/!-actin 3’/5’: These housekeeping genes were used to assess the extent 
to which the samples were degraded. Therefore the ratio of the probe sets for the 3’ and 
5’ site were analyzed. When the reverse transcriptase synthesis went well, a ratio of 1 
was expected since only then the reverse transcriptase enzyme fully synthesized 
complete cDNA. We used a ratio of maximal 3 as acceptable.  
 
Data analysis 
The output of a microarray experiments consist of a large amount of data corresponding 
to the  expression levels of thousands of genes. Data analysis requires sophisticated 
computational methods. Before analysis data need to be normalized to allow 
comparison between microarrays  to  control possible variation among experiments. For 
normalization, we used the robust multi-array average (RMA) approach, a method that 
uses a transformation to correct arrays for background, normalizes them using a formula 
based on a normal distribution and uses a linear model to estimate expression values on 
a log scale.  
Classification algorithms are used to discover new categories within a data set (class 
discovery: unsupervised classification) or to assign objects to a priori defined categories 
(class prediction; supervised classification). Specifically for analysis of gene expression, 
unsupervised classification (Class Discovery) is a learning algorithm that clusters 
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unspecified data based on a similar gene expression pattern; supervised analysis (Class 
Comparison, Class Prediction) is a learning algorithm that uses already defined 
(labeled) data in order to identify a set of genes that characterize the pre-specified data. 
The list of differentially expressed genes that constitute a  gene expression signature is 
accompanied by a false discovery rate (FDR) [131] or a P-value corrected for multiple 
testing to give a measure of significance for the results. Hierarchical cluster analysis is 
the most common unsupervised classification algorithm used in microarray analysis and 
allows to graphically represent results of unsupervised or supervised analysis in a tree 
diagram (dendogram) [132]. 
Supervised classification is also used to construct predictive algorithms. Predictive 
algorithms are developed on a “training” data set, where the categories to which objects 
belongs are known and evaluated on an independent “test” data set, in which objects are 
assigned to previously defined categories. To keep in mind, the gene lists obtained from 
hypothesis testing do not necessarily provide the best prediction. Different methods can 
be used to construct predictor algorithms (i.e:  a SVM_support vector machine; 
PAM_predictive analysis of microarrays; kTSP_k-top scoring pairs). 
  
Power of Gene Expression classification in leukemia  
A decade ago, gene expression profiling (GEP) was successfully introduces in 
haematological research. Golub and colleagues were the first pioneers that showed the 
power to use a class discovery method to distincguish AML and ALL as well as B- and 
T-ALL [133]. From this first work, a new word started to rise and nowadays, gene 
expression profiling is widely used in science. Yeoh et al. showed that distinct 
expression profiling could identify all leukemia subtypes that were  important at that 
time for clinical classification (T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, MLL 
rearrangements, hyperdiploid >50 chromosomes) and could be used for risk-
stratification of pediatric ALL patients  [9]. Nowadays, microarray technology is a 
powerful approach to improve diagnosis in haematological malignancies [134,135], and 
to discover new therapeutic targets [136] for the development of new therapies. Several 
studies confirmed that leukemia subtypes are characterized by specific gene expression 
patterns (class prediction) [9,133,137,138], while others were able to identify new 
categories (class discovery) [55,139,140,141].  
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In ALL, microarray technology was able to discriminate patients, according to the B-
and T-lineage, different stage of maturation or carrying specific genomic 
rearrangements. These studies showed the potential of GEP to facilitate the 
identification of specific leukemia subtypes.  
The international Microarray Innovations in Leukemia (MILE) Study Group has been 
the largest gene expression profiling study in haematology. MILE was a collaborative 
project, designed to assess the clinical accuracy of gene expression profiles for 16 acute 
and chronic leukemia subclasses, myelodysplastic syndromes (MDSs) and the control 
group (non-malignant disorders and normal bone marrow). In stage I of the MILE 
study, gene expression profiling of 2,143 patients (with leukemia and myelodysplastic 
syndromes) were generated with the aim to identify class signatures. In stage II, the 
gene expression profiling-based diagnostic accuracy was validated in an independent 
cohort of 1,191 patient samples, revealing a robust performance of this method to 
classify patients. This study demonstrated for the first time, the possibility to integrate 
the microarray technology in routine diagnostic procedures. 
The following studies were able to identified new categories (class discovery) that allow 
the prediction of patients categories related to prognosis [55,142-144]. Both in B- and 
T- lineage ALL, gene expression based classifiers have been created for the prediction 
of prognosis, revealing the clinical heterogeneity that characterized distinct genetic 
leukemia subgroups. 
Concerning  T-ALL, Ferrando and colleagues revealed that distinct gene expression 
signatures were strongly associated to aberrant expression of main oncogenic 
transcription factors and this division seemed to reflect a specific stage of T cell 
developmental arrest. However, these specific signatures clustered also patients lacking 
the activation of known oncogenes, revealing that other unknown transcription factors 
could raise similar patterns of gene expression. In addition, in this work each group 
revealed by hierarchical clustering was associated with response to treatment and 
prognostic significance [55]. A following study identified the “early T-cell precursor” 
ALL cases showing the increased genomic instability and poor outcome for this 
subgroup that maintained stem cell-like features [86]. Moreover, a new subgroup of 
patients with CASP8AP2 deletion and poor early treatment response in T-ALL was 
identified [145]. 
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Nowadays, numerous efforts are made to successfully integrate microarray technology 
with haematological diagnostic procedures. A recent study used combined interphase 
fluorescence in situ hybridization (CI-FISH), single nucleotide polymorphism (SNP), 
and gene expression profiles (GEP) in T-ALL children stratified according to minimal 
residual disease (MRD) risk categories (AIEOP-BFM ALL2000). This approach 
provided an accurate, genomic diagnosis and a complementary GEP-based 
classification of T-ALL in children, showing a successful diagnosis in over 90% of 
cases and improving patients risk stratification [146]. 
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Model organisms have been shown to be very useful for studies of human diseases and 
biological processes during development and differentiation. The high degree of 
evolutionary conservation  of  genome and basic cellular processes among both 
vertebrate and invertebrate organisms, allow using animals as models to study many 
human diseases. Of these, vertebrate models have been widely used to gain insight in 
understanding human leukemia. 
Zebrafish model 
In the last decades,  D.rerio (zebrafish) emerged as a useful model to study human 
diseases, owing to  its numerous advantageous features: zebrafish (zf) can develop 
spontaneous tumors [147-149], most oncogenes and tumor suppressors are conserved 
between zf and human [150,151] and it can be easily genetically manipulated. In 
comparison with the murine model, the high fecundity (hundreds of fertilized eggs per 
couple) and the low maintenance cost of zebrafish allow to use this model to perform 
also large-scale forward genetic screens and pharmacological tests in a high-throughput 
manner. Zebrafish embryos develop externally facilitating observations and 
manipulation at different stages during development. Moreover, zf embryos and larvae 
are transparent, a characteristic that makes them an excellent model for real-time 
monitoring of internal organ development as well as for transplantation. In addition, the 
introduction of a stable transparent transgenic line allows real-time monitoring also in 
adult organisms [152]. Multiple approaches can be used in zebrafish to induce 
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leukemia, such as the creation of transgenic models, (xeno)transplantations, chemical or 
insertional mutagenesis.  
One of the main strategies to induce cancer in zf is through the creation of transgenic 
animals that express activated oncogenes (usually mammalian oncogenes) in a tissue-
specific manner,  thus mimicking the human disease. The first transgenic model 
developed in zebrafish was a T-cell leukemia: the rag2 promoter was used to drive 
mouse Myc overexpression in zf lymphoid cells [111]. To visualize cells carrying the 
oncogene, a chimeric EGFP-mMyc trangene was created. Wild-type fish embryos were 
microinjected with the vector with the transgene and 50% of F0 fish developed T-cell 
leukemia. Tumor cells initially grow in the thymus and than disseminate to other 
organs. Moreover these tumor cells could engraft irradiated wild-type adult zebrafish. 
Following studies aimed to improved this model which resulted in the establishment of 
a stable mMyc transgenic line [153] and a conditional line under heat shock control 
[154]. Numerous transgenic models have been developed using the same approach: a 
transgenic line over-expressing bcl2 fused to EGFP under the rag2 promoter was 
developed to block apoptosis in T-ALL cells [155]; a pre-B ALL model was generated 
by induced over-expression of the TEL-AML1 fusion gene [156] and another T-ALL 
model was established by over-expression of human NOTCH1 under the rag2 promoter 
[157]. Recently, another T-ALL transgenic model was created by over-expression of 
human MYC under the rag2 promoter [112] and also two lines for the study of Acute 
Myeloid Leukemia (AML) have been established [158,159].  Moreover, several 
transgenic zf models have been created for the study of  solid tumors, such as melanoma 
[160] and rhabdomyosarcoma [161].  
Transplantation of tumor cells from a donor- to recipient-animal provides information 
about the malignancy of the tumor and this assay has been used to test the ability of zf 
leukemic cells to propagate in a host [111]. This approach is very useful to study 
migration, homing, survival, and proliferation of tumor cells post-transplantation. In this 
context, xenotransplantation provides the opportunity to study human tumor cells in 
vivo. Zebrafish was largely used for transplantation and xenotransplantation of different 
human cells. As already underlined, the transparency of both embryos/larval fishes and 
the stable casper line are a great advantage, because they allow real-time observation of 
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injected cells. Of note, in transplants to zebrafish embryos immunosupression has not 
been used, as immature T- and B- cells are not present until 3-4 day post fertilization 
[162]. In addition, the zebrafish immune system starts to be functional at 28 days [163]. 
Instead, irradiation is often used to suppress the immune system of adult fish to prevent 
rejection of transplanted cells. Several studies have already demonstrated how almost 
all zebrafish models of leukemia created until now present leukemic cells that can 
engraft and perpetuate the tumor in zf recipients [111,156,157,164]. Concerning 
xenografting, the ability of mammalian cancer cells to successfully engraft in the 
zebrafish was established for solid tumors [165,166]. Moreover in  a recent paper it has 
been shown that Jurkat cells could be successfully transplanted in the yolk/blood 
circulation of zebrafish embryos [167], showing that zebrafish embryos can be 
successfully used to perform xenotransplantion of hALL cell lines.  
Tumor initiation and progression usually require genetic mutations and/or chromosomal 
translocations, resulting in the activation of oncogenes or inactivation of tumor 
suppressors. Genomic instability is considered a risk factor for tumor initiation and 
increasing cancer susceptibility. Forward genetic screens performed in zebrafish are 
useful to study the phenomenon of genomic instability and cancer susceptibility. This 
type of study uses chemical or insertional mutagenesis of zebrafish. Chemical 
mutagenesis is used to mutagenize the genome; wild-type male zebrafish are treated 
with a chemical mutagen (ethylnitrosourea, ENU) that causes genomic mutations in the 
premeiotic germ cells. ENU-treated males are then coupled to wild-type females to 
produce a F1 offspring carrying the genomic mutations. At this point eggs can be 
collected by squeezing of a F1 female and fertilization with UV-inactivated sperm to 
produce haploid F2 embryos in which ENU induced mutations can be found (figure 4). 
ENU usually causes point mutations that could result in altered protein sequence, 
truncated proteins, impaired splicing of mRNA precursors or mRNA degradation.  
Instead, insertional mutagenesis requires the use of a retrovirus as insertional mutagen. 
The efficiency of the latter method is lower compared to chemical mutagenesis, 
however, the  important advantage the rapid detection of the gene effected by the 
insertion using the retroviral sequence as a “tag”.  
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These screening approaches aim to discover new mechanisms that can be involved in 
cancer biology. Using these approaches, two studies identified new interesting genes 
implicate in cancer development; in fact, the presence of heterozygosis mutations in b-
myb, a transcriptional regulator [168] and separase, a mitotic regulator [169] have been 
shown to be related to increased cancer susceptibility in adult fish. Moreover, with the 
use of chemical mutagenesis, a study identified multiple lines with heritable 
predisposition to T cell malignancy, recapitulating human T cell neoplasia and showing 
heritable transmission [164]. 
Another advantage of the zebrafish model is the possibility to perform high-throughput 
chemical screening. In these screens, thousands of embryos are arrayed in multi-well-
plates and are treated with chemicals during certain stage of development. Embryos are 
allowed to grow and scored for desired phenotype. At the same time also the toxicity of 
the compound is monitored.  Of note, this approach allows also small drug discoveries 
without knowing the specific molecular targets [170-172]. 
 
Murine model 
The mouse has been shown to have numerous advantages as organismal model to study 
human diseases; in fact, it shares physiological, anatomical and genomic similarities 
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with humans and it is relatively easy to genetically manipulate. Targeting specific genes 
by homologous recombination in mouse embryonic stem (ES) cells allows the creation 
of  transgenic murine models theoretically capable of mimicking the human disease 
driven by the introduced gene. Moreover, transgenic technology allows the creation of 
models that over-expresses oncogenes in a tissue-specific manner and/or with a 
temporal control. Despite these numerous advantages, the prohibitive  maintenance cost 
of mouse colonies forms a limitation for experiments such as large-scale genetic 
screens.  
The main techniques used to induce leukemia in the murine model are: 1) the creation 
of a transgenic line; 2) the use of retroviral transduction/transplantation; 3) 
transplantations. Nowadays, mostly transgenic mouse models are generated using a 
“knock-in” approach [173], in which a chromosomal translocation is generated de novo 
in a conditional manner. An example is the use of  the Cre-lox system to produce tissue-
specific and/or inducible transgene expression. The Cre recombinase recognizes and 
catalyzes DNA recombination between recognition sequences referred to as loxP sites 
[174,175]. Any DNA sequence flanked by loxP sites will be excised by recombination 
if Cre is present in the cell. This approach requires independent lines of transgenic 
animals: the first transgene must contain the gene of interest flanked by loxP sites, 
while the second transgene contains the coding sequences for the Cre recombinase 
protein placed under the control of tissue-specific regulatory elements. Crossing of 
transgenic animals will result in an animal model  each offspring harbouring the 
transgene and activation of the gene of interest only in those cells that express the Cre 
recombinase (tissue-specific). 
An alternative approach to created murine model of leukemia is the use of bone marrow 
(BM) transduction/transplantation (BMT). In this case, BM progenitors are isolated, 
transduced ex vivo with a retrovirus carrying the oncogene of choice. After 
characterization of effects on proliferation, differentiation and self-renewal, the BM 
progenitors can be transplanted into syngeneic recipient mice to observe the 
leukemogenic potential in vivo [76].  
Transplantations and Xenotransplantation models (from human to mouse) are very 
important not only for assaying tumor cell malignancy, but also to testing in vivo 
pharmacological inhibitors. The first experiments of human hematopoietic cells 
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xenotransplantation in irradiated, athymic nude (nu/nu) mice were not successful, as the 
immune system was not completely silenced (mice still had B cells producing 
antibodies, complement and natural killer (NK) cells). The introduction of two new 
murine models changed the world of xenotransplantations; the bg/nu/xid (BNX) was a 
mouse with three recessive mutations (beige/nude/X-linged immunodeficiency) to 
generate a more immuno-deficient model, while the SCID mice carried homozygous 
scid mutations. This mutation resulted in unsuccessful DNA rearrangement that 
impaired the rearrangement of immunoglobulin and T-cell receptor genes, resulting in 
T- and B- cells deficiency. The residual immunity in SCID mouse was due to the NK 
cells, complements and myeloid cells. The SCID model was improved by the 
development of non-obese diabetic (NOD)/SCID mice [177]: this mouse had less 
residual immunity since NOD mice had defects in the complement pathway and 
macrophage function. Xenotransplants in (NOD)/SCID mice presented high levels of 
human cells engraftment [178] and this murine model was largely used for studies of 
human malignancies in vivo. Moreover, the injected primary human ALL and AML 
cells were able to engraft the host organism maintaining the characteristics of the 
original  leukemia [179,180]. Several studies used the (NOD)/SCID xenografted model 
and interesting results have been found regarding the biology of leukemia. Particularly, 
a correlation between xeno-engraftment potential and leukemia aggressiveness in 
humans has been reported [181,182] and the kinetics of human cells engraftment in the 
mouse has been shown to  reflect the human disease (migration of leukemic cells from 
the BM to the spleen, PB an other organs) [179,182].  
A further recent improvement was obtained with the introduction of the NSG murine 
model, in which a deletion in the #-common chain in NOD/SCID mice resulted in the 
elimination of the residual NK cell activity, improving the environment for human cells 
engraftment [184]. Using this new murine model, Soulier and colleagues showed how 
xenograft leukemias appear to arise from minor aggressive subclones of T-ALL patients 
at diagnosis which after transplantation often resemble human leukemias at relapse 
[185]. 
Although the use of  zebrafish or murine models is very useful to gain insight in the 
research of leukemic disease, we have to keep in mind that these animal models mimic 
a leukemia that resembles but cannot perfectly reproduce the human disease and that is 
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due to the insuperable differences between animal and human BM microenvironments. 
Thus, studies on animal models can help to identify important conserved events of 
leukemogenesis or target genes that can be useful for developing therapy, but results 
need to be contextualized in human patients. 
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CXCR4 was described for the first time in 1994 as a seven-transmembrane domain 
receptor expressed on the surface of white blood cells [186]. Further studies revealed 
that CXCR4 was highly expressed on the surface of lymphocytes, neutrophils, 
monocyte and Hematopoietic Stem Cells (HSCs). CXCR4 belongs to the G-protein 
coupled chemokine receptor superfamily and selectively binds the CXC chemokine 
Stromal Cell-Derived Factor 1 (SDF-1) also know as CXCL12 [187,188]. CXCL12 is 
produced by stromal cells in the bone marrow (BM), lymph nodes, spleen, vessels and 
brain [189]. The interaction between CXCR4 and CXCL12 has been shown to be 
essential for development, organogenesis, vascularization and normal hematopoiesis 
[190-195]. Particularly, CXCR4-deficient mice show a marked decrease in B 
lymphopoiesis, myelopoiesis, bone marrow colonization and die during the perinatal 
period [192], while CXCL12-deficient mice have defects in myelopoiesis [190]. T-
lineage lymphopoiesis is not affected in mutant embryos, indicating that thymocyte 
maturation does not depend on  the CXCL12/CXCR4 axis. The interaction between 
CXCR4 and CXCL12 is known to regulate the retention and migration of CD34+ HSCs 
within niches in the bone marrow [195-197], the egress of immature B and T 
lymphocytes from the BM into the Peripheral Blood (PB) and lymphoid tissues [198] 
and direct naïve leukocyte trafficking [199]. In fact, CXCL12 is a chemokine that 
induces the migration of monocytes, neuthophils, pro- and pre-B lymphocytes and T-
lymphocytes [200-202]. Interesting, when B-cells develop into mature cells, they 
progressively lose the ability to respond to the CXCL12, even if CXCR4 continues to 
be expressed at high levels on the surface membrane [203-204]. On the contrary, T- 
lymphocytes do not lose the responsiveness to CXCL12, and also in this case CXCR4 is 
expressed in higher percentages on the surface of immature- compared to mature T 
lymphocytes [205].  
CXCR4 transcription is mainly regulated by two transcription factors; Nuclear 
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Respiratory Factor-1 (NRF-1) positively regulates CXCR4 transcription [206,207], 
while Yin-Yang 1 (YY1) is a negative transcription factor for CXCR4 [208]. 
Interestingly, several studies have shown an increase in YY1 activity in the presence of 
decreased expression levels of  MYC, a natural suppressor of YY1 [209]. 
However, multiple external factors can influence the expression of CXCR4 on  the 
surface membrane. Cytokines, including TGF-1!, IL-2, IL-4, IL-6, IL-7, IL-10 and IL-
15, and growth factors, such as EGF, VEGF, basic FGF and stem cell factor, and 
hypoxia (via hypoxia-inducible factor 1-") all induce up-regulation of CXCR4 
[210,211]. While contact with CXCL12, phorbol esters, pertussis toxin and 
inflammatory cytokines, including TNF-" and IFN-#, cause down-regulation of surface 
CXCR4 [210-212].  
The binding of CXCL12 to CXCR4 determines the activation of the chemokine 
receptor. This activation results in phosphorylation and internalization of CXCR4 via 
clathrin-coated pits. After internalization, CXCR4 can either be ubiquitinated and 
degradated in the lysosome [213], or recycled back to the cell surface [210,214]. 
Leukocytes have been shown to have large amounts of intracellular CXCR4 in store for 
prompt responses [214]. Upon activation of CXCR4, there is an increase of intracellular 
calcium levels [216] and diverse G-protein dependent and independent signalling 
pathway are activated leading to multiple biological responses [211,215], such as 
migration, adhesion and transcriptional activation (figure 5).! ./0! 1#02344! 205647! 18!
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Figure 5. General Signal Transduction Pathways and Regulation of CXCR4 [211] 
 
Concerning leukemia, CXCR4 is expressed both in lymphoid and myeloid leukemia. At  
the molecular level, CXCR4 activation promotes leukemia progression. In fact, the 
binding of CXCL12 to the receptor promotes activation of the PI3K/AKT and MAPK 
pathways, which mediate the survival and proliferation of leukemia cells [221]. 
Moreover, the activation of NF-$B pathway is also induced as well as the production of 
matrix metalloproteinases, IL-8 and VEGF, that can help to disrupt the extracellular 
matrix [221,222]. Several studies have suggested that increased CXCR4 expression may 
be associated to poor prognosis in various types of leukemia [223,224], as leukemia 
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cells can migrate into bone marrow niches that confer resistance to chemotherapy. A 
potential therapeutic strategy to overcome this phenomenon could be the use of specific 
inhibitors for CXCR4. Inhibition of CXCR4 may allow leukemia cells to be released 
from the protective niches of the bone marrow. In acute leukemias, CXCR4 levels are 
highest in acute promyelocytic leukemia (French–American–British [FAB] subtype 
M3), myelomonocytic AML (FAB subtypes M4 and M5) and B-lineage ALL [225], 
even if B-cells lose receptor functionality during the maturation process. Several studies 
have suggested that increased levels of CXCR4 expression have a prognostic 
significance in childhood ALL [32], adult AML [226-229] and B-cell CLL [230]. In 
vitro experiments using specific CXCR4 inhibitors (T140, TC140012, T134 and 
AMD3100) on pre-B cell ALL cells resulted in inhibition of CXCL12-induced 
chemotaxis and migration into bone marrow [231]. Moreover, a study on a mouse 
model of pediatric pre-B ALL suggested that the use of CXCR4 inhibitors could 
mobilize leukemic cells into the peripheral blood, impairing metastasis [232]. 
Moreover, CXCR4 inhibition may also be useful in the treatment of high-risk ALL, 
infant MLL-rearranged [233] or ALL carrying the fusion protein BCR–ABL [234]. 
Of note, the importance and the role played by the CXCR4/CXCL12 axis in relation to 
extramedullary leukemia (testicles, CNS, spleen, liver, ovaries) is less understood. The 
first work that investigated this phenomenon indicated that the CXCR4 expression 
could be predictive of extramedullary disease [32]. However, CNS-homing cells 
presented CXCR4 down-regulation in a mouse model of CNS pre-B ALL [37]. In 
addition, another study showed that in children with ALL relapses associated to testicles 
or CNS leukemia blast cells had a significantly lower CXCR4 levels than blasts from 
children with relapsed disease isolated to the bone marrow [235], suggesting that blasts 
were not tightly retained in the bone marrow and allowed to metastasize to the testicles 
and the CNS. Further studies are necessary to clarify the importance of the 
CXCR4/CXCL12 axis in determining extramedullary infiltration by blast cells.  
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Central nervous system (CNS) leukemia at diagnosis and CNS relapse continues to pose 
a significant challenge in the research of an efficient cure for children with Acute 
Lymphoblastic Leukemia (ALL). The prognosis of patients with isolated and mixed 
CNS relapse is particularly poor and treatments used for the cure are very invasive 
(intratechal chemotherapy and cranial irradiation). As CNS irradiation causes a lot of 
secondary negative effects (second cancers, neurocognitive deficits, endocrinphathy), 
efforts are made to improve haematological control and to reduce or avoid the use of 
cranial irradiation using alternative intrathecal treatment. However, CNS irradiation is 
still necessary for patients at high risk of relapse within the CNS, especially for those 
with leukemic involvement of CNS at diagnosis.  
Because little is know about how leukemic cells can invade the CNS, our studies aims to 
deepen the knowledge of molecular mechanisms that regulate this event. We used a 
gene expression profiling approach to gain in this aim. Moreover, our efforts addressed 
potential conserved molecular mechanisms in animal models to be translated to human 
patients.  
With the help of two T-ALL zebrafish models that develop CNS leukaemia, we were 
able to perform whole transcriptome profiles of leukemic cells identifying interesting 
genes that could explain different mechanisms used by leukemic cells to infiltrate the 
CNS. Among these genes the importance of cxcr4 expression in predisposing T-ALL 
cells to infiltrate the CNS was investigated in zebrafish/murine models as well as in 
pediatric human patients.  Moreover, the strong signature found in zebrafish group 
overexpressing huC-MYC (huMYC-ER) challenged us to clarify the importance and the 
role of the C-MYC oncogene in T-ALL  using a GEP approach that we had shown to be 
successful in identifying signatures inside a specific T-ALL subgroup (i.e: T-ALL 
patients carrying MLLT10 rearrangements inside the HOXA subgroup).  
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Central nervous system (CNS) leukemia at diagnosis and relapse continue to pose 
significant challenges toward more effective treatment of Acute Lymphoblastic 
Leukemia (ALL). To determine if zebrafish could model CNS disease in T-ALL, we 
performed histological analyses of CNS involvement in two D. rerio lines [hlk (n=10) 
and hMYC-ER (n=10)] with GFP+ T-ALL. Histological analyses of fish at the most 
advanced stage of disease showed both hlk and hMYC-ER lines had lymphoblastic 
infiltration of the CNS, in the meninges, in the optic nerve and retina, and in some 
animals, the brain parenchyma as well. Moreover, the degree of CNS infiltration was 
higher in hMYC-ER compared to hlk groups (p-value:0,04). FACS-purified cells from 
each fish with CNS involvement (by sorting for GFP) were analyzed for gene 
expression (GeneChip Zebrafish Genome Arrays, Affymetrix, Santa Clara, CA, USA), 
revealing significantly different profiles between hlk and hMYC-ER cancers. 
Particularly, an activation of cxcr4/cxcl12 axis and wnt/!-cathenin pathway was found 
in hMYC-ER and hlk cancers, respectively. Interesting, the cxcr4 expression positively 
correlated with the degree of CNS invasion, suggesting that higher expression of cxcr4 
increased the migratory response of T-lymphoblatsts towards the CNS environment. 
CNS involvement in hlk and hMYC-ER zebrafish cancers position both lines as useful 
models for studying CNS+ T-ALL and the different ability for hMYC-ER and hlk T-
lymphoblasts to infiltrate the CNS suggests that these lines can be used to explore 
different molecular mechanisms that drive CNS invasion in T-ALL.  
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Central nervous system (CNS) leukemia at diagnosis and relapse continues to pose a 
significant challenge in the research of an efficient cure for children with Acute 
Lymphoblastic Leukemia (ALL) [1,2,7]. The prognosis of patients with isolated and 
mixed CNS relapse is particularly poor and treatments used for the cure are very 
invasive (intrathecal chemotherapy and cranial irradiation). As CNS irradiation causes a 
lot of secondary negative effects (second cancers, neurocognitive deficits, 
endocrinopathy), numerous efforts are made to improve haematological control and to 
reduce or avoid the use of cranial irradiation using alternative intrathecal treatment [3-
6]. However, CNS irradiation is still necessary for patients at high risk of relapse within 
the CNS, especially for those presenting CNS leukemia at diagnosis [7]. Because little 
is know about how leukemic cells can invade the CNS, our studies aims to deepen the 
knowledge of molecular mechanisms that regulate this event. Leukemic cells can 
infiltrate the CNS both at diagnosis and relapse in hALLs and this event is more 
frequent in T-ALL compared to B-ALL [7]. For this reason, we focused this project on 
T-ALL and we decided to study the phenomenon of CNS infiltration with the help of 
zebrafish models. Zebrafish (zf) is an attractive model organism for studying cancer; in 
fact, zebrafish can develop spontaneous tumours that resemble those in humans [8-12] 
and this model allows large-scale genetic screens that can be useful to identify 
conserved cancer pathways. In addition, tumor suppressors and oncogenes are 
conserved between human and zebrafish genomes [12,14]. Regarding our specific topic, 
leukemia is not a spontaneous tumor that spreads in zebrafish. However, next to 
spontaneous occurring tumors, malignancies can also be induced in the zebrafish model 
through chemical- (ethylnitrosourea, ENU) and retrovirus insertional- mutagenesis 
[15,16] or through the development of transgenic models that over-express tumor genes 
in a tissue-specific manner [17,18]. In the last ten years, several transgenic zebrafish 
models that develop leukemia have been created, both for T-ALL [17,19-23], pre-B-
ALL [24] and AML [25,26]. Moreover, the transparency of zebrafish embryos and the 
introduction of a transparent stable zebrafish line (casper) [27] give a big advantage for 
real-time monitoring of labelled tumor cells engraftment after transplantation. For our 
study, it is important to know that there are significant similarities between the 
anatomical structures of the CNS (i.e: Blood Brain Barrier (BBB), Blood Retinal 
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Barrier (BRB), meninges) of adult and 3 days post fertilisation (dpf) larval zebrafish 
and that of higher vertebrates [28,29]. To determine if the zebrafish can be a good 
model to study CNS disease in T-ALL, we used two approaches: first, we tried to 
establish an in vivo model of CNS leukemic invasion through serial 
xenotransplantations with human pediatric T-ALL cell lines in wild-type (wt) zebrafish 
of 3 dpf; second, we performed histological analysis of the CNS of two stable T-ALL 
D.rerio lines (hMYC-ER [23] and hlk [30]) developing GFP+ T-ALL. Concerning the 
first approach, the ability of mammalian cancer cells to successfully engraft zf embryos 
and induce neovascularisation is well described for solid tumors [31,32], even if human 
metastatic melanoma cells transplanted in zebrafish embryos move, proliferate and 
survive without engrafting the host tissues [33]. A recent paper showed successful 
Jurkat cells transplants in the yolk/blood circulation of zebrafish embryos [34], 
supporting our choice to perform xenotransplantion of hALL cell lines. Injection of 
labelled human leukemic T-ALL cell lines was performed in wt larval zf at 3 dpf, 
divided in two groups depending on the injection site:  CNS ventricle/parenchyma or 
yolk/blood circulation (figure1). 
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Figure 1. Site of injection of Jurkat cells in larval zebrafish of 3 dpf. Larval fishes were divided in 
two groups depending on the site of injection that could be at CNS (a) or Yolk (b) site. Red arrows 
indicate the site of injections in the two groups. 
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Both injection sites were important to observe the ability of human leukemic cells to 
move and invade other tissues apart from the injection site. Moreover, CNS injection (in 
the ventricles/parenchyma) gave immediate insight in the ability of leukemic cells to 
survive in this environment. For xenotransplantation larval fishes at 3 dpf were used to 
avoid rejection of transplanted cells by the zebrafish immune system, which starts to be 
functional from 28 dpf [38].  
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With the second approach, we analyzed the presence of T-lymphoblastic infiltration in 
the CNS of two stable zf lines (hlk and hMYC-ER) that both develop GFP+ T-ALL 
disease. Even if the time to leukemia is different in hlk and hMYC-ER lines (6-8 months 
and 3-4 months respectively), these two zf lines present a similar phenotype regarding 
the spread of disease; in fact, for both lines it is possible to distinguish a stage of 
“localized disease”, in which GFP+ bright masses arise from the thymic region and a 
“final stage” of disease, where GFP+ cells are spread in the entire fish (figure 2).  
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Figure 2. Whole mount fluorescent microscopy images exemplary of the localized and final stage of 
the disease. Stages were monitored in both hMYC-ER and hlk zebrafish models. (A) At the stage of 
localized disease, T-lymphoblasts (GFP+) had proliferated and were localized at the site of the thymus; 
(B) in the final stage of the disease, leukemic cells had spread to most parts of the body.!
Summarizing, in both zf models T-malignant cells originate in the thymus, spread to the 
peripheral blood, invading gills, retro-orbital area and disseminate into abdominal 
organs, such as the kidney-marrow (zf bone marrow equivalent), spleen, gut, muscles, 
skin and fat. hlk and hMYC-ER lines both develop T-ALL, but they are genetically 
different. Chemical (ENU) mutagenesis (not further characterized) was used to establish 
the hlk zf line, characterized by a dominant heritable predisposition to develop a clonal 
and transplantable T-ALL [30]. Instead, in the transgenic hMYC-ER T-ALL model, the 
rag2 promoter was used to drive the expression of human C-MYC oncogene in 
zebrafish lymphoid cells; also in this case, malignant cells were clonal and could engraft 
irradiated hosts [23]. Even if both these models have been well characterized, the 
presence of CNS infiltraton by T-ALL cells had not been investigated in these zf lines. 
We decided to perform histological analysis of heads of fishes and found for both zf 
lines the involvement of CNS. The discovery of CNS involvement in hlk and hMYC-ER 
zebrafish cancers position both lines as useful models for the study of CNS+ T-ALL. 
Moreover, the degree of CNS infiltration was different comparing hMYC-ER and hlk 
cancers, indicating a different ability of these zf T-ALL cells to infiltrate the CNS. Gene 
expression profiling (GEP) analysis on zebrafish T-ALL cells revealed distinct 
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expression signatures between hMYC-ER and hlk cancers; this observation let us to 
speculate on the presence of different molecular mechanisms that control the invasion 
of hMYC-ER and hlk T-ALL cells in the  CNS environment. 
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Zebrafish Care and Maintenance 
Fish were kept in colony at 28.5°C on a 12/12 hour (hr) circadian cycle. For all 
procedures, fish were anesthetized with 0.02% tricaine methanesulfonate (MS222). 
After xenotransplantation, larval fishes were maintain 1h at 28°C and than at 33°C to 
allow survival of both human leukemic cells and larval fishes.   
Leukemic Cells preparation and Transplants  
Xenotransplants (Table 1) were performed using leukemia derived cell lines (CCRF-
CEM, P12-ICHIKAWA, DND-41, TALL-1 and Jurkat). !3*106 cells were centrifuged 
and re-suspended in 1 ml of RPMI 1640 medium (10% FBS, 1% ampicilline and 1% 
glutamine). Cells were incubated at 37°C for 30 minutes with label CM-DiI, a lipophilic 
fluorescent tracking dye (Invitrogen, Paisley, UJ) according to the manufacturer’s 
instruction. Larval fish at 3 days post fertilisation (dpf) were used for xenotransplants. 
!50-200 labelled (CM-DiI) leukemic cells were injected per larval fish using a 
microinjector. Larval fishes were divided in two groups depending on the injection site:  
brain ventricle/parenchyma or yolk (Figure1a/b). Each group included 30-80 larval 
fishes. Microscopic observations were made with Leica DMR microscope, equipped 
with a digital camera DC500.  Fishes were observed by fluorescent microscopy daily 
and !5 fishes of each group were fixed in 4% paraformaldehyde at  2, 3, 4, 5, 6, 7 dpi 
for immunohistochemical analysis. All remaining fishes were fixed at 7 days post 
injection (dpi). 
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Table 1. Number of xenotransplantations of 5 human T-ALL cell lines performed per site of 
injection. 
Human Cell 
lines 
1° Transplant 2° Transplant  3° Transplant  4° Transplant  
TALL1 30 CNS 30 CNS/30YOLK 30 CNS/30YOLK  
DND-41 30 CNS/30YOLK 30 CNS/30YOLK 30 CNS/30YOLK  
P12-
ICHIKAWA 
30 CNS/30YOLK 30 CNS/30YOLK 30 CNS/30YOLK  
CCRF-CEM 30 CNS/30YOLK 30 CNS/30YOLK 30 CNS/30YOLK  
Jurkat 30 CNS/30YOLK 60 CNS/60YOLK 60 CNS/60YOLK 110CNS/130YOLK 
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In addition, injection of labelled Jurkat cells was performed in 30 Tg(fli1:EGFP)y1 
larval zebrafish of 3dpf for each group (injection in brain ventricle or yolk). In 
Tg(fli1:EGFP)y1 zebrafishes the vascular system is labelled with GFP. For confocal 
microscopy, fixed embryos were embedded with 0.7% low-melting agarose and placed 
on a Petri capsule. Stacks were recorded using %40 immersion objective (SP5 spectral 
confocal system; Leica). All images were analyzed with ImageJ software 
(http://rsb.info.nih.gov/ij/). Using confocal microscopy injected fishes were monitored 
for real-time monitoring of malignant cells behaviour. 
Histology, Immunoflorescent analysis (IF) and Immunohistochemistry (IHC) 
Xenotransplanted larval fishes for each group (injected in CNS or yolk) were fixed at 2, 
3, 4, 5, 6 and 7 dpi in 4% paraformaldehyde, paraffin-embedded and sectioned (5µm). 
For IF, whole-mount antibody staining for Ki67 [1:200 mouse monoclonal anti-human 
Ki-7 #M7240 (Dako, Denmark, EU)], HDAC1 [1:200 rabbit polyclonal anti-human 
nuclei #sc-7872 (Santa Cruz Biotechnology, Dallas, TX)] and DAPI [1:10000 (Sigma-
Aldrich, Milano, Italy)] staining was performed. IF images were obtained on a video-
confocal microscope (Vico, Ecliple Ti80, Nikon), equipped with a digital camera. 
5 WIK lck::EGFP+/+ (used like healthy controls), 5 hMYC-ER and 5 hlk fishes at the 
stage of localized disease  and the heads of 10 hMYC-ER and 10 hlk fishes at the last 
stage of disease, were fixed in 4% paraformaldehyde, paraffin-embedded and sectioned 
(5µm). Hematoxylin and eosin (H&E) staining was performed using standard 
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procedures. For IHC, staining was performed using an anti-GFP antibody [1:400 
dilution; mouse monoclonal antibody #sc- 9996 (Santa Cruz Biotechnology, Dallas, 
TX)] with resolution of GFP+ tissues using a DAB detection kit (Dako, Denmark, EU).  
Microscopy and analysis of quantitative microscopy  
Adult hMYC-ER and hlk fishes were screened for abnormal GFP patterns with an 
Olympus szx 12 fluorescent microscope and camera (Center Valley, PA) and Optronics 
Picture frame software (Goleta, CA). H&E, HIC and IF images were obtained on a 
video-confocal microscope (Vico, Ecliple Ti80, Nikon), equipped with a digital camera. 
For quantitative microscopy analyses images were analyzed with the software open 
source ImageJ. To obtain a comparable measure of the degree of infiltration, we 
analyzed IHC stained slides at the level of the optic chiasm for each specimen. Images 
at the same resolution (10X) were converted to 8-bit greyscale images, and then a 
threshold was applied. ROIs (regions of interest) were manually selected and the 
percentage of CNS infiltration was measured as the ratio between the area involved by 
lymphoblast infiltration (the only area detected in black) and the total area of the CNS 
(considering the total area delimited by the zebrafish skull).   
Flow Cytometry  
The body (except the head) of 10 hMYC-ER and 10 hlk- sacrificed fishes at the last 
stage of disease was placed in PBS1X. Cells were dissociated through pestle mechanic 
movements and passed two times trough 35µm filters (Becton Dickinson (BD), San 
Jose, CA) before analysis. GFP+ positive cells were isolated using a BD fluorescence-
activated cell sorting (FACS) Vantage Instrument (Becton Dickinson). GFP intensity, 
forward-and side-scatter were used for gating. After sorting, cells were centrifuged and 
immediately put on Trizol (Invitrogen, Karlsruhe, Germany).    
RNA extraction and Microarray whole transcriptome expression analysis 
Total RNA from single fish was extracted from FACS GFP+ purified cells using Trizol 
according to the manufacturer’s instruction (Invitrogen, Karlsruhe, Germany). RNA 
concentration was determined using QBit 2.0 Fluorometer (Life Technology, Carlsbad, 
California, U.S.). Total RNA was stored at -80°C. To perform microarray experiments, 
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RNA quality and purity control was assessed on the Agilent Bioanalyzed 2100 (Agilent 
Technologies, Waldbronn, Germany) using “Eukaryote total RNA Assay”. Only RNA 
samples that passed quality controls (6 hMYC-ER and 3 hlk samples) were used to 
perform microarray (Affymetrix GeneChip Zebrafish Genome Arrays) analysis. In vitro 
transcription, hybridization and biotin labelling were performed according to GeneChip 
3’IVT Express kit protocol (Affymetrix, Santa Clara, CA). Microarrays data  (.CEL 
files) were generated using Affymetrix GeneChip Command Console Software 
(AGCC). All microarrays passed the quality controls: scale factor, number of present 
calls, internal probe calls, Poly-A controls and the ratio GAPDH/!-actin 3’/5’.  
Statistical analysis 
Microarray data (.CEL files) were analyzed using Command Expression Console 
(Affymetrix). The .CEL files were normalized using the justRMA algorithm and 
analyzed for supervised and unsupervised analysis, using R-Bioconductor (Version 
2.15.3). Unsupervised analysis (Class Discovery) clusters together unspecified (new) 
specimens based on similar gene expression patterns and filtering only for probe sets 
that present a variance >90%. Supervised analysis (Class Comparison, Class Prediction) 
is a learning algorithm that uses already defined (labelled) data in order to identify a set 
of genes that characterize the pre-specified data. In order to find differently expressed 
probe sets between two groups of interest (in our case hMYC-ER and hlk), we applied a 
Shrinkage t-test on the normalized .CEL files [56]. We used a local false discovery rate 
(lfdr) as correction of the p-value. A lfdr < 0,05 was considered significant for genes 
differently expressed between the two groups. Differently expressed probe sets derived 
from the Shrinkage t-test were used for clustering analysis. Hierarchical clustering 
analysis was used to cluster the specimens in an unsupervised manner using Euclidean 
Distance and Ward’s Method.  
GraphPad Prism 5 software program (GraphPhad Software, La Jolla, CA, U.S.A.) was 
used to perform Pearson correlation analysis, between expression levels of cxcr4a and 
cxcr4b and degree of CNS infiltration. 
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Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) v9.05. STRING, 
based on text mining, was used in order to investigate potential gene/protein networks 
within the list of differently expressed genes between hMYC-ER and hlk groups. 
Reverse-transcription and real-time polymerase chain reaction 
250 ng of RNA extracted from GFP+ cells of single fishes, was reverse transcribed 
using Superscript II (Invitrogen, Karlsruhe, Germany) and random primers following 
standard techniques. SYBR-Green Real-time quantitative PCR (qRT-PCR) was 
performed using the Platinum SYBR-Green qPCR SuperMix UDG (Invitrogen, 
Karlsruhe, Germany) and the 7900 HT Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA). qRT-PCR was performed in triplicates (both for 
housekeeping and genes of interest) for each sample and standard curve of 3 serial 
dilutions was used as control for each plates. qRT-PCR was executed for detecting 
expression level of cxcr4a, cxcr4b and hMYC genes, while !-actin was used as 
housekeeping gene to normalize gene expression data. Primers are listed in the table 2. 
The specificity of the primers was examined with the corresponding dissociation curve. 
To allow comparison between samples, transcript quantification was performed after 
normalization with !-actin using the Ct method and results were calculated according to 
the following formula 2-&ct [46]. Analysis of expression was performed using the 
GraphPad Prism 5 software and statistical significance was calculates as a P value using 
non-parametric Mann-Whitney test. Two tailed 95% confidence intervals were used to 
assess the significance of the data (P< .05).     
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Testing the possibility to establish a model of CNS leukemic infiltration in zebrafish 
The first efforts of this project focused on the establishment of an in vivo model in 
zebrafish that could mimic the phenomenon of leukemic infiltration into the CNS in T-
ALL patients. A total number of ~100-200 transplantations of 5 pediatric T-ALL cell 
lines (table 1) have been performed in larval fishes at 3 days post-fertilization (dpf) as 
previously described (Figure1). Among cell lines injected, Jurkat cells showed a clear 
predisposition to move away from the site of injection invading other loci. On the 
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contrary, CCRF-CEM, DND-41, P12-ICHIKAWA and TALL-1 cell lines did not show 
this ability to move from the site of injection and after 7 days post injection human 
labelled cells were no longer detected in 70-80% of injected larval fishes. Moreover, 
whole-mount analysis on larval fishes injected with T-ALL1 and DND-41 excluded the 
hypothesis of an increased proliferation of these cells causing the loss of the membrane 
dye; no human cells were detected in larval fishes analyzed (data not shown). These 
data suggest that these cell lines are not fit to survive in the zebrafish environment. 
Instead, larval fishes of both groups (injection at the CNS or yolk) transplanted with 
Jurkat, already after 6 hours post-injection (hpi) showed labelled cells both at the site of 
injection (100% larval fish transplanted) and in blood vessels circulating together with 
zebrafish blood cells or accumulated in the ventral caudal region (50% and 10% of 
larval fishes xenotransplanted in the yolk and CNS, respectively) (Figure 3A/4A). To 
better localize the position of Jurkat cells, xenotransplants with Jurkat cells were 
performed in 30 Tg(fli1:EGFP)y1 zebrafish at 3 dpf for both groups: at the CNS site 
and at the yolk. In vivo confocal microscopy showed the presence of Jurkat cells in the 
blood vessels and capillaries from 6 hours onwards and Jurkat cells that were blocked or 
stayed adhered to the wall of blood vessels (Figure 5A and B). Similar results were 
obtained for both groups after longer times post cell injections. Interesting, at 7 days 
post-injection (dpi) 10% of larval fishes of both groups presented Jurkat cells at several 
sites away from the original site of injection, showing the ability of Jurkat cells to 
survive and circulate in zebrafish tissues (Figure 3B/4B). Whole body 
immunofluorescence analysis on larval fishes injected in the CNS or yolk and fixed at 
different time points after injection, where performed. Analysis on larval fishes fixed at 
2 (figure 6 A and B) and 7 dpi revealed the presence of Jurkat cells positive for anti-
Ki67 (marker of proliferating cells) [47] and HDAC (marker of human nuclei) staining. 
However, the total number of cells had not increased from 2 to 7 dpi (data not shown) 
so we can assume that cell death of Jurkat cells had also occurred. 
Lymphoblastic CNS infiltration in hMYC-ER and hlk T-ALL zebrafish models 
To understand if hMYC-ER and hlk zebrafish lines could be good models for the study 
of CNS infiltration by T-ALL cells, we performed detailed histological analysis of the 
CNS at the “localized” and “final” stages of the disease in both zebrafish T-ALL lines 
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(figure 2). First, we performed histological analysis of the CNS for 5 hMYC-ER and 5 
hlk fishes at the stage of localized disease and we observed signs of T-ALL cell 
infiltration. At this early stage of the disease, the sites and extend of CNS infiltration 
were different from one fish to the other. In fact T-ALL cells could be present in the 
neural tube, the parenchyma, the pineal gland and meninges. However, all fishes 
presented CNS involvement to some extend. (figure 7). Histological analysis performed 
at the last stage of the disease for 9 hMYC-ER and 8 hlk fishes, showed a more sizeable 
infiltration of the CNS for both zebrafish lines, with involvement of meninges, optic 
nerve, retina and some infiltration of the parenchyma (figure 8). We found CNS 
infiltration in 8/9 hMYC-ER fishes, compared to 5/8 hlk fishes. For fishes presenting 
CNS involvement, we observed a distinct trend of lymphoblastic infiltration among the 
groups: the hMYC-ER fishes showed a more massive infiltration of the CNS compared 
to the hlk line, while the latter presented a thin layer of CNS infiltration but important 
signs of infiltration under the skin (figure 9). We proceeded with quantitative 
microscopy image analysis to measure the level of CNS infiltration in the two zebrafish 
lines (9 hMYC-ER fishes and 8 hlk fishes), and we found a significant difference in the 
degree of CNS infiltration between the hMYC-ER and the hlk group (Mann-Whitney T-
test, p-value: 0,04) (figure10).  
Gene expression signatures and networks activated in hMYC-ER and hlk models   
To identify active networks that could explain the different ability of hMYC-ER and hlk 
cancers to infiltrate the CNS, we performed whole transcriptome analysis of T-ALL 
cells extracted from the body of hMYC-ER and hlk fishes, of which the heads were used 
for histological analysis. Suitable RNA was available for 6 hMYC-ER and 3 hlk fishes 
all with CNS infiltration. Using a class discovery approach, unsupervised hierarchical 
cluster analysis separated hMYC-ER and hlk groups, underlining a strong gene 
expression profile distinction between hlk and hMYC-ER cancers (figure 11). Class 
comparison analysis, using shrinkage T-test revealed 683 probe sets differently 
expressed between hMYC-ER and hlk lines (lfdr<0,05) (figure 12). Considering genes 
with >1,2-fold change of expression, a set of 317 genes with human homologous genes 
was identified. Among these 215 and 102 human homologous genes were up-regulated 
in the hMYC-ER and hlk group, respectively (table 3). Using STRING (Search Tool for 
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the Retrieval of Interacting Genes/Proteins) analysis, on genes up-regulated in the 
hMYC-ER and hlk group separately, the human homologous gene list revealed to be 
enriched for genes related to motility, cell adhesion and leukocyte transendothelial 
migration (KEGGs pahways). In particular, for the hMYC-ER group, we found an 
activation of the cxcr4/cxcl12 axis, whereas for the hlk group, activation of the wnt/!-
catenin pathway was revealed (figure 13). Specifically, a >2-fold change in cxcr4a and 
>1,3-fold change in cxcr4b expression was observed in hMYC-ER vs. hlk cancers. The 
up-regulation of two distinct gene networks related to cell motility support the 
hypothesis that molecular mechanisms underlying extramedullary organ infiltration in 
hMYC-ER and hlk zebrafish may be different. 
Expression levels of cxcr4a and cxcr4b reflect degree of CNS infiltration 
Here we focused at first on the cxcr4/cxcl12 axis in the two zebrafish lines. Data of gene 
expression profiling on cxcr4a/b expression from array analysis, were validated by 
qRT-PCR. Moreover, we were able to increase the number of samples, by adding 3 
hMYC-ER and 4 hlk samples. These samples had been included also in the quantitative 
microscopy image analysis. qRT-PCR results confirmed the presence of a significant 
different expression of cxcr4a and cxcr4b (p-value 0,0004) between hMYC-ER and hlk 
cancers (figure 14). Importantly, the expression levels of both cxcr4a and cxcr4b 
positively correlated with the degree of CNS infiltration measured by quantitative 
microscopy image analysis (Pearson Correlation R2=0,039 and R2=0,069 respectively) 
(figure 15). 
High expression levels of hMYC are associated with increased cxcr4 transcription 
T-ALL cells presenting high expression of cxcr4a and cxcr4b derived from the hMYC-
ER zebrafish line. This transgenic model presents an induced over-expression of hMYC. 
We analyzed by qRT-PCR the expression levels of hMYC and confirmed that T-
lymphoblasts from the hMYC-ER zebrafish line expressed high levels of human C-MYC 
(data not shown). Several works already showed how hMYC could physically interact 
with hYY1, mutually inhibiting their biological functions in a dose dependent manner 
[35]. As the transcription factor YY1 is the main repressor of CXCR4 transcription [36], 
we speculated that the induced over-expression of hMYC in hMYC-ER zebrafish T-
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lymphoblasts sequestered zfYy1, with consequent increased transcription of cxcr4a and 
cxcr4b  (figure 16). To support this hypothesis, alignment of the protein sequence, 
revealed a high identity between hYY1 and zfYy1 (76% identity) and the domain of 
interaction with MYC, was shown to be completely conserved between h- and zf-YY1 
[35] (figure17).  
Expression of hMYC modifies zf Yy1 activity in the hMYC-ER model 
YY1 can function both as transcriptional activator or repressor of specific target genes 
[35]. Unsupervised hierarchical analysis considering target genes that are activated or 
repressed by YY1 [37] revealed separate clustering of hMYC-ER and hlk groups (figure 
18) and target genes follow the expected direction (activation or repression) in the hlk 
comparing to the hMYC-ER cancer. These analyses of gene expression profiling 
supported our hypothesis: in the hMYC-ER zebrafish line, the biological function of 
zfYy1 is inhibited by the induced over-expression of hMYC and through this 
meachnism zfYy1 target genes are differently expressed compared to the hlk group, 
where zfYy1 maintains its transcriptional activator or repressor function. This 
assumption is supported not only by YY1 target gene expression data from a single 
target gene (like cxcr4a and cxcr4b), but by considering all main YY1 target genes that 
are homologous between human and zebrafish (table 4). Interestingly, hMYC-ER and 
hlk groups present the same expression level of yy1a and yy1b (data not shown). 
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Although numerous efforts are made to improve haematological control and to reduce 
or avoid the use of cranial irradiation using alternative intrathecal treatment [5], CNS 
irradiation is still necessary for 2-20% of patients at high risk of CNS relapse [2]. The 
molecular mechanisms that allow ALL cells to enter and infiltrate the CNS are still 
largely unknown. In this study we aimed at identifying a beneficial  D.rerio model that 
could mimic CNS infiltration by T-ALL cells, which may be used to deepen our insight 
into the biological mechanisms that regulate this phenomenon. First, we tried to 
establish an in vivo model through xenotransplants of childhood T-ALL cell lines in 
larval fishes at 3 dpf. Only Jurkat cells showed a clear predisposition to move from the 
original site of injection, circulate, invade other loci and survive in the host organism. 
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The ability of Jurkat cells to survive in the recipients was clear; fluorescent cells were 
detectable in all fishes transplanted both at 2 and 7 dpi. At these time points, labelled 
cells were visualized both at the site of injection (100% larval fishes xenotransplanted in 
yolk or CNS) and circulating in vessels or blocked/adhered in the ventral caudal vein or 
capillaries (50% of  larval fishes xenotransplanted in yolk and 10% larval fishes 
xenotransplanted in the CNS). As yolk at 3 dpf is largely vascularised, the presence of 
circulating cells in 50% larval fishes injected in the yolk is not so surprising. Contrary, 
the presence of circulating cells in 10% of larval fishes injected in the brain ventricles, 
indicated the ability of Jurkat cells to migrate. Moreover, the presence of Jurkat cells, 
which was still detected at 7 dpi in the head of 100% of larval fishes injected in the 
ventricles, underlines the ability of Jurkat cells to survive in the zf CNS environment. 
However, the observation that the number of Ki67 positive cells was higher in larval 
fishes fixed at 2 compared to 7 dpi and that the number of HDAC positive cells did not 
increase from 2 to 7 dpi (data not shown), indicated that there was also considerable cell 
death/apoptosis of Jurkat cells. In conclusion, Jurkat cells can survive, circulate and 
infiltrate zf tissues, however, the number of cells does not increase and Jurkat cells are 
not able to really engraft the host organs. Moreover, even if it has been established that 
the immune system started to be functional at 28 dpf, there are also studies that showed 
the presence of immature T-lymphocyte moving towards the thymus at 4 dpf [39]. The 
latter could explain the death of injected  Jurkat cells in our experiments. All together 
these data suggest that the model of xenografted zebrafish is not useful for studying the 
mechanisms that allow T-ALL cells to infiltrate the CNS. However, xenografting in 
zebrafish can be useful as recipient of human leukemic cells with a possible application 
for testing new experimental inhibitors of circulating human leukemia in vivo using 
high through-put approaches. Using such approaches bypasses the problem of the 
presence of T-lymphocytes at 4 dpf, as chemotherapeutic compounds act in leukemic 
cells but also repress the zf immune system at the same time [40].  
At this point, to study the phenomenon of CNS infiltration by T-ALL cells, we decided 
to proceed using a different approach. We performed histological analysis of the CNS 
of two stable T-ALL D.rerio lines ([hMYC-ER [23] and hlk [30]) that developed GFP+ 
T-ALL. Histological analysis performed at the stage of localized disease showed the firs 
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signs of lymphoblastic infiltration in the CNS (meninges, pineal gland, neural tube, 
parenchyma) for both groups, indicating a genetic predisposition of these leukemic cells 
to also invade the CNS. Histological analysis at the last stage of disease also revealed 
the presence of CNS involvement (meninges, pineal gland, optic nerve, retina, 
parenchyma). Interestingly, the type of CNS invasion found at this stage in these 
models was very similar to CNS infiltration found in pediatric patients at time to death 
in the 1970s. In fact, we found different degrees of infiltration at the meningeal level 
[48], always correlated to optic nerve involvement [49]. These data underline the ability 
of these zf models to mimic the human CNS disease. Moreover, at this stage we 
observed that this event was more frequent in hMYC-ER (88,8%) compared to the hlk 
(62,5%) line and the degree of CNS infiltration was higher in hMYC-ER compared to 
hlk groups (p-value:0,04). These data suggested a different ability for hMYC-ER and hlk 
T-lymphoblasts to infiltrate the CNS. This assumption was supported by whole 
transcriptome analysis performed on FACS-purified cells (through sorting for GFP) 
from the body of each fish presenting CNS infiltration. In fact, Gene Expression 
Profiling (GEP) analysis revealed the presence of two distinct activated motility 
networks and specific gene expression signatures in hMYC-ER and hlk cancers 
respectively. The different trend of CNS infiltration and the different gene expression 
profiles suggested the presence of different mechanisms that regulate and drive motility 
and invasiveness of hMYC-ER and hlk T-lymphoblasts. Particularly, Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING) analyses showed an activation of 
cxcr4/cxcl12 axis and wnt/!-cathenin pathway in hMYC-ER and hlk cancers, 
respectively. The discovery of CNS involvement in hMYC-ER and hlk zebrafish cancers 
position both lines as useful models for CNS+ T-ALL and different pathways may be 
explored for relevant molecular mechanisms that drive CNS invasion. 
For the moment, we focused on cxcr4/cxcl12, the axis activated in the group with a 
higher degree of CNS infiltration. GEP analysis showed a >2-fold change (FC) and a 
>1,3 FC in cxcr4a and cxcr4b expression in hMYC-ER vs. hlk cancers respectively and 
analysis of qRT-PCR for cxcr4a and cxcr4b validated arrays data. The zebrafish model 
presents two copies of mammalian CXCR4 (cxcr4a and cxcr4b) deriving from genomic 
duplication, which occurred during teleost evolution. The observation that during zf 
! ! )*!
embryogenesis cxcr4a and cxcr4b expression patterns are similar to those of the single 
mammalian CXCR4 gene [41] suggested that zebrafish gene pairs spited mammalian 
gene functions between the two copies [42]. Particularly, cxcr4a conserved the majority 
of CXCR4 functions, while cxcr4b seems to have acquired also other functions in early 
development [41]. Of note, in this study we found that both the expression of cxcr4a 
and cxcr4b positively correlated (R2=0,039 and R2=0,069 respectively) with the degree 
of CNS infiltration found through quantitative microscopy image analysis in hMYC-ER 
and hlk histological preparations. CXCR4 is a chemokine receptor, particularly 
important for haematopoiesis and also for trafficking T-lymphocytes [43]. The higher 
CXCR4 expression and activation in T-lymphocyte increased the migratory response of 
these cells towards its specific ligand CXCL12 gradient. One could speculate that the 
expression level of CXCR4 in leukemic cells could influence the migratory response of 
these cells towards tissues/organs that express the CXCL12, such as bone marrow, 
lymph nodes, spleen and brain [50]. In zebrafish, the expression of both cxcr4a and 
cxcr4b and cxcl12a and cxcl12b in the brain of adult fish has been documented [51]. A 
link between the over-expression of CXCR4 and the increased motility of leukemic 
cells is well documented for AML and CML [52-54]. However, the role of 
CXCR4/CXCL12 axis is not so clear in ALL. In fact, there are discordant hypotheses 
regarding the role of the CXCR4/CXCL12 axis and CNS infiltration in ALL: high 
levels of CXCR4 expression by childhood lymphoblasts have been associated with 
extra-medullary organ infiltration [44]. Alternatively, CNS-homing cells showed 
CXCR4 down-regulation in a mouse xenograft model of CNS pre-B leukaemia with 
levels of CXCR4 expression inversely proportional to the rapidity of CNS disease 
development [45]. Moreover, another study showed that in children with ALL relapses 
associated to testicles or CNS leukemia blast cells had a significantly lower CXCR4 
level than blasts from children with relapsed disease isolated to the bone marrow [55]. 
Further analyses are necessary to clarify the role of CXCR4 expression in predicting the 
ability of hALL cells to infiltrate the CNS. For the moment, with this work we showed 
that higher levels of cxcr4a and cxcr4b seem to confer to T-lymphoblasts an increased 
ability to infiltrate the CNS.  
! ! )+!
Another aspect we investigated was the identification of a possible role of MYC in 
regulating cxcr4a and cxcr4b transcription. Several works already showed the  physical 
interaction of hMYC with hYY1, mutually inhibiting their biological functions in a 
dose dependent manner [35,36]. We speculated that the induced over-expression of 
hMYC in hMYC-ER zebrafish T-lymphoblast caused the total sequestering of the zfYy1 
transcription factor (the main transcriptional repressor of CXCR4) with consequent 
increased levels of cxcr4a and cxcr4b transcription. This hypothesis was supported by 
the unsupervised analysis considering only hYY1 target genes [37], in which hMYC-ER 
and hlk cancers cluster separately: we observed that YY1 target genes moved in 
opposite directions between the two zebrafish lines. Particularly, in the hMYC-ER fishes 
zfYy1 seems not be functional, while in the hlk group zfYy1 target genes move in the 
expected way (activated or repressed). Our data suggest a possible role for c-MYC in 
regulating cxcr4a and cxcr4b transcription and consequently in determining the 
migration of T-ALL cells towards the CNS. High levels of C-MYC could increase 
CXCR4 transcription, conferring to these cells a predisposition to invade tissues 
expressing the CXCL12, such as the brain.  
In conclusion, with this work we found two stable zf lines (hMYC-ER and hlk) that are 
good models of CNS+ T-ALL; these zf lines can have useful applications not only in 
the study of mechanisms used by T-lymphoblasts to infiltrate the CNS, but also for 
testing specific pharmacological inhibitors that can block this phenomenon. This 
discovery is very important, because it allows to bypass the problem of lack of human 
patient material available for such studies. Moreover, these two zf lines presented 
different active gene networks suggesting the presence of two diverse mechanisms that 
regulate the motility of their T-lymphoblasts and resulting in different abilities to 
infiltrate the CNS. These results revealed the presence of more than one molecular 
mechanisms that can determine CNS infiltration, giving a different predisposition to T-
ALL cells to invade the CNS. Particularly, we observed that cxcr4a ad cxcr4b 
expression is not necessary to infiltrate the CNS, but higher expression levels of these 
chemokine receptors significantly increase the ability of T-ALL cells to invade the 
CNS. Moreover, we found in hMYC a modulator of zfYy1 transcriptional function with 
consequent effects on cxcr4a ad cxcr4b transcription. Further studies are necessary to 
! ! ),!
better characterize the molecular mechanisms found in these zf lines (cxcr4/cxcl12 axis 
and wnt/!-cathenin pathway) in relation to CNS invasion also in human patients. 
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Figure 3: Fluorescent microscopy images show larval fishes injected with labelled Jurkat cells at the site 
of the yolk at 6 hours (panel A) and at 7 days (panel B) post-injection: (A) At 6 hour post injections in 
50% of larval fishes Jurkat cells had moved away from the site of injection (green arrow) and were 
detected in the ventral caudal region (red arrow). (B) At 7 days post injection, Jurkat cells had continued 
to move and were detected in the ventral caudal vein and in the 10% of larval fishes also in the head (red 
arrows). 
 
!
Figure 4: Fluorescent microscopy images show larval fish injected with labelled Jurkat cells in the 
ventricles/parenchyma at 6 hours (panel A) and at 7 days (panel B) post-injection: (A) At 6 hours post 
injections, Jurkat cells had moved away from the site of injection (green arrow) and were detected in the 
ventral caudal region (red arrow) in the 10% of larval fishes injected. (B) At 7 days post injection in 10% 
of larval fishes Jurkat cells were detected at various sites away from the site of injection, like the ventral 
caudal region and near the yolk (red arrows). 
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In vivo confocal images show Jurkat cells in zf blood vessel
 
Figure 5A/B: In vivo confocal images show Jurkat cells (labelled in red) in blood vessels (labelled in 
green) of zebrafish Tg(flil:EGFP) larval fishes at 6 hours post injection. Figures show the majority of 
Jurkat cells adherent to the wall of vessels (at this position only few Jurkat cells move/circulate) at the 
level of the ventral caudal vein. 
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Figure 6: Whole body immunofluorescent analysis of larval fishes transplanted with Jurkat cell line after 
2 dpi. Panel A: exemplar fluorescent microscopy images show the presence of Jurkat cells (some 
underlined with red arrow) at different section levels in larval fishes injected in the YOLK (1, 2, 3, 4). 
These images show the presence of many circulating labelled cells that pass also through the brain blood 
vessels (1, 2). Panel B: exemplar fluorescent microscopy images reveal the presence of Jurkat cells (red 
arrow) at different section levels in larval fishes injected in the CNS (1, 2, 3, 4). There are few cells seen 
in blood vessels, but Jurkat cells are detectable in the CNS (1, 2) and also in the tail (4). 
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IHC analyses reveal the presence of CNS infiltration at different stages of the disease in zf 
T-ALL  models 
 
 
Figure 7 (left pannel): Transversal sections of CNS of fish at the stage of localized disease. Exemplar 
pictures of T-lymphoblast (DAB stained with PO-anti-GFP) infiltration (red arrows) in the CNS at 
several sites: pineal gland (a), neural tube (b), meninges (c). 
Figure 8 (right pannel): Images of histological preparations (transversal section) of CNS of fishes at the 
last stage of disease. Exemplar pictures of T-lymphoblast (DAB stained with PO-anti-GFP) infiltration 
(red arrows) involving the optic nerve (a) the meninges (b) and the parenchyma (c) near the ventricles. 
 
! ! *'!
Different degree of CNS infiltration between hMYC-ER and hlk zebrafish models 
!
Figure 9 (left pannel) : Comparison of CNS infiltration between hMYC-ER (A) and hlk (B) zebrafish 
models at the same section level (optic nerve). Pictures underline the different T-lymphoblast (DAB 
stained with PO- anti-GFP) infiltration at the meningeal level (red arrows): hMYC-ER showed important 
meningeal infiltration (A) compared to the thin layer infiltrated in the hlk group (B). On the other hand 
hlk T-lymphoblasts had consistently infiltrated the skin (*). 
Figure 10 (right graphic): Significant different degree of CNS infiltration between hMYC-ER and hlk 
zebrafish models at the last stage of disease. CNS infiltration was analyzed by quantitative microscopy 
image analysis of microscopic sections at the level of the optic nerve (Mann-Whitney T-test, p-value: 
0,04). Y-axis shows the % of CNS infiltration measured by quantitative microscopy analyses. 
 
Whole-transcriptome analysis reveals a different signature between hMYC-ER and hlk 
cancers 
!
Figure 11 (left): The heatmap shows the results of unsupervised hierarchical clustering analysis, filtering 
for probe sets that present a variance >90%. Unsupervised analysis clustered the 6 hMC-ER (orange) and 
3 hlk (blue) samples in two arms, revealing distinct gene expression signatures that separated the two zf 
lines. 
Figure 12 (right): Supervised analysis, using Shrinkage T-test, identified 683 probe sets differently 
express between hMYC-ER (orange) and 3 hlk (blue) groups. The heatmap was created using only probe 
sets with a significant different expression from the comparison between groups (lfdr<.05)..  
 
! ! *(!
Different networks related to cell motility are active in hMYC-ER and hlk zf 
models 
!
Figure 13: Using STRING (Search Tool for the Retrieval of Interacting Proteins) two distinct protein-
protein interaction networks both related to cell motility were retrieved for hMYC-ER (first figure) and 
hlk (second figure) cancers respectively. Differentially expressed cell motility related genes were 
identified for the two fish lines by GEP analysis and homologous human counter parts were analyzed for 
protein-protein interactions. 
! ! *)!
 
 
hMYC-ER expresses higher levels of both cxcr4 and cxcr4b compared to the hlk group 
!
Figure 14: Validation of gene expression data of cxcr4a and cxcr4b expression by qRT-PCR. hMYC-ER 
(red) lymphoblasts expressed higher levels of both cxcr4a (left graphic) and cxcr4b (right graphic) 
compared to the hlk samples (green) (Mann Whitney T-test, p-value: 0,0004). 
 
 
Expression levels of cxcr4 and cxcr4b correlate with the degree of CNS infiltration in hMYC-ER 
and hlk models 
!
Figure 15: Positive correlation between the expression levels of cxcr4a (left) and cxcr4b (right) measured 
by qRT-PCR and the percentage of CNS infiltration (measured by quantitative microscopy image 
analysis) (Spearman Correlation). 
 
 
Hypothesis of mechanism that regulate cxcr4 transcription in hMYC-ER group 
!
Figure 16: Hypothesis of the mechanism of regulation of cxcr4a and cxcr4b transcription in hMYC-ER 
fishes. The induced over-expression of hMYC sequestered all zfYY1, inhibiting its biological function as 
a transcriptional repressor of cxcr4. The absence of free zfYy1 allowed an increase in cxcr4 transcription. 
! ! **!
 
 
High identity between human and zebrafish YY1 
!
Figure 17: Protein alignement of Human-Zebrafish-Mouse YY1 sequence revealed a high identity 
between human and zebrafish YY1 (76% identity). Moreover, the domain necessary for the interaction of 
YY1 with MYC is completely conserved (red cube) between the two species [35]. 
 
 
Hierarchical clustering based on main YY1 target genes separate hMYC-ER and 
hlk models 
!
Figure 18: Unsupervised hierarchical analysis considering all main YY1 target  genes (C) or separately 
target genes that are upregulated (A) or downregulated (B) by YY1, divide hMYC-ER (orange) and hlk 
(blue) cancers. Of note, in hMYC-ER group the function of Yy1 seems to be impaired and target genes 
behave in the opposite way compared to the the hlk group. 
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Table 2. Primers used for qRT-PCR 
 
 
 
 
 
 
 
Table 4. Probe sets of the main YY1 target genes homologous between human and 
zebrafish 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENES PRIMERS 
Forward: 5’-TCATCATCTCCAAGCTGTCG-3’ cxcr4a 
Reverse: 5’-CTCCGTCACGAAGATCCATT-3’ 
Forward: 5’-CTTATTGCGCCTTTTTGAGC-3’ cxcr4b 
Reverse: 5’-ATCCCGTATACTGTAGGGAGGAA-3’ 
Forward: 5’-CCCTCAACGTTAGCTTCACC-3’ hMYC 
Reverse: 5’-CCTCCTCGTCGCAGTAGAAA-3’ 
Forward-5'-AAATCGCTGCCCTGGTCGTT-3' !-actin 
Reverse-5'-CTGTCCCATGCCAACCATCA-3' 
BC!DEFE! *GHIE!JEKJ!KLGDEK!DEFEJ!MN8GEDMOLKEP!IQ!((6!
<20K$3! T2G$,'%)G$GU$V37!
?I<3! T2G$G$GU$V37!
?I<K! T2G$)-'+G$GU$V37!
<14$3$3! T2G%--,*G$GU$V5V37!
/5D3(! T2G%)$$)G$GU$V37!
W5@3! T2G(*('G$GU$V37!
W5@>! T2G(*+,G$GU$V37!
D(&! T2G%-(%G$GU$V37!
D32D$! T2G$*%('G$GX$V37!
T2G%-*+,G$GX$V37!($))6!
T2G%%)$$G$GX$V37!
<<4$&! T2G$($%(G$GX$V37!
BC!DEFE! *GHIE!JEKJ!KLGDEK!DEFEJ!PHRF8GEDMOLKEP!IQ!((6!
3<73$3! T2G'+&*G$GX$V37!
<37! T2G$-*,G$GU$V37!
5D$! T2G,%&(G$GX$V37!
<@<2'3! T2G$(-((G$GU$V37!
<@<2'K! T2G)*,+G$GU$V37!
<@?3! T2G$+%)*G$GU$V37!
<@?K! T2G%',(-G$GU$V37!
502D"=0$! T2G&+&G$GX$V37!
">$! T2G('$G$GU$V37!
T2G$%,+)G&GU$V3V37!
T2G$%,+)G$GX$V3V37!
T2G$%,+)G%GU$V37!
<=<>?!
T2G$%,+)G$GX$V37!
! ! *,!
Table 3. Genes differently expressed between the hMYC-ER and the hlk group with a 
FC>1.2 that have a human homologous gene 
SC!*GHIE!.EK! :GHMN!$*! BC!DEFE! 3#! TMULF!DEFE!
T2G%&,'%G$GU$V37! -2@! K&B=7(3! %J,)! ABCDEF!
T2G+%,*G$GU$V37! -2@! A=7$$2! %J+$! GDE::!
T2G%+&)G$GX$V37! -2@! YB<Z)&(%&! %J**! 0HIJ!
T2G(,)G$GU$V37! -2@! "7Q! %J'+! KEL!
T2G)$&G$GU%V37! -2@! 571?! %J'*! MENJ!
T2G)&*G$GU%V37! -2@! <>/%! %J&(! <OP6!
T2G,&'(G$GX$V37! -2@! 5KZ<K'*'! %J%&! H>006:!
T2G&'$&G$GU$V37! -2@! >3</<! %J$'! OH<P:!
T2G&*$&G$GX$V37! -2@! 84=<K! %J$$! /ID<!
T2G%&')-G$GU$V37! -2@! 5D20>$! %J-%! M0>QO:!
T2G$%++%G$GX$V37! -2@! /5)57$3! %J--! PMRME:!
T2G+%+$G$GU$V37! -2@! 1>Y&! $J,+! NO'B!
T2G'*)&G$GU$V37! -2@! 51@$$3! $J,&! MN=::!
T2G$-)++G$GU$V37! -2@! <>Q(! $J,$! <OLF!
T2G+-,'G$GU$V37! -2@! 50?3'0! $J+,! MQJH?!
T2G'*)&G$GU%V37! -2@! 51@$$3! $J+(! MN=::!
T2G$*+(&G$GX$V37! -2@! 83?',3! $J+(! /HJ?7H!
T2G$%(,-G$GU$V37! -2@! [3B$3! $J+&! SHC:!
T2G%()*)G$GX$V37! -2@! YB<Z*&$'%! $J*,! PJ0:7!
T2G%%,((G$GX$V37! -2@! 2"4D4$! $J**! >KI0I:!
T2G%$+$'G$GU$V37! -2@! YB<Z$&)+)'! $J*)! <:7%$#FB!
T2G$&,(%G$GX$V37! -2@! D7D=$$K! $J*)! 0E0D::!
T2G'+*)G$GX$V37! -2@! ?I1,K! $J*(! JTN7A!
T2G$G$GU$V37! -2@! ?I<3! $J*&! JT<!
T2G$$%,-G$GX$V37! -2@! ?">=! $J*%! JKOD!
T2G,%--G$GX$V37! -2@! 43D7?'K! $J*-! IH0EJ?A!
T2G',+-G$GU$V37! -2@! B464K! $J)+! CIUI!
T2G%))G$GU$V37! -2@! ?08%3! $J)(! JQ/6H!
T2G$%&))G%GX$V37! -2@! 075$3! $J)-! QEM:!
T2G$-))+G$GU$V3V37! -2@! 26=@&! $J(,! >UD=B!
T2G$$&,+G$GX$V37! -2@! 83?$*%3! $J(,! /HJ:V6H!
T2G),''G$GX$V37! -2@! DDD>0$! $J(,! OQMK6!
T2G%'*'&G$GX$V37! -2@! 5I=B2%K! $J((! U\]^;%!
T2G*-,,G%GX$V37! -2@! 2=350QK! $J('! >DHMQL!
T2G)(&$G$GX$V37! -2@! 51<5$! $J('! MN<M:!
T2G$),'-G%GX$V37! -2@! 23K$$KK! $J('! >HA::A!
T2G,%))G$GX$V37! -2@! YB<Z,%&%$! $J(%! MLH:!
T2G$-)&+G$GX$V37! -2@! 55KD'! $J(%! MMA0?!
T2G$+'*'G$GX$V37! -2@! ><420$<! $J($! O<I>Q:<!
T2G+--'G$GX$V37! -2@! 83253! $J(-! /H>MH!
T2G%%$,(G$GX$V37! -2@! 5"Z>Q0IDL+/&G(! $J',! 'D/RF?!
T2G'*$)G$GX$V37! -2@! =232D3! $J',! D>H>0!
! ! +-!
T2G$$$&&G$GX$V37! -2@! >DI54(K! $J'*! O0TMIF!
T2G+&%&G$GU$V37! -2@! <048&! $J')! <QI/B!
T2G'(,%G$GX$V37! -2@! B34=7$! $J''! CHIDE:!
T2G$+$,'G$GX$V37! -2@! D"Q&<&! $J''! 0KLB<B!
T2G%'&$*G$GU$V37! -2@! <>Q=&! $J'%! <OLDB!
T2G$$-)'G$GX$V37! -2@! 3D4D! $J'%! H0I0:!
T2G*+(,G$GX$V37! -2@! 5I=0$! $J'%! MTDQ:!
T2G*+)%G$GX$V37! -2@! 3<5KB%! $J'$! H<MAC6!
T2G*-+)G$GX$V37! -2@! ?3DQ+"D&! $J'-! JH0LWK0B!
T2G$-,(%G$GX$V37! -2@! <>2%4! $J'-! <O>6I!
T2G$('%G$GX$V37! -2@! YB<Z***&'! $J&,! OAK!
T2G*&%%G$GX$V37! -2@! 5D5K$! $J&+! M0MA:!
T2G$'&-)G$GU$V3V37! -2@! D><>'K! $J&*! 0O<O?!
T2G)'&*G$GU$V37! -2@! D7D=)! $J&(! 0E0DR!
T2G$--&$G$GX$V37! -2@! A6Z8Q+)B$$! $J&'! 4H4B!
T2G$++,+G$GU$V37! -2@! 0Y/%! $J&'! Q'P6!
T2G$&%),G$GX$V37! -2@! 25D2I$! $J&&! >M0>T:!
T2G(%,,G$GU$V37! -2@! 5=@$%! $J&&! MD=:6!
T2G*,*'G$GU$V37! -2@! <><'(! $J&%! <O<?F!
T2G%(&')G$GX$V37! -2@! DD3D><$K! $J&%! 00H0O<:A!
T2G,()G$GU$V37! -2@! YB<Z,%)&$! $J&%! <N=RA:!
T2G$%$'+G$GU$V37! -2@! "=#5! $J&%! KD4M!
T2G%(%+*G$GX$V37! -2@! 7"3$! $J&%! EKH:!
T2G*$,G$GU$V37! -2@! >23D$! $J&%! O>H0:!
T2G+%$%G$GU$V37! -2@! D5?K,3! $J&%! 0MJA7!
T2G%((&-G$GX$V5V37! -2@! 7028$! $J&%! EQ>/:!
T2G&+))G$GX$V37! -2@! <3D2"=$3! $J&-! <H0>KD:!
T2G$&,$%G$GU$V37! -2@! =<12$! $J&-! D<N>:!
T2G%$-)(G$GU$V37! -2@! #D5&)! $J%,! 40MBR!
T2G$)&$,G$GX$V37! -2@! <41<Q! $J%+! <IN<L!
T2G%+-G$GU$V37! -2@! <7==K%! $J%*! <EDDA:!
T2G$-()&G$GU$V37! -2@! ?5"%3! $J%*! JMK6!
T2G%--*&G$GX$V37! -2@! D7KD$K! $J%)! 0EA0:!
T2G&$'%G$GU$V37! -2@! Y5A"?(! $J%)! 'MGKJF!
T2G%(,$)G$GX$V37! -2@! >1Q%! $J%)! ONL6!
T2G$)$$$G$GU$V37! -2@! 75/Y$! $J%(! EMP':!
T2G',+*G$GX$V37! -2@! 3/53$! $J%(! HPMH:!
T2G$-&-$G$GX$V37! -2@! <>+%K! $J%(! <OW6!
T2G&'$%G$GX$V37! -2@! 3D$K$! $J%(! H0:A:!
T2G$$'+)G$GU$V37! -2@! 0>0?$! $J%(! QOQJ:!
T2G%-%&-G$GU$V37! -2@! B?8K! $J%(! CJ/A!
T2G$,-',G$GX$V37! -2@! >QQ&! $J%'! OLLB!
T2G%)(&&G$GX$V37! -2@! YB<Z$$%-,(! $J%'! MOQ6!
T2G'*)-G$GX$V37! -2@! D5?K$-! $J%'! 0MJA:9!
T2G%$*,)G$GX$V37! -2@! 2D5)Q3$! $J%'! >0MRLH:!
! ! +$!
T2G,)$*G$GX$V37! -2@! 51<5&K! $J%'! MN<MB!
T2G*)%+G$GX$V3V37! -2@! Y685D! $J%&! 'U/M0!
T2G+&(G$GX$V37! -2@! D>@Q3! $J%&! 0O=L!
T2G&**$G$GU%V37! -2@! <4>=$%! $J%%! <IOD:6!
T2G'$*,G$GU$V37! -2@! D7D'3$! $J%%! 0E0?H:!
T2G%),(G$GX$V37! -2@! B?>5! $J%%! CJOM!
T2G$-+-'G$GU$V37! -2@! Y<'/%! $J%%! '<?P6!
T2G*)$(G$GX$V37! -2@! 324+K3! $J%%! H>IWA!
T2G%%--G$GX$V37! -2@! ?3D&Q'! $J%$! JH0BL?!
T2G$'*%*G$GX$V37! -2@! D"'Q%K! $J%$! 0K?L6A!
T2G$&%$+G$GX$V37! -2@! "=1+->K! $J%$! KDNW9O!
T2G$%%,(G%GX$V37! -2@! K1D$! $J%-! AN0:!
T2G%(-'G$GX$V37! -2@! "DDQ! $J%-! K00L!
T2G$-)*)G$GU$V37! -2@! <>5%! $J%-! <OM6!
T2G%'-(G$GX$V37! -2@! 23K4&! $J%-! >HAIB!
T2X88@G$G(&GU$V37! -JT<XQ>! YB<Z)(*',! $J%$! ITH>!
T2G*)&+G$GU%V37! -JT<XQ>! <34?&3! $J%$! <HIJB!
T2G%(&(-G$GX$V37! -JT<XQ>! 3>13! $J%$! HON!
T2G$++$$G%GX$V37! -JT<XQ>! YB<Z,%*,,! $J%$! /HJ69?H!
T2G$(&)%G$GU$V37! -JT<XQ>! YB<Z$$-%()! $J%$! EJQJ6FR!
T2G%%)-*G$GU$V37! -JT<XQ>! 43<7K! $J%%! IH<EA!
T2G$-($,G$GX$V37! -JT<XQ>! 72"?*$! $J%%! E>KJV:!
T2G$&%)&G$GX$V37! -JT<XQ>! 043<$! $J%%! QIH<:!
T2G,$%&G$GX$V37! -JT<XQ>! 81@Q$! $J%%! /N=L:!
T2G%'*(G$GX$V37! -JT<XQ>! 5"Z>Q0IL%'4$$G*! $J%%! 0KLB<6H!
T2G%&**(G$GX$V37! -JT<XQ>! =3D$4'3! $J%%! DH0:I?!
T2G&(&,G$GX$V37! -JT<XQ>! YB<Z+(*+,! $J%%! <::%$#F?!
T2G,+%G$GU$V37! -JT<XQ>! #?D$! $J%%! 4J0:!
T2G$*$%(G$GX$V37! -JT<XQ>! YB<Z$(+)-&! $J%%! <>QABI6!
T2G$&*(%G$GU$V37! -JT<XQ>! 5?8=! $J%&! >Q=6!
T2G*)++G$GX$V37! -JT<XQ>! D41>$3! $J%&! 0INO:!
T2G$('-%G$GX$V3V37! -JT<XQ>! ?2D5(! $J%&! J>0MF!
T2G%',%&G$GU$V37! -JT<XQ>! D02D! $J%'! 0Q>0!
T2G$&-+'G$GX$V37! -JT<XQ>! />3<'! $J%'! POH<?!
T2G$%*%-G$GU$V37! -JT<XQ>! Y>//<+K! $J%'! 'OPP<W!
T2G+-)-G$GU$V37! -JT<XQ>! ?057! $J%'! JQME!
T2G$-*'%G$GU$V37! -JT<XQ>! YB<Z((%(,! $J%'! PM0A0:!
T2G%(,$%G$GX$V37! -JT<XQ>! B/23! $J%'! CP>!
T2G$-%$)G$GU$V3V37! -JT<XQ>! YB<Z$$%-$(! $J%'! <KA:!
T2G$--(-G$GX$V37! -JT<XQ>! 3>"D12%! $J%(! HOK0N>6!
T2G$,&*+G$GU$V37! -JT<XQ>! 5?3>&3! $J%(! MJHOB!
T2G$''*,G$GU$V37! -JT<XQ>! YA$-! $J%(! 'G:9!
T2G(,-)G$GX$V37! -JT<XQ>! 72?7(! $J%(! E>JEF!
T2G%)-,)G$GU$V@V37! -JT<XQ>! /3<4$! $J%(! PH<I:!
T2G$++&)G%GX$V37! -JT<XQ>! 81@D$3! $J%)! /N=0:!
! ! +%!
T2G$+'%%G$GX$V3V37! -JT<XQ>! 8</1%! $J%)! /<PN6!
T2G**&+G$GX$V37! -JT<XQ>! 34>/$+3$! $J%)! HIOP:WH:!
T2G*'&,G$GX$V37! -JT<XQ>! ?08%>! $J%)! JQ/6O!
T2G$$($%G$GX$V37! -JT<XQ>! D4<B%! $J%)! 0I<C6!
T2G$*--(G$GX$V37! -JT<XQ>! 235B28%! $J%)! >HMC>/6!
T2G&-$$G$GX$V37! -JT<XQ>! 4>423>&! $J%*! IOI>HOB!
T2G$+'-&G$GU$V37! -JT<XQ>! YB<Z(((*%! $J%*! MELBW!
T2G$*%'%G$GX$V37! -JT<XQ>! Y8D&)4%! $J%*! '/0BRI6!
T2G$%(-,G$GU$V37! -JT<XQ>! 5"Z>Q0IDL+'3+G+! $J%*! /HJ69VH!
T2G%&)(%G$GX$V37! -JT<XQ>! ?D>6$K! $J%+! J0OU:!
T2G'%$%G$GU$V37! -JT<XQ>! 4>/3! $J%+! IOPH!
T2G%(**-G$GU$V37! -JT<XQ>! <7D5! $J%+! <E0M:!
T2G*-*&G$GX$V37! -JT<XQ>! <K@&K! $J%+! <A=B!
T2G&**'G$GX$V37! -JT<XQ>! =0Q$! $J%,! DQL:!
T2G$(%)%G$GU$V37! -JT<XQ>! 57Q&+4! $J%,! MELBWI!
T2G&)%,G$GX$V37! -JT<XQ>! 37D%3%K! $J%,! HE06H6!
T2G%)')-G$GU$V37! -JT<XQ>! 7744$! $J&-! EEII:!
T2G%&-'$G$GX$V37! -JT<XQ>! <3?Q%K$! $J&-! <HJL6A!
T2G$&-),G$GX$V37! -JT<XQ>! Y<&/*K! $J&-! '<BPVA!
T2G$(,))G$GU$V37! -JT<XQ>! >0==>%>! $J&-! OQDDO6O!
T2G$-(%'G$GU$V37! -JT<XQ>! 2K81@%! $J&-! >A/N=6!
T2G$%$$&G$GX$V37! -JT<XQ>! 5"Z>Q0IL%')"$'G'! $J&$! MP<:!
T2G$'+,&G$GX$V37! -JT<XQ>! 0@1B! $J&$! Q=NC!
T2G$%(')G$GU$V37! -JT<XQ>! 6D8&3! $J&$! U0/BH!
T2G%-&')G$GU$V37! -JT<XQ>! 57Q&(4! $J&$! ,Y@BF2!
T2G**+-G$GU$V37! -JT<XQ>! <>*'! $J&$! <OV?!
T2G*'(G$GX$V37! -JT<XQ>! YB<Z()$$)! $J&$! 0OIKJF!
T2G%',+,G$GU$V37! -JT<XQ>! ?I4$-! $J&$! JTI:9!
T2G$(*+$G$GU$V37! -JT<XQ>! #2Q%! $J&&! 4>L6!
T2G$&,,'G%GX$V@V37! -JT<XQ>! D/D7$! $J&&! 0P0E:!
T2G$'$),G$GX$V37! -JT<XQ>! 54<%(3&%3! $J&&! MI<6FHB6!
T2G'(&(G$GU$V37! -JT<XQ>! D7D'3&! $J&(! 0E0?HB!
T2G(()(G$GU$V37! -JT<XQ>! 504?! $J&(! MQIJ!
T2G$-%$)G%GU$V37! -JT<XQ>! YB<Z$$%-$(! $J&(! <KA:!
T2G)*,+G$GU$V37! -JT<XQ>! <@<2'K! $J&(! <=<>?!
T2G(+-,G$GX$V37! -JT<XQ>! B2=3! $J&)! C>D!
T2G%((-G$GU$V5V37! -JT<XQ>! <7KD%! $J&)! <EA06!
T2G$')&,G$GU$V37! -JT<XQ>! D<K>$! $J&)! 0<AO:!
T2G*'*$G$GX$V37! -JT<XQ>! 7?0?$,+K! $J&)! EJQJ:7W!
T2G,))*G$GU$V37! -JT<XQ>! >=3[K$$! $J&)! ODHSA::!
T2G$*&,'G$GX$V37! -JT<XQ>! 4?8%K! $J&+! IJ/6!
T2G%(*&-G$GU$V37! -JT<XQ>! 705! $J&+! EQM!
T2G$,'+)G$GX$V37! -JT<XQ>! YB<Z$-&*(-! $J&+! A/M06!
T2G$*%(+G$GX$V37! -JT<XQ>! 3K<0$! $J&,! HA<Q:!
T2G$&,,-G$GX$V37! -JT<XQ>! 54<%(3$! $J&,! MI<6FH:!
! ! +&!
T2G%*-(G$GX$V37! -JT<XQ>! 5"Z>Q0IL+4$&G'! $J'-! MGH0V9!
T2G,-+)G$GX$V37! -JT<XQ>! 32/B08$+3! $J'-! H>PCQ/:W!
T2G,%%-G$GU$V37! -JT<XQ>! ?3Q$)! $J'$! JHL:R!
T2G(&*G$GU$V3V37! -JT<XQ>! 0D/K&3! $J'$! Q0PAB!
T2G$+'$)G$GX$V37! -JT<XQ>! 5040=KD$! $J'$! MQIQDA0:!
T2G$%'+-G$GU$V37! -JT<XQ>! "?Z),-%'-*! $J'$! MK4H:!
T2G$%&&G$GX$V37! -JT<XQ>! B45K! $J'%! CIM!
T2G*),$G$GX$V37! -JT<XQ>! YB<Z$-$*)$! $J'&! CDH::!
T2G$,%%*G$GU$V37! -JT<XQ>! 7D)&! $J'&! E0RB!
T2G$$+-G$GU$V37! -JT<XQ>! =<<2D$! $J'&! D<<>0:!
T2G$+$,+G$GX$V37! -JT<XQ>! 5"Z>Q0IDL
$,%?$'G*!
$J'&! Q0M:FI:!
T2G&%))G$GX$V37! -JT<XQ>! =3D0D4>! $J'&! DH0Q0IO!
T2G,&+G%GU$V3V37! -JT<XQ>! <ID&<$! $J''! <T0BH?!
T2G$'$%-G$GX$V37! -JT<XQ>! =Q3"=$! $J''! DLHKD:!
T2G$,%&)G$GU$V37! -JT<XQ>! 4?1'K! $J''! IJN?!
T2G%&%,'G$GU$V37! -JT<XQ>! 4@=! $J''! ID=!
T2G$,(+'G$GU$V37! -JT<XQ>! <<><$%(! $J''! <<O<:6F!
T2G%)---G$GX$V37! -JT<XQ>! B2K$-3! $J'(! C>A:9!
T2G%$$+*G$GX$V37! -JT<XQ>! 54<%3&! $J'(! MI<6HB!
T2G&,'(G$GX$V37! -JT<XQ>! 0DK'$4(! $J'(! Q0A?:IF!
T2G'+)G$GU$V37! -JT<XQ>! DDD$2$'KK! $J'(! 000:>:?A!
T2G$+-*'G$GU$V37! -JT<XQ>! <>,,4%! $J'(! <O77I6!
T2G%$&,'G$GU$V37! -JT<XQ>! @"2D%3! $J')! =K>06!
T2G$*'(%G$GU$V37! -JT<XQ>! YB<Z()'))! $J'*! DK0MDH0BH!
T2G,$$-G$GX$V37! -JT<XQ>! A6Z8<$'3$-! $J'+! HE/F!
T2G(,+$G$GU$V37! -JT<XQ>! 37D)#$K%! $J'+! HE0R4:A6!
T2G$$)+G$GU$V37! -JT<XQ>! <35D3! $J'+! <HM0:!
T2G$)$,(G$GX$V37! -JT<XQ>! 5044! $J'+! MQII!
T2G$($*-G$GU$V5V37! -JT<XQ>! YK7K%3! $J'+! 'AEA6!
T2G%-,$-G$GU$V37! -JT<XQ>! 51@$,3! $J'+! MN=:F!
T2G,,+%G$GX$V37! -JT<XQ>! 71@! $J',! EN=!
T2G$&'*%G$GX$V37! -JT<XQ>! 235B2D&! $J',! >HMC>0B!
T2G$*$'$G$GX$V37! -JT<XQ>! 5Q"4K! $J(-! MLKI!
T2G$+',(G$GX$V37! -JT<XQ>! 5"Z>Q0IL',/,G)! $J(-! KCM/7!
T2G%(-($G$GU$V37! -JT<XQ>! 4?=K$! $J($! IJDA:!
T2G'++'G$GU$V37! -JT<XQ>! 2B2K! $J(&! >C>!
T2G,,*)G$GU$V37! -JT<XQ>! Q48%K! $J(&! LI/6!
T2G+%,$G$GU$V5V37! -JT<XQ>! 3<#2%K! $J(&! H<4>6A!
T2G+&-$G$GU$V3V37! -JT<XQ>! /58$! $J(&! PM/:!
T2G$',+%G$GX$V37! -JT<XQ>! 5"Z>Q0IL&=%%G*! $J('! IK0Q!
T2G)+$G$GX$V37! -JT<XQ>! 235>$! $J((! >HMO:!
T2G$'-)&G$GX$V37! -JT<XQ>! 0?4%! $J((! QIJ6!
T2G%(&,+G$GU$V37! -JT<XQ>! YB<Z+)*(,! $J()! I00>:!
T2G(($(G$GX$V37! -JT<XQ>! 0DK'$4&K! $J(*! Q0A?:IB!
T2G$&+)%G$GU$V37! -JT<XQ>! K"Q! $J(+! AKL!
! ! +'!
T2G$)*(%G$GX$V37! -JT<XQ>! <DD0>$! $J(+! <00QO:!
T2G*)'&G$GU$V37! -JT<XQ>! 83?$$)K! $J(+! OQDDORA!
T2G%()-+G$GX$V37! -JT<XQ>! 8/"7! $J(+! /PKE!
T2G$&*,$G$GX$V37! -JT<XQ>! <3>?%3! $J(,! <HOJ6!
T2G((*&G$GU$V37! -JT<XQ>! 324$$! $J(,! H>I::!
T2G$+)*%G$GX$V37! -JT<XQ>! 5"Z</%$$L),"$'G*! $J(,! 0HD=:!
T2G%&,%+G$GX$V37! -JT<XQ>! 8/4&! $J)-! /PIB!
T2G*')*G$GU$V37! -JT<XQ>! 502"=<(! $J)-! MQ>KD<F!
T2G*$-%G$GU$V37! -JT<XQ>! DD>D8K! $J)$! 00O0/!
T2G$*$&*G$GU$V37! -JT<XQ>! 2123K! $J)%! >N>H!
T2G$$$)$G$GX$V37! -JT<XQ>! 5"Z>Q0IL$3*G%! $J)%! QK/?CB!
T2G(((G$GU$V37! -JT<XQ>! =0621B$! $J)%! DQU>NC:!
T2G)+&&G$GX$V37! -JT<XQ>! A00%! $J)&! GQQ6!
T2G'%)%G$GU$V37! -JT<XQ>! "B8%KD%K! $J)&! KC/6A06!
T2G+-)(G$GU$V37! -JT<XQ>! 4?1%! $J)'! IJN6!
T2G*'$*G$GU$V37! -JT<XQ>! 5/&KD(! $J)'! MPBA0F!
T2G%&&*)G%GX$V37! -JT<XQ>! D>4"?$! $J))! 0OIKJ:!
T2G$**',G%GX$V3V37! -JT<XQ>! <IK3! $J))! <TAH!
T2G$--*-G$GX$V37! -JT<XQ>! 8KD$3! $J)*! /A0:!
T2G$%&G$GU$V37! -JT<XQ>! </2=3$! $J)+! <P>DH:!
T2G$(%$%G$GX$V37! -JT<XQ>! YB<Z,%$'-! $J)+! <:%$#6:!
T2G$-*-(G$GU$V37! -JT<XQ>! ?347$! $J*-! JHIE:!
T2G(,,'G$GX$V37! -JT<XQ>! /"K3>/3! $J*$! PKAHOP!
T2G%$**'G$GX$V37! -JT<XQ>! <3?Q%>$! $J*%! <HJL6O!
T2G$*((%G$GU$V37! -JT<XQ>! <<><)K! $J*%! <<O<R!
T2G$(+%'G$GU$V37! -JT<XQ>! YB<Z$('-*-! $J*&! <PME6!
T2G$,($)G$GU$V37! -JT<XQ>! ?85>)K! $J*(! J/MOR!
T2G,'')G$GX$V3V37! -JT<XQ>! D@=! $J*(! 0=D!
T2G$-,-'G$GU$V3V37! -JT<XQ>! 3>>&3! $J*)! HOOB!
T2G)*+%G$GX$V37! -JT<XQ>! ?D=>! $J*)! J0DO!
T2G$*+$*G$GX$V37! -JT<XQ>! 42"B$! $J**! K>KC:!
T2G$,&,(G$GX$V37! -JT<XQ>! 5"Z>Q0IL&,=$G%! $J**! ZMN=:!
T2G$+$$%G%GX$V37! -JT<XQ>! YB<Z$-$-*%! $J*+! >HK:?!
T2G$$$+G$GX$V37! -JT<XQ>! B81>%! $J*+! C/NO6!
T2G$*-+(G$GX$V37! -JT<XQ>! "B/?! $J*,! KCPJ!
T2G&-$%G$GX$V37! -JT<XQ>! Q"8$K! $J*,! LK/:A!
T2G$%**+G$GU$V37! -JT<XQ>! 3675%! $J+-! HUEM6!
T2G%%*+$G$GX$V37! -JT<XQ>! <34K$! $J+-! <HIA:!
T2G$'%&(G$GU$V37! -JT<XQ>! <>'-! $J+$! <O?9!
T2G$%()(G$GX$V37! -JT<XQ>! #37$! $J+$! 4HE:!
T2G%)&'G$GX$V37! -JT<XQ>! 0=DD$! $J+%! QD00:!
T2G'*%(G$GX$V37! -JT<XQ>! [3?&K! $J+&! SHJB!
T2X88@G$G$$GU$V37! -JT<XQ>! 5IQ! $J+'! MTL!
T2G+-+-G$GU$V37! -JT<XQ>! ?"783! $J+'! JKE/!
T2G$+&'$G$GU$V37! -JT<XQ>! =2D%K! $J+)! D>06!
! ! +(!
T2G)&)%G$GX$V37! -JT<XQ>! >0D712! $J+*! OQ0EN>!
T2G$*$+,G$GX$V37! -JT<XQ>! <7>5D43! $J+*! <EOM0I!
T2G$)'%&G$GU$V37! -JT<XQ>! 7/23D)! $J++! JQOB9!
T2G)&%+G$GX$V37! -JT<XQ>! ?I1$0! $J++! JTN:Q!
T2G$+$(+G$GX$V37! -JT<XQ>! 54<'3'K! $J+,! MI<?H?!
T2G,)&&G$GX$V37! -JT<XQ>! 287=%! $J,$! >/ED6!
T2G$'$(,G$GX$V37! -JT<XQ>! />3<,K! $J,%! POH<7!
T2G$&$'%G$GX$V37! -JT<XQ>! 573D%3! $J,&! MEH06!
T2G$*%--G$GU$V37! -JT<XQ>! ?072=4! $J,'! JQE>DI!
T2G$*),%G$GX$V37! -JT<XQ>! D2Q</3! $J,'! 0>L<P!
T2G+$(&G$GU$V37! -JT<XQ>! <4>=B! $J,'! <IOD?!
T2G$$,**G$GX$V37! -JT<XQ>! 422<&&! $J,(! I>><BB!
T2X88@G$G*-GU$V37! -JT<XQ>! /1D@! $J,(! PN0=!
T2G*&G$GX$V37! -JT<XQ>! 5"Z>Q0IL*)Q$)G*! $J,)! >>A0:!
T2G$$%%%G$GX$V37! -JT<XQ>! 3=Q5$K! $J,)! HDLM:A!
T2G$&,*%G$GU$V37! -JT<XQ>! YB<Z)'$$'! $J,+! OOKE?!
T2G&()G$GU$V37! -JT<XQ>! B373%3! $J,+! CHEH6!
T2G+$*)G$GU$V37! -JT<XQ>! D3@(! $J,+! 0H=F!
T2G*%(*G$GX$V37! -JT<XQ>! 235B08$K3! %J--! >HMCQ/:A!
T2G*+-$G$GX$V37! -JT<XQ>! YB<Z$$-(+)! %J--! EM0HD6!
T2X88@G$G%)GU$V37! -JT<XQ>! K4=Q! %J--! AIDL!
T2G)%+(G$GU$V37! -JT<XQ>! B<5/K! %J-%! C<MP!
T2G$)$+&G$GU$V37! -JT<XQ>! >4<! %J-'! OIIB!
T2G%$+++G$GU$V37! -JT<XQ>! [3?%3! %J-'! SHJ6!
T2G'-,(G$GX$V37! -JT<XQ>! 355$! %J-(! HMM:!
T2G)$G$GX$V37! -JT<XQ>! <@<4$%K! %J-)! <=<I:6!
T2G$'--'G$GU$V37! -JT<XQ>! <><&'3! %J-*! <O<B?!
T2G$-('%G$GU$V37! -JT<XQ>! /5>&K*! %J-+! PMOBAV!
T2G)&+%G$GX$V37! -JT<XQ>! //"D! %J$-! PPK0!
T2G$)+,%G$GX$V37! -JT<XQ>! ?DD%K! %J$-! J006!
T2G$+$(G$GX$V37! -JT<XQ>! ?3<8$! %J$-! JH</:!
T2G$)&,&G$GX$V37! -JT<XQ>! 3K/>%K! %J$'! HAPO6!
T2G$$)'G$GU$V37! -JT<XQ>! <I8"D$! %J$(! <T/K0:!
T2G'))$G$GX$V37! -JT<XQ>! 5I=0%K! %J$(! MTDQ6!
T2G)'-*G$GX$V37! -JT<XQ>! 7B8K2%! %J$*! EC/A>6!
T2G$%-%-G$GX$V37! -JT<XQ>! <>Q$)! %J$+! <OL:R!
T2G$(-((G$GU$V37! -JT<XQ>! <@<2'3! %J$,! <=<>?!
T2G%'%)%G$GX$V37! -JT<XQ>! D40Q//$! %J$,! 0IQLPP:!
T2G$***)G$GX$V37! -JT<XQ>! 7D/$K! %J%$! E0P:!
T2G$+()%G%GX$V37! -JT<XQ>! 8DB5! %J%*! /0CM!
T2G$(-+,G$GU$V37! -JT<XQ>! 20?$! %J%+! >QJ:!
T2G%$((-G$GU$V37! -JT<XQ>! >DI54(3! %J%,! O0TMIF!
T2G$&-(+G$GX$V37! -JT<XQ>! 54<$%3*K! %J&)! MI<:6HV!
T2G$()&'G$GU$V37! -JT<XQ>! 7<03&! %J&+! E<QHB!
T2G+-%(G%GX$V37! -JT<XQ>! A6Z83$$>-&! %J',! 0H<MKDB!
! ! +)!
T2G$'($-G$GX$V37! -JT<XQ>! D2?7%! %J((! 0>JE6!
T2G%($'-G'GU$V37! -JT<XQ>! <>+$! %J(+! <OW:!
T2G(%)'G$GX$V37! -JT<XQ>! D>Y2=&! %J(,! 0O'>DB!
T2G,+*-G$GX$V37! -JT<XQ>! Y>//<%! %J)-! 'OPP<6!
T2G*)$%G$GX$V37! -JT<XQ>! 5D"$! %J),! M0K:!
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CXCR4 expression and CNS infiltration: a study of murine 
models xenografted with human T-ALL cells 
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The CXCR4/CXCL12 axis seems to be particularly important for metastasis of different 
epithelial, mesenchymal and haemopoietic cancers. Activation of CXCR4 increased 
direct migration of cancer cells towards its specific ligand CXCL12 gradient. As 
CXCL12 is expressed in different type of tissues/organs (bone marrow, liver, spleen, 
kidney, lymph node and CNS), we can speculate that the expression level of CXCR4 in 
leukemic cells, could influence the ability of these cells to infiltrate extramedullary 
tissues, such as the CNS. At the moment, there are discordant hypotheses regarding the 
role of the CXCR4/CXCL12 axis and CNS infiltration in ALL. Through this study, we 
aimed to better clarify the importance of CXCR4/CXCR4 expression in determining the 
ability of T-lymphoblasts to infiltrate the CNS. We decided to use mice xenografted 
with primary pediatric T-ALL cells as we found that also this xenografted murine model 
can present infiltration at the meningeal level with different seriousness. Preliminary 
data revealed that also in the murine model, the expression levels of CXCR4 in T-ALL 
cells have a tendency to correlate with the degree of CNS infiltration at the meningeal 
level. This data underline the importance of CXCR4 expression as a possible conserved 
mechanism able to predispose T-lymphoblasts to enter the CNS. Further studies on a 
larger cohort of xenografted mice are actually ongoing. 
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Acute Lymphoblastic Leukemia (ALL) is the most frequent type of childhood 
malignancy [1] characterized by an uncontrolled growth of immature cells of the T- or 
B- lymphoid lineage. Leukemic cells colonize the bone marrow (BM) and often  also 
extramedullary organs, such as !30-50% spleen or liver [2] and < 5% Central Nervous 
System, CNS [3-4]. The ability to infiltrate the CNS gives a great advantage to 
lymphoblastic cells; in fact, the presence of the Blood Brain Barrier (BBB) impairs the 
entrance of chemotherapeutic compounds and malignant cells that escape into the CNS 
are protected from therapy. The presence of leukemic cells that survive to chemotherapy 
in extramedullary organs is problematic, because it can easily result in leukemic relapse. 
T-cell Acute Lympholastic Leukemia (T-ALL) represents  15% of pediatric ALLs and 
forms a high-risk group of patients. In fact, T-ALL is often associated to  increased 
white cell counts, hepatosplenomegaly, increased risk of leptomeningeal infiltration at 
diagnosis [5] and high risk of CNS relapse [6-7]. For this reason, T-ALL patients 
usually receive intrathecal chemotherapy associate to cranial irradiation, a treatment that 
can result in a number of complications (secondary tumours, growth impairment, 
neurocognitive deficits and endocrinopathy) [7]. The introduction of intensified 
treatment protocols has improved the outcome of children with T-ALL (five-year 
relapse-free survival rates of about 75%), and numerous efforts have been made to 
reduce or avoid the use of cranial irradiation [8]. However, cranial irradiation is still 
necessary for patients at high risk, especially for those that present CNS involvement 
already at diagnosis as well as at relapse [7]. Little is know about how leukemic cells 
can infiltrate the CNS; several studies claimed the discovery of ‘the key mechanism’ 
that allowed ALL cells to invade, survive and colonize the CNS, but results are diverse. 
Holland et al. showed an important role  for RAC2, AEP and ICAM1 expression in 
their study of a murine model of childhood pre-B ALL that developed CNS leukemia 
[9]. Buonamici et al. found a direct relation between CCR7 expression and the ability to 
infiltrate the CNS in a murine model xenografted with human T-ALL cell lines [10]. 
Moreover, there are discordant hypothesis regarding the importance of the 
CXCR4/CXCL12 axis and CNS infiltration; high levels of CXCR4 expression in 
lymphoblasts seem to be predictive of extramedullary organ infiltration in childhood 
ALL patients [11], however CNS-homing cells showed CXCR4 down-regulation in a 
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mouse model of CNS pre-B ALL [12] and children with ALL relapse associated to 
testicles or CNS leukemia showed blast cells with lower CXCR4 levels than blasts from 
cases with isolated bone marrow-relapses [13]. As we also found a positive correlation 
between cxcr4 expression levels and the degree of CNS infiltration in two T-ALL 
zebrafish models (chapter 1 of this thesis), we were particularly interested in studying 
the importance of the CXCR4/CXCL12 axis in human T-ALL metastatic behavior. The 
CXCL12/CXCR4 axis plays an important role in regulating the engraftment of CD34+ 
haematopoietic stem cells into the bone marrow [14-15], the egress of preB and T 
lymphocytes from the BM into the Peripheral Blood (PB) and lymphoid tissues [16] and 
in directing naïve leukocyte trafficking [17]. The interaction of CXCR4 with CXCL12 
activates the receptor, increasing the ability of cells to migrate towards a CXCL12 
chemo-attracting gradient and this is true for cancer cells as well [18-19]. At this point, 
we suppose that the deregulation of CXCR4 expression in T-ALL cells could increased 
the homing of malignant cells towards tissues expressing CXCL12. CXCL12 is 
constitutively expressed in several human organs, particularly in extramedullary tissues 
that are often found to be involved in leukemic infiltration: bone marrow, lymph nodes, 
liver, spleen, kidney and brain [19-20]. The metastatic role of CXCR4 is well 
documented for both solid tumors [18] and haematological diseases, such as malignant 
CD34+ Acute Myeloid Leukemia (AML) and Chronic Lymphoblastic Leukemia (CLL) 
[21-23]. However, the importance of this axis for T-ALL is not clear. Through this 
study, we aimed to better clarify the importance of CXCR4 expression in determining 
the ability of T-lymphoblasts to infiltrate the CNS. We decided to study this 
phenomenon using NSG, or NOD/SCID gamma, (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) 
murine models xenografted with a set of primary T-ALL cells of pediatric patients.  
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T-ALL xenografts establishment 
Primary T-ALL cells were obtained from bone marrow (BM) of newly diagnosed 
pediatric patients, according to the guidelines of the local ethics committees. For 
xenografts establishment, 6- to 9-weeks-old mice were injected intravenously (i.v.) with 
! ! ,(!
10 x 106 T-ALL cells in 300 'l of Dulbecco's Phosphate Buffer Saline (PBS). NSG 
mice were purchased from Charles River (Wilmington, MA). Procedures involving 
animals and their care  were conform  institutional guidelines that comply with national 
and international laws and policies (EEC Council Directive 86/609, OJ L 358, 12 
December, 1987). T-ALL engraftment was monitored by periodic blood drawings and 
flow cytometric analysis of CD5 and CD7 markers over a 5-month period. Mice were 
sacrificed when more than 40% of cells in the PB resulted positive for the CD7 or CD5. 
TCR analysis 
The recombination, insertion and deletion of Immunoglobulin (Ig) and T-cell receptor 
(TCR) gene segments results in an individual gene sequence unique for each 
lymphocyte, named N-region. This genes junctional region can be considered a 
fingerprint-marker specific of each lymphocytes and consequentially, of each lymphoid 
neoplasia. We used this biological characteristic to check that xenografted cells from 
each mouse maintained the rearrangement of  the leukemia of the patient of origin. 
Histology and scoring system 
Skulls of sacrificed xenotransplanted mice were fixed in 4% paraformaldehyde, 
decalcified, paraffin-embedded and sectioned (5µm) according to standard procedures. 
Hematoxylin and eosin (H&E) staining was performed using standard protocols. 
Histopathological examination was performed in a blind fashion and details concerning 
experimental design were revealed only at the end of the analysis. T-lymphoblasts 
infiltration was found in the bone marrow of the skull, in dental alveoli, oral and 
rhinopharingeal mucosa, orbital space, middle ear and meninges.  
The following scoring system was used to classify the degree of lymphoblastic 
infiltration: 
Bone marrow 
0.  No invasion/colonization 
1. Focal or multifocal invasion/colonization with partial effacement of preexisting 
hematopoietic population 
2. Diffuse invasion with almost complete or complete effacement of preexisting 
hematopoietic population and focal disruption of bony encasement 
! ! ,)!
3. Diffuse invasion with complete effacement of preexisting hematopoietic 
population and extensive disruption of bony encasement 
 
Dental alveoli 
0. No invasion 
1. Focal or multifocal invasion with partial effacement of periodontal ligament and 
dental pulp 
2. Diffuse invasion with almost complete or complete effacement of periodontal 
ligament and dental pulp 
3. Diffuse invasion with complete effacement and disruption of the alveolar socket 
 
Oral and rhinopharingeal mucosa 
0. No invasion 
1. Focal or multifocal infiltration and expansion of lamina propria and submucosa 
2. Segmental infiltration and expansion of lamina propria and submucosa 
3. Diffuse infiltration and expansion of lamina propria and submucosa with 
disruption of mucosal architecture and multiple infiltrative extension into the 
surrounding soft tissues 
 
Orbital space 
0. No invasion 
1. Focal or multifocal infiltration with partial obliteration of orbital soft tissues 
2. Diffuse invasion with almost complete or complete obliteration of orbital soft 
tissues and focal invasion of extraorbital structures 
3. Diffuse invasion with almost complete or complete obliteration of the orbits and 
extensive invasion of extraorbital structures 
 
Middle ear 
0. No invasion 
1. Focal or multifocal infiltration and expansion of lamina propria and submucosa 
2. Diffuse infiltration and expansion of lamina propria and submucosa 
3. Diffuse infiltration and expansion of lamina propria and submucosa with with 
disruption of mucosal architecture and multiple infiltrative extension into the 
surrounding soft tissues 
 
Meninges 
0. No invasion 
1. Focal or multifocal infiltration of dura mater with partial expansion and 
obliteration of arachnoid space 
2. Segmental to diffuse infiltration of dura mater with extensive expansion and 
obliteration of arachnoid space 
! ! ,*!
3. Diffuse infiltration of dura mater with extensive expansion and obliteration of 
arachnoid space and focal/multifocal compression and degeneration of the 
subjacent neuroparenchyma 
Flow Cytometry and CXCR4 expression analysis 
Cells derived from both the spleen and the peripheral blood of 29 xenoengrafted mice 
were analyzed, by Flow cytometry (FCM) for CXCR4 expression. Briefly, 5*105 cells 
both from the mice spleen and PB, after haemolysis with ACK Lysis buffer (8.29 g/L 
NH4Cl, 1mM EDTA and 1g/L KHCO3), were stained with FITC-conjugated antibody 
against human CD45, a PE-coniugated antibody against human CXCR4, a PC5-
conjugated antibody against human CD7 and an APC-conjugated antibody against 
human CD3, following manufacture’s instructions. Unlabeled cells were first acquired 
to ensure labeling specificity. Jurkat cells were used to test the efficient staining of all 
antibodies. Relative percentages of different subpopulations were calculated based on 
live- gated cells (as measured by the physical parameters of side scatter and forward 
scatter). In particular the percentage of CXCR4 positive cells was calculated on the 
gated human CD45+ population. All antibodies were provided by BD (Becton 
Dickinson, San Jose, CA) and all samples were analyzed on the Navios Flow cytometer 
(Beckman Coulter, Brea, CA). 
RNA extraction, Reverse-transcription and Real-time polymerase chain reaction 
Total RNA from ! 5*105 cells extracted from the spleen of each mouse using Trizol, 
according to the manufacturer’s instruction (Invitrogen, Karlsruhe, Germany). RNA 
concentration was determined using NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies Inc, Wilmington, DE). RNA quality and purity control was 
assessed with the Agilent Bioanalyzed 2100 (Agilent Technologies, Waldbronn, 
Germany) using “Eukaryote total RNA Assay”. 1 µg of RNA was reverse transcribed 
using Superscript II (Invitrogen, Karlsruhe, Germany), and random primers following 
standard techniques. SYBR-Green Real-time quantitative PCR (qRT-PCR) was 
performed using the Platinum SYBR-Green qPCR SuperMix UDG (Invitrogen, 
Karlsruhe, Germany) and the 7900 HT Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA). qRT-PCR was executed for detecting expression level of 
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human CXCR4, while GUS was used as housekeeping gene to normalize gene 
expression data. qRT-PCR was performed in triplicates (both for housekeeping and 
genes of interest) for each sample and standard curve of 3 serial dilutions was used as 
control for each plates. Primers are listed in table 2. The specificity of the primers was 
examined with the corresponding dissociation curve. To allow comparison between 
samples, transcript quantification was performed after normalization with GUS using 
the Ct method and results were calculated according to the following formula 2-&ct, as 
previously described [24]. Analysis of expression was performed using the GraphPad 
Prisim 5 software. 
Mice xenografted with Jurkat cells 
NOD-SCID-common # chain knock-out mice were obtained from Jackson Laboratory, 
USA and maintained in specific pathogen-free (spf) animal facility. Ten week old mice 
were injected with 10x106 Jurkat cells i.v. and sacrificed after 21 days. 
Spleens were homogenized and the recovered cell suspension was washed in Complete 
Medium (RPMI 1640 containing 10% FBS, sodium pyruvate, glutamax, 2-
mercaptoethanol, non-essential aminoacids, penicillin and streptomycin) (GIBCO). Reb 
blood cells were lysed with ACK Lysis buffer (8.29 g/L NH4Cl, 1mM EDTA and 1g/L 
KHCO3). Blood was treated with ACK Lysis buffer and the leukocytes fraction washed 
in complete medium.  
For FACS analysis, ex-vivo cells were pre-incubated with blocking anti-FC# Receptor 
mab (HB197 hybridoma supernatant) prior to labeling with appropriate antibodies. 
Mabs conjugated with biotin, FITC, allophycocyanin, or allophycocyanin-Cy7 specific 
for the following antigens were used: hCD45 (LuBioScience GmbH); mLy6G and 
mLy6C (Becton Dickinson AG); mCD11b and hCD184 (CXCR4) (BioLegend). All 
samples were acquired with a BD LSR FortessaTM FACS (BD Biosciences) and 
analyzed with FlowJo software (Tree Star).  
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Murine models xenografted with pediatric T-ALL cells and CNS lymphoblastic 
infiltration 
The first efforts of this work investigated if murine models xenografted with pediatric 
T-ALL cells developed lymphoblastic CNS infiltration. We started with histological 
analysis of a first set of 18 xenografted mice heads. This analysis showed that 
xenografted mice developed T-ALL CNS disease to variable extends. Infiltration was 
observed in the bone marrow of the skull (BM), dental alveoli, oral and rhinopharingeal 
mucosa, middle ear, orbital space and meninges. The meningeal infiltration was of 
particular interest for this study where meningeal infiltration was used as a measure of 
the ability of T-ALL cells to eventually infiltrate the CNS. For each location analyzed 
mice presented different degrees of infiltration (figure 1A and B). A score for the degree 
of infiltration was applied ranging from 1-3 (table 1) according to the scoring system 
described in Material and Methods. Once we knew that, like the zebrafish model, also 
the murine model xenografted with pediatric T-ALL cells could be useful to study the 
phenomenon of CNS infiltration, we proceeded with the analysis of a second set of 
histological preparations of 29 xenografted mice heads. This second set of analysis is 
still ongoing. 
Murine models xenografted with pediatric T-ALL expressed variable levels of 
CXCR4  
We found that also mice xenografted with pediatric T-ALL cells developed CNS 
disease with variable degrees of infiltration. At this point, we decided to use the murine 
model to better understand the importance of CXCR4/CXCR4 (protein and mRNA) 
expression in relation to extramedullary infiltration in T-ALL. For all 29 mice included 
in the second set of histological analysis we measured CXCR4 expression both at 
protein and mRNA levels. The aim of this analysis was to clarify the biological 
meaning for human T-ALL cells to have high or low levels of CXCR4 in relation to 
their ability to infiltrate the CNS in an in vivo murine model.  
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Flow Cytometry (FCM) was used to detect human (CD45+) CXCR4 positive cells in 
samples derived both from mice spleen and Peripheral Blood (PB). With this analysis 
we wanted to investigate the relation between the percentage of human CXCR4+ cells 
and the seriousness of CNS infiltration. Data revealed among mice the presence of 
variable percentages of hT-ALL cells that were double positive (CD45+/CXCR4+) in 
specimens of the spleen and PB (figure 2A and B). However, we have to consider that 
the amount of CXCR4 at T-cells surface can be influenced by the presence of CXCL12 
in mouse spleen and vessels. As the binding of CXCL12 to CXCR4 causes the 
internalization of the chemokine receptor, the human cells (CD45+) that were found to 
be negative for CXCR4 can be attributed to interactions with CXCL12 in the murine 
environment and not to a real absence of CXCR4.  
 Levels of CXCR4 in Jurkat cells xenografted in the mouse   
To have an idea of the influence of the mouse microenvironment on CXCR4 
expression, we evaluated the percentage of CD45+/CXCR4+ cells in a murine model 
xenografted with the Jurkat cell line. Jurkat cells derived from in vitro culture expressed 
high levels of CXCR4 and cells were 100% double positive (CD45+ /CXCR4+) by 
FCM analysis. After xenografting, Jurkat cells extracted from spleen and PB showed 
partial loss of positivity, strongly suggesting the influence of murine CXCL12 on 
CXCR4 protein expression at the human T-cell surface (figure 3).  
Variable amount of CXCR4 are expressed by leukemic cells infiltrating mouse spleen 
At this point, we decided to measure CXCR4 expression using qRT-PCR to obtain a 
measure of chemokine receptor quantifications that would be less dependent on short-
term dynamic interactions with the microenvironment (e.g. CXCL12 levels). qRT-PCR 
was performed on samples extracted from mice spleen. Also for CXCR4 transcription 
we found a range of expression levels among mice (figure 4). Interestingly, no 
correlation was found between the expression of CXCR4 at the protein and mRNA 
level. 
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CXCR4 transcription tends to reflect the degree of CNS infiltration (preliminary 
results)  
For the moment, data of both histological analysis and qRT-PCR were available for 7 
matched sample pairs of the first set of 18 xenografted mice heads analyzed. 
Preliminary results show how CXCR4 expression levels tend to correlate with the 
degree of CNS infiltration (figure 5). Further analysis will be performed when 
histological analysis data will be completed also for the new set of 29 xenografted mice.   
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The ability of lymphoblasts to infiltrate the CNS continues to represent a great 
challenge in the cure of patients with ALL that present this complication. To deepen 
insight into the mechanisms that allowed ALL cells to invade the CNS is very important 
but also difficult at the same time. In fact, little material coming from ALL patients is 
available for studies, especially for material directly extracted from the cerebrospinal 
liquor of ALL patients with CNS involvement. To overcome these limitations, we 
decided to use NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) murine models xenografted with 
primary T-ALL cells of a set of pediatric patients. It has been largely shown how 
primary leukemic cells transplanted into murine recipients (NSG) cause the 
development of a disease, which is very similar to human leukemia. The first efforts of 
this study were focused in understanding if the T-ALL xenografted NSG murine model 
could also mimic the phenomenon of CNS disease. In a first set of histological analysis 
of mice, we found the presence of human T-ALL cells in the meninges of 12/18 
samples. Moreover, we found different degrees of infiltration (figure 1), that we divided 
in 3 levels depending on the meningeal layer interested and the amount of T-
lymphoblasts infiltrated in the meninges (table 1). These data showed that also the 
xenografted murine model can be a useful model for the study of CNS infiltration by 
human T-ALL cells. However, we have to underline that the presence of CNS 
involvement was more frequent in the mouse models compared to the pediatric T-ALL 
patients’ cohorts. Indeed, the mouse model could present CNS infiltration even if this 
situation had not presented itself in the donor patient at diagnosis. However, even if this 
xenografted model does not directly reflect the situation in the matched human patients, 
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it is very useful to deepen insight into mechanisms that regulate CNS homing by human 
T-ALL cells. Different results have been obtained by studies on mechanisms that allow 
CNS leukemia: particular importance was given to RAC2, AEP and ICAM1 expression 
in the pre-B mouse model [9] and to CCR7 expression in a T-ALL xenografted murine 
model [10]. Moreover, the expression levels of CXCR4 have been shown to give 
discordant results in determining CNS infiltration by blast cells [11-13]. 
 As we also found a positive correlation between cxcr4 expression levels and the degree 
of CNS infiltration in two T-ALL zebrafish models (chapter 1 of this thesis), we 
decided to use the murine model to understand if CXCR4 expression levels might 
predict the ability of T-ALL cells to infiltrate the CNS. Data of flow cytometry revealed 
the presence of different percentages of human (CD45+) CXCR4 positive cells in the 
peripheral blood and Spleen among mice (figure 2A/B). However, we have shown that 
CXCR4 protein expression levels are affected by dynamic changes due to the presence 
of the ligand CXCL12 in the mouse microenvironment. That is not surprising 
considering that human and murine CXCL12 present a high identity at the protein level 
(!92%) and that also in mice  CXCL12 is produced by stromal cells at different sites, 
such as BM, lymph nodes, spleen, vessels and brain [29]. When CXCL12 binds the 
CXCR4, the chemokine receptor is temporary internalized from the surface membrane 
of cells and no longer detectable by FCM. The latter can explain the presence of human 
cells that result to be CXCR4 “negative” by flowcytometry. To understand the influence 
of the microenvironment on CXCR4 surface membrane expression, we observed flow 
data obtained from a mouse model xenografted with Jurkat cells (figure 3). Also in this 
case, Jurkat cells that are 100% CXCR4 positive during in vitro culture showed 
diminished positivity of CXCR4 in an in vivo model (data of Spleen and Peripheral 
blood). These data underline the notion that CXCR4 surface expression in T-ALL cells 
is indeed highly variable and under direct influence of the microenvironment of an in 
vivo model. This influence makes it difficult to quantify the real amount of CXCR4 
expression in T-ALL cells. To have a measure of the intrinsic CXCR4 expression we 
decided to measure CXCR4 mRNA transcription through qRT-PCR analysis. qRT-PCR 
analysis revealed that in general T-ALL cell have a high expression of CXCR4, however 
also at the transcriptional level we found variability among samples (figure 4). 
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Interestingly, preliminary data for 7 samples included in the first set of histological 
analysis revealed that in the murine model, CXCR4 expression of T-ALL cells have a 
tendency to correlate with the degree of CNS infiltration at the meningeal level (figure 
5). These data seem to confirm previous results obtained in the zebrafish model 
(Chapter 1 of this thesis) and underline the importance of CXCR4 expression levels as a 
conserved mechanism able to predispose T-ALL cells to enter the CNS. These 
preliminary results will be validated when histological analysis of the new set of 29 
cases will be concluded.   
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Figure 1. Histological analysis of two xenografted murine models with different degrees 
of CNS infiltration 
!
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Variable amount of human CXCR4 positive T-ALL cells in murine model 
 
Figure 2: Graphics show the variable percentage of human CXCR4 positive cells (gated on CD45+) 
found in the spleen (A) and Peripheral Blood (B) of xenoengrafted mice. Data obtained by FCM. Each 
bar corresponds to mice xenografted with different patients. Y-axis shows the percentage of CXCR4+ 
cells, calculated on amount of CD45+ cells. 
 
Influence of mouse microenvironment in CXCR4 expression at the T-cell surface 
 
Figure 3: Figures show the variation of CXCR4 expression in the surface of Jurkat cells from in vitro 
culture (A) to in vivo environment (B/C). (A) Image shows that all Jurkat cells (100%) in vitro culture are 
positive for CXCR4; (B-C) figures show variation of CXCR4 expression when Jurkat cells are 
xenotransplanted in murine model; particularly, Jurkat cells extracted from the spleen (B) or peripheral 
blood (C) of xenografted mouse partially lose their positivity. 
 
 
 
! ! $-)!
Variable amount of CXCR4 are expressed by leukemic cells infiltrating mouse spleen  
 
Figure 4: Dot plot show the expression levels of CXCR4 in human T-ALL cells extracted from the spleen 
of different xenoengrafted mice. Data from qRT-PCR after normalization with the housekeeping gene, 
according to the formula formula 2-&ct [24]. Y-axis represents the RQ-value.  
 
 
CXCR4 transcription levels tend to correlate with the degree of CNS infiltration 
 
Figure 5: Preliminary data available for 7 cases. X-axis represents transcription level of CXCR4, Y-axis 
represents the degree of CNS infiltration at the meningeal level. Each dot corresponds to different sample. 
Pearson-correlation analysis was performed showing that results are not significant (p-value >.05). 
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Table 1: Results of histological analysis for the first set of 18 xenografted mice are 
summarized in this table. The score associated to each different structures reflect its 
degree of infiltration. 
 
#01 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 0 
Tot 2 
#02 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 1 
Orbital space 0 
Middle ear 0 
Head 
Meninges 1 
Tot 4 
#03 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 1 
Orbital space 0 
Middle ear 1 
Head 
Meninges 1 
Tot 5 
#04 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 1 
Orbital space 0 
Middle ear 1 
Head 
Meninges 1 
Tot 5 
#05 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 1 
Head 
Oral and rhinopharingeal mucosa 1 
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Orbital space 0 
Middle ear 2 
 
Meninges 2 
Tot 8 
#06 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 3 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 2 
Orbital space 1 
Middle ear 2 
Head 
Meninges 2 
Tot 10 
#07 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 2 
Tot 4 
#08 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 0 
Tot 2 
#09 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 1 
Middle ear 1 
Head 
Meninges 1 
Tot 5 
#10 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 1 
Tot 3 
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#11 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 1 
Orbital space 0 
Middle ear 0 
Head 
Meninges 1 
Tot 4 
#12 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 1 
Orbital space 0 
Middle ear 0 
Head 
Meninges 2 
Tot 5 
#13 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 1 
Orbital space 0 
Middle ear 1 
Head 
Meninges 1 
Tot 5 
#14 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 1 
Tot 3 
#15 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 0 
Tot 2 
#16 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 1 Head 
Dental alveoli 0 
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Oral and rhinopharingeal mucosa 0 
Orbital space 1 
Middle ear 0 
 
Meninges 0 
Tot 2 
#17 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 0 
Tot 2 
#18 
Anatomical 
segment 
Structures Degree of infiltration/colonization 
Bone marrow 2 
Dental alveoli 0 
Oral and rhinopharingeal mucosa 0 
Orbital space 0 
Middle ear 0 
Head 
Meninges 0 
Tot 2 
 
 
 
 
 
Table2. Primers used for qRT-PCR 
GENES PRIMERS 
Forward: 5’-CAGCAGGTAGCAAAGTGACG-3’ CXCR4 
Reverse: 5’-ATAGTCCCCTGAGCCCATTT-3’ 
Forward: 5’-GAAAATATGTGGTTGGAGAGC-3’ GUS 
Reverse: 5’-CGAGTGAAGATCCCCTTTTTA-3’ 
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Gene Expression Profiling analysis of ALL pediatric patients 
with Central Nervous System infiltration at diagnosis 
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Central nervous system (CNS) infiltration by leukemic cells in children with de novo 
acute lymphoblastic leukemia (ALL) is until the present day a major concern. Padiatric 
patients   with this unfavorable characteristic have a lower event-free survival and 
undergo intensive therapy directed against the central nervous system. The molecular 
mechanisms contributing to central nervous system infiltration are unclear. In order to 
explore potential biologic properties of ALL cells infiltrating the central nervous 
system, we applied whole-genome gene expression profiling to identify differently 
expressed genes that may characterize this phenomenon comparing ALL patients with 
(CNS+) and without (CNS-) central nervous system infiltration. We analyzed the gene 
expression profiles of pediatric patients  with de novo acute lymphoblastic leukemia 
committed to either the T- or B-cell lineage, of which 4 and 7 patients respectively, 
were positive for central nervous system infiltration at diagnosis. However we failed to 
find a strong signature that could identify CNS+ and CNS- patients. Results underlined 
the difficulty to study this phenomenon directly on human patients with this approach, 
as a high heterogeneity is present inside both T- and B-ALL and different mechanisms 
could drive blast cells in the CNS environment. 
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Childhood Acute lymphoblastic leukemia (ALL) is an aggressive tumor characterized 
by abnormal proliferation of lymphoblastic progenitor cells. ALL is committed to either 
the B- (B-ALL !85%) and the T- (T-ALL !15%) cell lineage and represents a large 
heterogeneous group with distinct morphology, immunophenotype and genetic 
abnormalities that are used to stratify patients into risk-groups ranging from standard-
risk to high-risk [1][2]. The presence of lymphoblasts infiltrating the Central nervous 
system (CNS) is an event that can be present both at diagnosis (<5%) and relapse (!30-
40%)[3][4] in ALL patients and is an unfavorable feature that stratifies patients in the 
high risk group. The presence of CNS infiltration is not always accompanied by clinical 
symptoms and  is usually detected through a lumbar puncture of the cerebrospinal fluid 
(CSF) [3]. Over the past years, the 5-year event free survival rate (EFS) of ALL 
pediatric patients has considerably improved due to more appropriate risk stratification 
and treatment. Although the overall EFS has increased significantly, reaching 
percentages above 85% [5], there are still patients that remain of  major concern, such  
as patients with CNS infiltration [6]. In the seventies and eighties of last century, 
leukemic patients with CNS infiltration were mostly treated with cranial irradiation, 
even if cranial irradiation caused many secondary diseases, such as secondary cancer 
development. Recently, numerous efforts have been made to reduce the use of 
radiations and two studies demonstrated that cranial irradiation could be completely 
omitted using intensive triple intrathecal therapy (methotrezate, hydrocortisone and 
cytarabine) [3][4] [7]. Even if at reduced dosage, cranial irradiation is still 
recommended to treat patients that have been assigned to the  high-risk group with CNS 
relapses, such as those that presented CNS leukemia at diagnosis (>5 White Blood 
Cells/µL with blasts) and/or T-cell phenotype ALL with high WBC counts [8].  
Several studied investigated mechanisms used by lymphoblasts to infiltrate the CNS, 
but results are variable. Two studies tried to identify a common mechanism used by 
ALL cells to infiltrate the CNS, without distinguishing between B- and T- lineage ALL; 
Gunnar Cario and colleagues studied the differences in gene expression between 
children with- and without- CNS infiltration in ALL, proposing the up-regulation of 
interleukin-15 as predictor of the ability of blasts to infiltrate the CNS. However, these 
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results have not been reproduced in other studies [9]. Indeed, Crazzolara and colleagues 
focused their attention on CXCR4, showing that higher expression levels of this 
chemokine receptor could be predictive of blasts ability to infiltrate extramedullary 
organs in ALL pediatric patients. However, in their work, data regarding CNS 
infiltration were not shown [10]. On the contrary, other studies investigated possible 
mechanisms of CNS infiltration focusing in specific ALL subgroups; Buonamici and 
colleagues identified in the CCR7 expression the key signal directing T-lymphoblasts 
towards the CNS using a murine model xenografted with human T-ALL cell lines.  
Also the latter study lacks confirmation by and validation in further studies [11]. 
Holland and colleagues underlined an important role played by RAC2, AEP and 
ICAM1 expression in determining CNS involvement in a mouse model xenografted 
with human pre-B pediatric ALL cells [12]. Instead, in another study performed in a 
pre-B ALL murine model, CNS-homing cells showed CXCR4 down-regulation both at 
the transcriptional and protein level, complicating the understanding of the role played 
by CXCR4 in determining CNS infiltration [13]. Moreover, another study showed that 
in children with ALL relapses associated to testicles or CNS leukemia blast cells had a 
significantly lower CXCR4 level than blasts from children with relapsed disease 
isolated to the bone marrow [28]. 
In conclusion, different results have been found in these works and the mechanism/s 
used by ALL cell to infiltrate the CNS is/are still poorly understood. As the mechanisms 
related to pathogenesis of CNS infiltration are unknown, the creation of a target-
directed therapy that could prevent this phenomenon is still a big challenge. In this 
study we aimed to investigate the presence of a specific gene expression signature that 
could characterize ALL patients with (CNS+) and without (CNS-) CNS infiltration at 
diagnosis. To achieve this aim we used the genome-wide Gene Expression Profiling 
approach on specimens of pediatric ALL patients enrolled in the “Associazione Italiana 
Ematologia-Oncologia Pediatrica” (AIEOP) ALL-2000 protocol and we separately 
analyzed   a T-ALL and a B-ALL patients at diagnosis. For each cohort, we compared 
CNS+ and CNS- patients; in this way, differentially expressed genes between the two 
groups (CNS+ vs. CNS-) were addressed. Moreover, we investigated in patients our 
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results previously obtained from studies of zebrafish and murine models; in particular, 
we analyzed the expression levels of CXCR4 in a T-ALL cohort.  
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Human leukemia samples  
Bone marrow or Peripheral Blood aspirates were collected from pediatric patients with 
B-ALL or T-ALL at diagnosis. All patients selected for this study were enrolled in the 
AIEOP ALL-2000 protocol. Patients’ parents or legal guardians did provide written 
informed consent for the use of patient material for biomedical research in accordance 
with the Declaration of Helsinki. For gene expression profiling analysis we used the 
following two cohorts: 
T-ALL cohort: 45 pediatric patients at diagnosis of T-ALL enrolled in the AIEOP 2000 
protocol. PB or BM specimens were available to perform GEP. Four patients showed 
CNS infiltration at diagnosis with more than 5 lymphoid blasts/µl in the cerebrospinal 
fluid (CSF) and 41 without CNS Infiltration. In Table 1 we reported the biological and 
clinical features of  T-ALL patients analyzed in this study.  
B-ALL cohort: 58 pediatric patients at diagnosis of B-ALL, enrolled in the AIEOP 2000 
protocol. PB or BM specimens were available to perform GEP. Seven patients showed 
CNS infiltration at diagnosis with more than 5 lymphoid blasts/µl in the cerebrospinal 
fluid (CSF) and 51 without CNS Infiltration. In Table 2 we reported the biological and 
clinical features of  B-ALL patients analyzed in this study. 
RNA isolation, quality controls and quantification 
Mononucleated cells (MNC) were isolated via the Ficoll-Paque method (GE Healthcare 
companies, Buckinghamshire, United Kingdom), which is based on density gradient 
centrifugation. Total RNA from MNC derived from bone marrow (BM) or peripheral 
blood (PB) aspirates was extracted using Trizol (Invitrogen, Karlsruhe, Germany), 
according to manifactures’ instructions. To perform gene expression experiments, 
extremely high quality of total RNA is required. To assess the quality of RNA, Agilent 
Bioanalyzer Expert 2100 (Agilent Technologies, Waldbronn, Germany) was used. RNA 
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concentration was determined using QBit 2.0 Fluorometer (Life Technology, Carlsbad, 
California, U.S.). NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies Inc, 
Wilmington, DE). The instruments provide the sample concentration in ng/µl and the 
absorbance of the sample at 260nm and 280nm. The ratio (260/280) ranging from 1.8 to 
2.1 indicate good quality of RNA (ratio < 1.8 means protein contamination and ratio > 
2.1 RNA degradation and truncated transcripts).  
Gene expression profiling 
Only RNA samples that passed the high quality controls were diluted to 100ng in a total 
volume of 3µl DEPC treated water to perform gene expression experiments. In vitro 
transcription, hybridization and biotin labelling were performed according to GeneChip 
3’IVT Express kit protocol (Affymetrix, Santa Clara, CA). The Affymetrix GeneChip 
Scanner was used to measure all intensities of the signals of each probe set on the 
GeneChip and stores all signals in a .DAT file (Raw image). Integrated software 
converts all raw signals into numbers, which were stored in a .CEL file. All GEP 
profiles used in these experiments were assessed for their comparability and quality, 
using different quality controls: Scale Factor, number of present calls, internal probe 
calls, Poly-A controls and the ratio GAPDH/!-actin 3’/5’.  
Statistical analyis 
Microarray data (.CEL files) were analyzed using Command Expression Console 
(Affymetrix). R-Bioconductor (Version 2.15.3) was used to analyze the .CEL files data 
in an unsupervised and supervised manner. Unsupervised analysis (Class Discovery) is 
a learning algorithm that clusters unspecified specimens together based on similar gene 
expression patterns and is therefore highly unbiased. Supervised analysis (Class 
Comparison, Class Prediction) is a learning algorithm that uses already defined 
(labeled) data in order to identify a set of genes that characterize the pre-specified data. 
The .CEL files first were normalized using the justRMA algorithm. justRMA is an 
algorithm fulfilling 2 steps, namely background adjustment of all the probe sets present 
on the GeneChip and quantile normalization to make the values of all the GeneChips 
comparable. In order to find differently expressed probe sets we applied a Shrinkage t-
test on the normalized .CEL files [19]. We used a local false discovery rate (lfdr) as 
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correction of the p-value; a ldfr < 0,05 was considered significant for genes differently 
expressed between 2 groups. Differently expressed probe sets derived from the 
Shrinkage t-test were used for clustering analysis. Hierarchical clustering analysis was 
used to clusterize the specimens in an unsupervised manner using Euclidean Distance 
and Ward’s Method. Euclidean Distance and Ward’s Method compute the distance 
between two groups in a metric space. qRT-PCR statistical analyses and graphs were 
generated by GraphPad Prism software (Version 5.0.0).  
Gene Ontology analysis 
Differently expressed genes between CNS infiltrate (CNS+) and non-infiltrated (CNS-) 
ALL pediatric patients were analyzed using Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7.  
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Gene Expression Profiling of pediatric T-ALL and B-ALL patients at diagnosis 
With this project we aimed to investigate the presence of a specific gene expression 
signature that could distinguish ALL patients with (CNS+) or without (CNS-) Central 
Nervous System infiltration at diagnosis. In order to identify different expression 
signatures between CNS+ and CNS- ALL patients at diagnosis, we performed Gene 
Expression Profiling (GEP) experiments (using Affymetrix HG U133 Plus 2.0 arrays) in  
45 T-ALL and 58 B-ALL pediatric patients enrolled in the AIEOP 2000 protocol. 
CNS infiltration in pediatric T-ALL patients 
We started with the analysis of 45 T-ALL pediatric patients, including 4 CNS+ cases. 
Using supervised analysis (Shrinkage T-test, lfdr <0,05), we identified 582 probe sets 
differently expressed between CNS+ (n=4) versus CNS- (n=41) patients (lfdr < 0.05). 
Unsupervised hierarchical clustering analysis (using the 582 probe sets differently 
expressed) separated the 45 patients in two main branches (figure 1); the branch on the 
right comprised only CNS- patients, while in the left arm the CNS+ patients clustered 
together with a small group of 5 CNS- patients. Interestingly, the 4 CNS+ patients 
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clustered together based on a similar gene expression signature using the 582 probe sets 
(517 genes) differently expressed between CNS+ versus CNS- patients. Particularly, we 
found 125 and 391 genes up-regulated in CNS+ and CNS- patients, respectively (table 
3). However, the majority of genes differently expressed between CNS+ and CNS- 
groups showed  a low fold change (FC) which could be attributed to the small number 
of CNS+ samples available for this analysis and by the presence of a group of CNS- 
patients that behaved similar  to CNS+ cases. The observation that some T-ALL CNS- 
patients behaved similar to CNS+ cases flattened differences between groups (CNS+ vs. 
CNS-) and contributes to the absence of a strong signature for patient with CNS 
infiltration at diagnosis. Moreover, these results lead to the assumption that CNS+ T-
ALL patients are a heterogeneous group and mechanisms that drive their T-
lymphoblasts towards the CNS could be diverse, impairing the extraction of a strong 
gene expression signature. This hypothesis is strengthened by results of unsupervised 
analysis (figure 2): CNS+ patients cluster independently of one another, suggesting a 
weak similarity in gene expression profiling. Interesting, the phenomenon of CNS 
infiltration at diagnosis in T-ALL seems  not  to depend on  the cytogenetic subgroup of 
patients that was predicted using a GEP classifier for cytogenetic subgroup [16]. In fact, 
two patients with CNS infiltration presented a TALLMO signature, while the others 
were predicted to be TLX1 and TLX3.  
We further investigated the list of  517 genes differently expressed between CNS+ 
versus CNS- patients at  the molecular level, in order to inquire more detailed 
information on potential gene networks that may be related to CNS infiltration. Gene 
ontology analysis using DAVID software revealed a significant (p-value=0,005) up-
regulation of the Wnt/"-catenin pathway (figure 3) in CNS- patients.  
In the light of a previous work [10] and results found in the chapter 1 and chapter 2, we 
decided to investigate the CXCR4 expression in T-ALL pediatric patients. The dot plots 
showed how in general blast cells of the T-lineage express high levels of CXCR4 (figure 
5), independently from CNS infiltration. Of note, we can notice a patient with lower 
expression of CXCR4 inside the group of CNS+ patient that strengths our hypothesis of 
more than one mechanism that can drive blast cells in the CNS environment. This 
analysis shows that CXCR4 transcription in blast cells is very high both in patients with- 
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and without- CNS infiltration. We have to remember that with the previous results 
(chapter 1 and 2) we showed that expression levels of CXCR4 are not necessary to 
infiltrate the CNS, but could confer an increased ability for lymphoblasts to infiltrate 
this environment.  
CNS infiltration in pediatric B-ALL patient 
We continued gene expression analysis in a cohort of 58 B-ALL patients, including 7 
CNS+ and 51 CNS- cases. Supervised analysis using Shrinkage t-test with lfdr 
correction (lfdr<0.05) resulted in 460 probe sets differently expressed between CNS+ 
and CNS- B-ALL patients at diagnosis. The dendogram of hierarchical clustering 
revealed a highly similar gene expression signature for the 7 CNS+ B-ALL patients and 
11 CNS- B-ALL patients that cluster together in one branch (figure 4). . We further 
investigated the list of probe sets (343 known genes) differently expressed between 
CNS+ versus CNS- patients. Particularly, 138 genes and 206 genes were up-regulated in 
the CNS+ and CNS- group respectively. Also in this case genes present  low FCs  that 
could  be attributed to the presence of a group of CNS- patients with a  signature similar 
to that of CNS+ cases. We performed gene ontology analysis, using DAVID software 
and identified  in the B-ALL cohort, gene networks  related to cytoskeleton remodeling 
pathways. In table 4 we reported genes and pathways related to cytoskeleton remodeling 
that were found to be down-regulated in CNS+ patients. This may indicate that 
pathways related to cytoskeleton remodeling could play a role in the mechanisms used 
by B-ALL cells to infiltrate the CNS.  
Expression of IL-15 in T-ALL and B-ALL  
CNS infiltration is more likely to occur in T-ALL than in B-ALL patients [8]. B- and T-
ALL patients do not differ only in cell lineage but also in genetic landscape, 
transcriptome and treatment. At this point, we wanted investigate in both the T-ALL 
and B-ALL cohort, the expression of Interleukin-15, a gene that has been shown to be 
important in determining CNS invasion [9]. Moreover, we were interested in IL-15 
because it can enhance CXCR4 transcription [27]. In our cohort, IL-15 is significantly 
more expressed in T- compared to the B-lineage ALL samples (figure 6). 
! ! $%%!
4/."#../,1&
In the previous chapters of this thesis the gene networks that seem to facilitate the 
entrance of lymphoblasts in the CNS were studied in animal models (zebrafish and 
mouse xenografted with human T-ALL cells). Here we investigated this aspect in 
pediatric patients samples using whole transcriptome analysis. We examined the 
presence of gene expression profiling signatures that could distinguish patients with 
(CNS+) or without (CNS-) CNS involvement.  
We started our analysis on a cohort of 45 T-ALL pediatric patients at diagnosis in which 
4 cases where CNS+. Applying supervised analysis we identified 582 known genes 
differently expressed between CNS+ and CNS- T-ALL patients (lfdr<0.05), however 
these genes presented a low FC which is indicative of a limited distinction in gene 
expression profiling between the two groups  (CNS+ vs. CNS-). Interesting, gene 
ontology analysis (DAVID) identified an up-regulation of the Wnt/"-catenin pathway in 
the group without CNS infiltration; in Chapter 1 of this thesis we already found that the 
activation of this pathway was present in the zf line (hlk), which showed low levels of 
CNS infiltration. One might speculate that an increased activation of the Wnt/"-catenin 
pathway determines a reduced ability of T-lymphocyte to infiltrate the CNS. 
Next we applied a supervised analysis on patients with de novo B-ALL and we 
identified 460 probe sets differently expressed between CNS+ and CNS- B-ALL 
patients. However, also in this case the FCs were not high. For the B-ALL cohort gene 
ontology analysis showed that several genes up- (n=2) and down- (n=10) regulated were 
directly involved into cytoskeleton remodelling pathways, suggesting that CNS 
infiltration could be associated with alterations in the cytoskeleton. However, as 
indicated by the low FCs also for B-ALL we failed to find a strong signature that 
distinguished patients with- and without- CNS involvement. 
Both these two gene expression analyses on a T- and B-ALL cohort failed to identify a 
strong signature that identified patients with CNS involvement at diagnosis. The 
intricacy to find a strong signature that identifies CNS+ cases in both T- and B-ALL 
cohorts could be due to several causes; 1) the small number of patient analyzed  (n=4 
CNS+T-ALL and n=7 CNS+ B-ALL); 2) the presence of a group of patients without 
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CNS infiltration that cluster together with the CNS+ cases, flattening the difference 
between CNS+ and CNS- and 3) the mechanisms that allow lymphoblasts to infiltrate 
the CNS could be many and entailing different gene networks activation and different 
gene expression profiles for samples of ALL patients with CNS disease.  
It is surprising to observe how in both T- and B-ALL cohort, a group of patients without 
CNS infiltration had a very similar signature to CNS+ cases. In this respect we should 
remember that the current methodology to diagnosis the presence of CNS infiltration in 
pediatric ALL patients uses cytological analysis of a smear of CSF. Several studies have 
already shown the importance of using more sensitive techniques, such as flow 
cytometry (FCM) or PCR-methods, to detect CNS disease. In fact, using FCM and PCR 
for CSF analysis, several patients classified as CNS- resulted having a subclinical 
infiltration of the CSN [17][18][19][20][21] and the presence of small numbers of 
leukocytes in the CSF at diagnosis remains a controversial risk factor [22][23][24].  As 
the classification of CNS disease is not still perfect, we can speculate that also our 
cohorts might include patients with subclinical CNS infiltration among the CNS- group, 
which could partially explain the rather weak gene expression signature for CNS+ 
patients. Moreover, the CNS- cases that clustered together with the CNS+ cases could 
represent this group. Of course that is only a speculation and further studies need to be 
performed to clarify this hypothesis.  
In this work, we also investigated if our previously results found to be related to an 
increased ability to infiltrate the CNS in animal models (Chapter 1 and 2) could be 
transferred to human ALL  samples. Particularly, we investigate the levels of CXCR4 
transcription in the T- ALL cohort and we found a high expression of CXCR4 both in 
CNS+ and CNS- patients. Notably, within the group of T-ALL CNS+ patients, we 
found 3 patients with very high- and one patient with lower- CXCR4 expression levels. 
We can speculate that these patients reflect both the zebrafish models with high- 
(hMYC-ER) and low (hlk) expression of CXCR4. When we look back at chapter 1, the 
expression levels of CXCR4 did not discriminate between CNS+ and CNS- specimens, 
but positive correlated with the seriousness of CNS infiltration. However, also patients 
without CNS infiltration showed high CXCR4 transcription levels indicating that 
expression levels of CXCR4 alone are not indicative of higher degrees of CNS 
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infiltration in human patients. At this point, it is necessary to underline that the 
phenomenon of CNS infiltration in human patients can not directly be compared to 
CNS infiltration in animal models: whereas CNS infiltration in zebrafish and murine 
models consisted of massive infiltration at the meningeal levels, CNS infiltration in 
human patients referred to blast cells (>5 WBC/µL with blasts) detected in the CSF and 
we might expect that the biological phenomenon we are observing is not exactly the 
same. In fact, in animal models we were in front of an extreme situation that could 
represent CNS leukemia in patients in the 1970s [25] fortunately no longer observed in 
human patients. The passage from animal model and human patients is not so linear. As 
several events related to microenvironment can influence CXCR4 transcription [26], 
further analysis need to investigate not only the expression level of CXCR4, but also its 
regulation in human T-ALL.  
Analysis of expression of IL-15, an interleukin related to the ability to infiltrate the CNS 
[9] and capable to increase CXCR4 transcription, revealed increased expression levels in 
T- compared to B- lineage. Interesting, B-cells lose the ability to respond to CXCL12 
during maturation, even if the chemokine receptor CXCR4 continues to be highly 
expressed on the membrane surface [14][15]. These observations suggest that T-
lymphoblasts present both higher expression of IL-15 and functional CXCR4, two 
factors that seem  advantageous for lymphoblasts to infiltrate the CNS and which could 
partially suggest why the incidence of CNS infiltration is higher in T- compared to B-
ALL. 
Further studies are needed to understand if mechanisms favoring  CNS invasion 
observed in animal models can be translated to human patients. Moreover, further 
studies are required that directly address CNS+ disease in human patients.  
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Supervised analysis of the T-ALL cohort using the 582 probe sets differently expressed 
between CNS+ and CNS- patients at diagnosis 
 
Figure 1: CNS+ patients are underlined in blue (n=4), CNS- patients in orange (n=41). 
Hierarchical clustering of the T-ALL patients (n=45) was made using the 582 probe sets found 
with the Shrinkage T-test with lfdr <0.05. X-axis represents patients while the Y-axis shows the 
probe sets of the list. Euclidean distance and Ward’s method were used for clustering. The 
dendogram reveals two main branches; the branch on the right comprises only CNS- patients, 
while in the left branch the CNS+ patients clustered together with 5 CNS- patients. 
Unsupervised analysis hierarchical clustering of T-ALL patients at diagnosis 
 
Figure 2: CNS+ patients are underlined in blue (n=4), CNS- patients in orange (n=41). CNS+ 
patients (blue) cluster independently in different branches in an unsupervised analysis, revealing 
a different gene expression profiling between samples. 
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Activation of Wnt/"-catenin pathway in CNS- T-ALL pediatric patients 
 
Figure 3: Pathway analyses tools DAVID 6.7 revealed a significant activation of the Wnt/"-
catenin pathway in T-ALL patients without CNS infiltration. Red stars indicate genes of the 
Wnt/"-catenin pathway that resulted significantly upregulated in the gene list derived from the 
comparison between CNS- vs. CNS+ groups. 
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Supervised Analysis of the B-ALL cohort using the 460 probe sets differently expressed 
between CNS+ and CNS- patients at diagnosis 
 
Figure 4: Hierarchical clustering of the B-ALL patients (n=58) with CNS infiltration (blue) and 
without CNS infiltration (orange) at diagnosis based on a list of 460 probe sets obtained after 
applying a Shrinkage T-test with lfdr <0.005. The CNS+ B-ALL patients cluster together with a 
highly similar gene expression signature. X-axis represents the patients and the Y-axis the 
genes. For clustering we used Euclidian distance and Ward’s method. 
 
Figure 6: Dot plot for IL-15 in T-ALL and B-ALL. The dot plot shows expression levels of 
IL-15 for T-ALL and B-ALL patients. Data show higher expression levels in T- compare to B-
lineage. X-axis represents the T- and B-ALL subgroups and the Y-axis the genes expression 
data for IL-1 
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CXCR4 expression in a cohort of T-ALL 
 
Figure 5: Graph represents gene expression profiling (GEP) data for the expression of a probe 
set representing the CXCR4 gene. Each dot corresponds to one patient. The expression value of 
CXCR4 for each patient is given in log2 scale after normalizing GEP data with justRMA 
algorithm normalization. X-axis represents patients and the Y-axis the genes expression. Dot 
plot shows CXCR4 expression levels on a cohort of 45 T-ALL pediatric patients. The blue dots 
represent the 4 CNS+ cases. In red are underlined CNS- patients that clusterized with CNS+ 
cases in the supervised analysis.  
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Table 3. Genes differently expressed between CNS+ and CNS- T-ALL patients 
*GHIE!.EK! :EFE!!.QUIOE! $N8GEDMOLKEP!\F! 3#!
%$*'+'V37! 9;$! 9]U_! $J&'!
%$'))-V37! R.^X$! 9]U_! $J&'!
%-((''V5V37! 9;%! 9]U_! $J&$!
$()-&(,V37! HiCj! 9]U_! $J%+!
%%-&-*V37! 9T%''! 9]U_! $J%)!
%''*$-V37! C;^kl! 9]U_! $J%&!
%&),$-V37! W;HC&,! 9]U_! $J%$!
$(((($&V37! HRXU%! 9]U_! $J$,!
$(),+%*V37! X.^*! 9]U_! $J$,!
%&(,$&V37! m]S++-! 9]U_! $J$,!
%%'-&)V5V37! CWg;$! 9]U_! $J$,!
$((,-'%V37! ]TkSg)! 9]U_! $J$*!
$((',,,V37! ;XU^iS$g! 9]U_! $J$*!
%&('*&V37! WiT)! 9]U_! $J$*!
%%**($V37! HT9T(! 9]U_! $J$*!
%%()($V37! kgi%i%! 9]U_! $J$)!
%$'-$%V37! i;XH$! 9]U_! $J$(!
$((()$-V37! X^l! 9]U_! $J$(!
%&%-%)V37! Mi;9'! 9]U_! $J$(!
%%-+-&V37! U.XWgHC$! 9]U_! $J$'!
%$+(+,V37! CHX;)! 9]U_! $J$'!
$()%%*$V@V37! X;M^iS*! 9]U_! $J$'!
%%'(,)V37! UC9''X$! 9]U_! $J$'!
%-',$+V5V37! WCC.&! 9]U_! $J$'!
%$(%)+V37! lRXX-*('! 9]U_! $J$'!
%&%%,(V37! ^SW$! 9]U_! $J$'!
$((%+&(V37! Ti]]T$g! 9]U_! $J$'!
%%+(-)V37! ]UW9i'X! 9]U_! $J$'!
%$$%--V5V37! iS9Xg%! 9]U_! $J$&!
%$+(,*V5V37! 9RUT$! 9]U_! $J$&!
$(('&-,V37! iRS'^&! 9]U_! $J$%!
%$)$$(V37! ]S$! 9]U_! $J$%!
$(()(,,V5V37! X;HH%$! 9]U_! $J$%!
$()-*&'V37! Cj9*%*,%'! 9]U_! $J$%!
%&$,,(V37! 9,128+%! 9]U_! $J$%!
%%'$*&V5V37! W;HC&-! 9]U_! $J$%!
%$,&))V37! Xni]! 9]U_! $J$%!
%%*(+(V37! X.XT$! 9]U_! $J$%!
%&(,%*V37! :Hj$! 9]U_! $J$$!
%&*+()V37! ;XH$^TU$! 9]U_! $J$$!
%-%,*,V5V37! 9;igmS! 9]U_! $J$$!
%$+'&*V5V37! Cm.SC$! 9]U_! $J$$!
%-&%$$V5V37! W.W;%! 9]U_! $J$$!
! ! $&%!
%&)'+$V37! SXM! 9]U_! $J$$!
%%(%*+V37! H;lXg%! 9]U_! $J$$!
%&(+$-V37! m]S$+%! 9]U_! $J$$!
%'&,(*V37! Cj9'--')'! 9]U_! $J$-!
%&+%,(V37! 9$*128'%! 9]U_! $J$-!
%%)+-%V5V37! Cj9,))$-! 9]U_! $J$-!
%%)*,-V37! Wj;]%! 9]U_! $J$-!
%$('%(V37! g.^&! 9]U_! $J$-!
%-'(*+V37! HHRH(l$! 9]U_! $J$-!
%$'('&V@V37! olR! 9]U_! $J$-!
%-(($+V5V37! 9WXMH! 9]U_! $J$-!
%%)--,V37! TH9T! 9]U_! $J$-!
$(())$&V5V37! TH\$,C'! 9]U_! $J$-!
%$*)&&V37! k;g$! 9]U_! $J$-!
%&-($)V37! 9*128&-! 9]U_! $J$-!
%%&(,$V37! ;]S$&(! 9]U_! $J$-!
%$(%+&V37! Cj9&&,%,-! 9]U_! $J$-!
%&%&$%V37! HHH);&! 9]U_! $J$-!
%$-%$,V37! UH$--! 9]U_! $J-,!
%%*$+*V37! 9gCC$! 9]U_! $J-,!
$((&$&&V37! 9,128*%! 9]U_! $J-,!
%$(,%%V37! ;iHU$! 9]U_! $J-,!
%-$'&)V37! iRS'i! 9]U_! $J-,!
%&$,*-V37! 9$'128$$+! 9]U_! $J-,!
%%*(*(V5V37! 9$'128$-%! 9]U_! $J-,!
%&*-*)V37! ]9U.]! 9]U_! $J-,!
%$%(*%V37! U.l&+C! 9]U_! $J-,!
%$',$*V37! H;lXX$! 9]U_! $J-,!
$((*&)-V37! C;HH;9! 9]U_! $J-,!
%$-(&$V37! ];%9$! 9]U_! $J-,!
$()&)*'V37! S9;C%! 9]U_! $J-,!
%'%&*-V37! W.MST%C! 9]U_! $J-,!
%$*(-&V37! U.l$*g! 9]U_! $J-,!
%%%'''V37! X;W9:&! 9]U_! $J-,!
%-%+$*V5V37! UU$+! 9]U_! $J-+!
%%*$)%V37! mg.g%)! 9]U_! $J-+!
%%**))V37! CR^'! 9]U_! $J-+!
%%$(%&V5V37! ;;X^T! 9]U_! $J-+!
$()''+%V37! X.H(j! 9]U_! $J-+!
%&$-))V5V37! 9C9]'! 9]U_! $J-+!
%$*'%*V5V37! MR;X! 9]U_! $J-+!
%%+&($V37! MiX.;$! 9]U_! $J-+!
$()*%$&V37! H]]! 9]U_! $J-+!
%&($)%V37! WTW'! 9]U_! $J-+!
%$$-)*V5V37! ^XU*! 9]U_! $J-+!
! ! $&&!
%%)-&)V@V37! 9XUH%! 9]U_! $J-+!
%$,,)+V37! m]S(+,! 9]U_! $J-*!
%$-*$(V5V37! UHR].%! 9]U_! $J-*!
%&'&-+V37! .kg^9H)! 9]U_! $J-*!
%'%&-'V37! fRg^! 9]U_! $J-*!
%$%,(,V5V37! ^]H.Xg! 9]U_! $J-*!
%$&-+*V5V37! iiS$T! 9]U_! $J-*!
%%*,-'V37! XmR%! 9]U_! $J-*!
%&-*-)V5V37! 9XWl%]%! 9]U_! $J-*!
%%,&$*V37! lH]X(! 9]U_! $J-*!
$(('(,(V37! U\WHl! 9]U_! $J-*!
%-%,-*V5V37! ]g]! 9]U_! $J-*!
%$'-)-V37! UUgH$! 9]U_! $J-*!
%$*$+*V37! Wk9(X9! 9]U_! $J-*!
%%,$'$V37! fT;&&! 9]U_! $J-*!
%&&(,,V37! Cj9*%+-)$! 9]U_! $J-*!
%&+++-V37! ^.S&X! 9]U_! $J-)!
$((&',&V3V37! .TM! 9]U_! $J-)!
$()&-&'V37! ^HT$! 9]U_! $J-)!
%%,+-&V5V37! ]kT.&! 9]U_! $J-)!
%%'*(,V5V37! 9$%128%&! 9]U_! $J-)!
%$,,&$V5V37! lCMC$%! 9]U_! $J-)!
%&%%(&V37! 9(128()! 9]U_! $J-)!
%$'$,*V5V37! Ui.Tg$! 9]U_! $J-)!
%%*%*'V37! U\]p%gH! 9]U_! $J-)!
%%(*$-V37! ^]g'! 9]U_! $J-)!
%%%%-'V5V37! ;;]&! 9]U_! $J-)!
%%*+%,V37! ^\C.C$g! 9]U_! $J-)!
%-*()'V@V37! j^.! 9]U_! $J-(!
%%$,))V37! ^H;$&*! 9]U_! $J-(!
%-&$(%V37! W;HC'-! 9]U_! $J-(!
%-+*$(V37! .W9j$! 9]U_! $J-(!
%%)'$%V37! H]RU;! 9]U_! $J-(!
%&$*$'V5V37! XH'g$! 9]U_! $J-(!
%$++-,V37! HX]l%! 9]U_! $J-'!
%$-,)+V5V37! ;.]'! 9]U_! $J-&!
%--)'(V37! ^XgX;XH! 9]UL! $J-'!
%$'-+-V@V37! H;l9UM! 9]UL! $J-'!
%-$)-)V5V37! HfH$! 9]UL! $J-(!
%$-%-+V@V37! gX^)! 9]UL! $J-(!
%$')()V@V37! W\j$9! 9]UL! $J-(!
%$,%)$V37! 9*128%)! 9]UL! $J-(!
%%,%*-V@V37! UUgH'! 9]UL! $J-(!
%$+(&&V5V37! k9lC$! 9]UL! $J-(!
%$&,&*V5V37! S.Up$! 9]UL! $J-(!
! ! $&'!
%%&-$)V@V37! m;X]g%! 9]UL! $J-)!
%$-'%+V5V37! M^U! 9]UL! $J-)!
%$&)((V37! \fMXi! 9]UL! $J-)!
%-$,$'V5V37! Ui9)&! 9]UL! $J-)!
%%%$,,V5V37! gR]&! 9]UL! $J-)!
%$)-&%V5V37! i;^R9&! 9]UL! $J-)!
%$$,(-V37! kg;'! 9]UL! $J-)!
%$&)',V37! U;US*! 9]UL! $J-)!
%-$*$*V37! W;HC',! 9]UL! $J-)!
%-+,&+V37! H;99! 9]UL! $J-)!
%%('*)V37! ^HX]l$! 9]UL! $J-)!
%-$'('V5V37! ]HiHHU! 9]UL! $J-)!
%-*$%'V5V37! ^]g(! 9]UL! $J-)!
%-%$*&V5V37! nimS$! 9]UL! $J-*!
%-')$*V5V37! X9T! 9]UL! $J-*!
%-,%(+V5V37! UW9&! 9]UL! $J-*!
%%')*)V37! .WiT'! 9]UL! $J-*!
%-*$)&V5V37! Xl.$! 9]UL! $J-*!
%-%$-,V37! X;SRH%! 9]UL! $J-*!
%&%%$,V@V37! kUH%$! 9]UL! $J-*!
%$$,),V37! MUH,-XX$! 9]UL! $J-*!
%--,,-V37! .;RW%+! 9]UL! $J-*!
%-$$'-V5V37! ;Xg(9! 9]UL! $J-*!
%$%*$*V37! HCilMW$! 9]UL! $J-*!
%$)$-(V@V37! HHH%;'! 9]UL! $J-*!
%%)$-+V37! m9&M$+! 9]UL! $J-*!
%-+''(V5V37! gXm$g! 9]UL! $J-*!
%-'*+,V37! SW]C$! 9]UL! $J-*!
%--*)*V5V37! SXW$%-X! 9]UL! $J-*!
%%',*,V5V37! kUH&)! 9]UL! $J-*!
%$+&--V37! 9$)128(&! 9]UL! $J-*!
%-%$)$V37! Hl]$! 9]UL! $J-*!
%--+%(V5V37! M\jk$! 9]UL! $J-*!
%$+)$%V5V37! .UU9'! 9]UL! $J-*!
%$%,,'V37! .Mj9%! 9]UL! $J-*!
%$*+))V37! 9HUS*! 9]UL! $J-*!
%--+(%V@V37! ^]g%! 9]UL! $J-*!
%%)-+%V5V37! U9XS'! 9]UL! $J-*!
%-%-'*V5V37! 9g:)! 9]UL! $J-*!
%%$($%V37! .WiW%%%! 9]UL! $J-*!
%-%'+-V5V37! TiTT! 9]UL! $J-+!
%$+&'(V37! .WiW$*)X! 9]UL! $J-+!
%-'$-'V37! U]XH9%! 9]UL! $J-+!
%--)',V37! ]k9g$! 9]UL! $J-+!
%-$%')V5V37! j.kg$! 9]UL! $J-+!
! ! $&(!
$((,&,*V5V37! H;;$'! 9]UL! $J-+!
%-+,&%V37! HHH'9! 9]UL! $J-+!
%$(%*&V5V37! .XTX&! 9]UL! $J-+!
%%(-,-V37! U\n]$! 9]UL! $J-+!
%%(-%(V37! R^US+! 9]UL! $J-+!
%-$(,&V5V37! m9&M$(! 9]UL! $J-+!
%%&+$+V5V37! ;US$! 9]UL! $J-+!
%--)$&V37! XH%W$! 9]UL! $J-+!
%$&)),V37! S9Mj$! 9]UL! $J-+!
%%'%(-V5V37! Ui9RUgH%! 9]UL! $J-+!
%%%)&&V37! .gC$:;$! 9]UL! $J-+!
%-&(,*V5V37! fgH'! 9]UL! $J-+!
%$$+*'V5V37! lX.)g! 9]UL! $J-+!
%$-$%(V5V37! gX]S$! 9]UL! $J-+!
%-(*'+V5V37! ;]S$%)! 9]UL! $J-+!
%$+)+$V5V37! UTS%C$! 9]UL! $J-+!
%%',&&V5V37! pWpT$9! 9]UL! $J-+!
%-++&-V5V37! UkH.)M! 9]UL! $J-+!
%%$(-&V5V37! lH]X&! 9]UL! $J-+!
%$*+*+V5V37! 9T9%*! 9]UL! $J-,!
%$*,-&V37! U.;]'! 9]UL! $J-,!
%%)''%V37! Xg.g$! 9]UL! $J-,!
%&&&))V37! Sg:j'! 9]UL! $J-,!
%-%&%)V37! iMW.%! 9]UL! $J-,!
%$*+,,V37! .WiW%$'! 9]UL! $J-,!
%-%)-$V5V37! M.X.US$! 9]UL! $J-,!
$((&&,)V3V37! 99T9$&! 9]UL! $J-,!
%--)&'V37! HS]$! 9]UL! $J-,!
%$&')*V37! ;]T%! 9]UL! $J-,!
%$%*+&V37! ;ggH)! 9]UL! $J-,!
%--*%*V5V37! X9.;%! 9]UL! $J-,!
%-,$$&V5V37! MW^%-g! 9]UL! $J-,!
%-$-+%V5V37! T9.]$! 9]UL! $J-,!
%$&))(V37! Uj:'! 9]UL! $J-,!
%$-'-*V37! HHW$X! 9]UL! $J-,!
%$$-%,V@V37! S^S$+! 9]UL! $J-,!
%'&'$'V37! HHRC%! 9]UL! $J-,!
%$%$)*V5V37! UWX;9g$! 9]UL! $J-,!
%%&-%(V5V37! XH$W$! 9]UL! $J-,!
%-*+%'V5V37! WXm! 9]UL! $J-,!
%-(')-V37! ]HXU%! 9]UL! $J-,!
%-$-'-V37! ^]XR%! 9]UL! $J-,!
%-+&)'V37! R]HH'X! 9]UL! $J-,!
%%+%-'V37! HUWg'! 9]UL! $J-,!
%%'**(V37! RfU$! 9]UL! $J-,!
! ! $&)!
%-$*-%V5V37! HHH$;$-! 9]UL! $J-,!
%%*'-%V5V37! k.H%&! 9]UL! $J-,!
%&))),V37! Cj9$--(-*',(! 9]UL! $J-,!
%&-$-)V37! m:T9! 9]UL! $J-,!
%%%)$)V5V37! kUH$)! 9]UL! $J-,!
%--*'(V5V37! ^]g$! 9]UL! $J-,!
%-$,-&V37! ko9;9$! 9]UL! $J-,!
%$%-%+V37! ;gW%(! 9]UL! $J-,!
%%*-'*V@V37! mg.g'! 9]UL! $J-,!
%&-%$&V37! 9$,128'&! 9]UL! $J-,!
%$%$-*V5V37! TM:,! 9]UL! $J-,!
%-$*')V37! .H(&! 9]UL! $J-,!
%--,%%V37! lTiC;$! 9]UL! $J-,!
%''+-'V37! UoU.W$! 9]UL! $J-,!
%%&$&%V5V37! .;RW+! 9]UL! $J$-!
%-%+-(V5V37! Xg99$! 9]UL! $J$-!
%$%-+$V@V37! H;;9%X! 9]UL! $J$-!
%$$(-&V5V37! ;Xg$'! 9]UL! $J$-!
%-+$$'V5V37! RU^%-C%! 9]UL! $J$-!
%$%($%V5V37! 9X;W$! 9]UL! $J$-!
%$$&(+V5V37! 9Rm$! 9]UL! $J$-!
%%+&&*V37! HffH%X! 9]UL! $J$-!
%$+(%%V5V37! WXH$U! 9]UL! $J$-!
%-&+&&V5V37! .^jC]%! 9]UL! $J$-!
%&$+)-V37! g;fT$! 9]UL! $J$-!
%%(,*,V37! HCilM^%! 9]UL! $J$-!
%%%(-+V5V37! X;^Ck$! 9]UL! $J$-!
%'$)$$V5V37! S]T9&X! 9]UL! $J$-!
%%$,*%V5V37! UTS'! 9]UL! $J$-!
%%&$&+V5V37! TM:&)! 9]UL! $J$-!
%-(&%%V5V37! W.S$! 9]UL! $J$-!
%&',%'V5V37! m]S)+*! 9]UL! $J$-!
%&)%),V37! m]S)%+! 9]UL! $J$-!
%-&%(+V37! T;XH$! 9]UL! $J$-!
%%)-*-V37! 9,128$'%! 9]UL! $J$-!
%-%-%'V37! XU]X$! 9]UL! $J$-!
$((($%(V37! ^9S9$! 9]UL! $J$-!
%$*)()V37! UWX;9X'! 9]UL! $J$-!
%-&%&,V5V37! 9]j.&! 9]UL! $J$-!
%$%+-+V37! ]SX.9%RH! 9]UL! $J$-!
%%&-$,V37! SXW$%,g! 9]UL! $J$-!
$((+*+%V3V37! Cj9$--$&-((*! 9]UL! $J$-!
%$&(*,V5V37! iH&--! 9]UL! $J$-!
%$'*)+V@V37! R^ln$L(! 9]UL! $J$-!
%-&',$V5V37! 9iH(*! 9]UL! $J$-!
! ! $&*!
%%,*)(V37! m]S%-*! 9]UL! $J$-!
&,+&(V37! UgS$! 9]UL! $J$-!
%$'),-V37! .XS$g! 9]UL! $J$-!
$(((*&-V3V37! 9SC$! 9]UL! $J$-!
%-+)+(V@V37! g;T%! 9]UL! $J$$!
%-(*'-V5V37! ;gW'%! 9]UL! $J$$!
%-,-%'V5V37! U\]9;RH! 9]UL! $J$$!
%$'&$(V@V37! 9XC;! 9]UL! $J$$!
%%*%(*V5V37! 9$-128')! 9]UL! $J$$!
%--),(V37! HHH%;$X! 9]UL! $J$$!
%&)%(,V37! U.l'! 9]UL! $J$$!
%'$%&&V@V37! 9%$128+$! 9]UL! $J$$!
%'-(('V37! XlXH+C! 9]UL! $J$$!
%&*&&&V37! ;ggH'! 9]UL! $J$$!
%-$$-$V5V37! g9CXS$! 9]UL! $J$$!
%-)))(V5V37! g9C%C$! 9]UL! $J$$!
%'&%,(V37! ;gW%*! 9]UL! $J$$!
%%(+-$V37! Sg:j&%! 9]UL! $J$$!
%-%)%$V37! R;S&! 9]UL! $J$$!
%--*-%V5V37! TT:%'! 9]UL! $J$$!
(+,,'V37! 99%T$X! 9]UL! $J$$!
$())&'-V37! U]j;T+! 9]UL! $J$$!
%-+*($V37! ]XHX! 9]UL! $J$$!
%%*&,&V37! X]j,! 9]UL! $J$$!
%%+$%&V5V37! XgMT$%! 9]UL! $J$$!
%%($-&V37! W;HC&+! 9]UL! $J$$!
%&+,'-V37! lCS$%! 9]UL! $J$$!
%$&,(*V5V37! 9iH&(-! 9]UL! $J$$!
%%*,-&V@V37! 9$,128%-! 9]UL! $J$$!
%%%()+V37! k^^.$! 9]UL! $J$$!
(**&,V37! T]T$! 9]UL! $J$$!
%%$*$+V5V37! XlXH$&! 9]UL! $J$$!
%-&&++V37! X;;g%! 9]UL! $J$%!
%%(-'$V37! WHMjUHM+! 9]UL! $J$%!
%&&((,V5V37! fTS\$! 9]UL! $J$%!
%$($++V37! U.l%'! 9]UL! $J$%!
%&**'$V37! UC9%(X&)! 9]UL! $J$%!
%-++*)V5V37! HXl%! 9]UL! $J$%!
%-$)+&V@V37! .j:'! 9]UL! $J$%!
%-''+-V5V37! 9,128$)! 9]UL! $J$%!
%$%*(,V5V37! .9S*C%! 9]UL! $J$%!
%-$%)'V37! 9jHi! 9]UL! $J$%!
$((&%(%V3V37! g;fT&! 9]UL! $J$%!
%%%'-)V5V37! H];9%! 9]UL! $J$%!
%%*(,,V37! Wg%$T%! 9]UL! $J$%!
! ! $&+!
%$*(&+V37! U^UW%! 9]UL! $J$%!
%-'$,%V37! 9T&*! 9]UL! $J$%!
%%,-$-V37! 9gC! 9]UL! $J$%!
%-,,)%V37! iHj;! 9]UL! $J$%!
%-$%%'V5V37! U;;W$! 9]UL! $J$%!
%$&*,,V5V37! H.H;X! 9]UL! $J$%!
$(),-,+V5V37! .H(&gH$! 9]UL! $J$%!
%$*(&,V37! 9$+128%(! 9]UL! $J$%!
%%)$*)V5V37! kUH'%! 9]UL! $J$%!
%-,,,)V@V37! H9W$! 9]UL! $J$%!
%%*%(%V37! C;H$-! 9]UL! $J$%!
%&(+%+V37! H;iCRT%! 9]UL! $J$%!
%-&(-)V5V37! WiT$%! 9]UL! $J$%!
%&,&+%V37! MHU$! 9]UL! $J$%!
%&$$-$V37! HHH%;(i! 9]UL! $J$%!
%%-,%(V37! ]XX&(! 9]UL! $J$%!
%$$,'*V5V37! H;;9%9! 9]UL! $J$%!
%%$--)V5V37! U]:%*! 9]UL! $J$&!
%-$$+&V5V37! 9MT'! 9]UL! $J$&!
%$+%)-V37! TTX$! 9]UL! $J$&!
%%($%'V37! HHH$;,g! 9]UL! $J$&!
%$)()&V37! X]l;T$%! 9]UL! $J$&!
%&-,)*V5V37! kUH*! 9]UL! $J$&!
%%%(''V5V37! fMU9$C$! 9]UL! $J$&!
$()+)+-V5V37! \.MT9%! 9]UL! $J$&!
%-,)*(V5V37! M];]HkC$! 9]UL! $J$&!
%%(%,'V5V37! .;XHH9$! 9]UL! $J$&!
$((&&'+V3V37! ]S:$! 9]UL! $J$&!
%--(,+V5V37! MUH,-g$! 9]UL! $J$&!
%%-(-,V37! ;gW%)! 9]UL! $J$&!
%$,$(+V5V37! ]XX$(! 9]UL! $J$&!
%--,$*V5V37! U;H;! 9]UL! $J$&!
%$$-%%V5V37! X.;:! 9]UL! $J$&!
%'$++$V37! j;%f&! 9]UL! $J$&!
%%&%--V5V37! CU^$! 9]UL! $J$&!
%%+'&&V37! ]S\X! 9]UL! $J$&!
%%%,-,V5V37! gX^'! 9]UL! $J$&!
%$%'($V37! Ui9RUgH%C! 9]UL! $J$&!
%'&,,(V37! H.X;$! 9]UL! $J$'!
%%(&,&V37! ^X.XT%g! 9]UL! $J$'!
%%%&+*V5V37! nHU&(! 9]UL! $J$'!
%%,%)(V37! UlR! 9]UL! $J$'!
%-$+)+V5V37! .gC$:! 9]UL! $J$'!
%$%&&%V37! ;gC%! 9]UL! $J$'!
%-++*,V@V37! H;HS)! 9]UL! $J$'!
! ! $&,!
%%,%)'V37! SCp&,*&,! 9]UL! $J$'!
$((,-&+V37! UiH.%! 9]UL! $J$'!
%-*,))V5V37! ^C^$! 9]UL! $J$'!
%%$*-(V5V37! URli$! 9]UL! $J$'!
%-&',)V5V37! WiT$! 9]UL! $J$'!
$((&&-'V37! CUW$'g! 9]UL! $J$'!
%$'&(%V5V37! l;XU! 9]UL! $J$'!
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Pathway Gene Name Description 
Formation of actin bundles, 
filaments and cytoskeleton 
AKAP13     
ARRB1 
EZR 
MAPK8 
PDCD6IP 
PKN2 
RANBP9          
RICTOR 
SMARCA4!
!
TPR!
A kinase anchor protein 13 
Arrestin, Beta 1 
Ezrin 
Mitogen-activated protein kinase 8 
Programmed Cell-Death 6 interacting protein 
Protein kinase N2 
RAN binding protein 9 
RPTOR independent companion of MTOR, complex 2 
SWI/SNF-Related Matrix-Associated Actin-Dependent 
Regulator Of Chromatin 
Translocated promoter region 
Binding & linkage of actin 
cytoskeleton 
EZR Ezrin 
 
Formation of actin stress 
fibers 
AKAP13 
 
ARBB1 
         
PDCD6IP 
 
PKN2         
 
SMARCA4 
A kinase anchor protein 13 
 
Arrestin, Beta 1 
Programmed Cell-Death 6 interacting protein 
Protein kinase N2 
 
SWI/SNF-Related Matrix-Associated Actin-Dependent 
Regulator Of Chromatin 
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Gene Expression Profiling defines T-ALL patients carrying C-MYC 
rearrangements within a group with high expression of C-MYC 
!-.$3!"$&
GEP analysis performed on zebrafish models revealed the presence of a strong signature 
distinguishing the group overexpressing hC-MYC (hMYC-ER). Even if this part is not 
directly related to CNS invasion, these observations challenge us to clarify the 
importance and the role of C-MYC oncogene in T-ALL patients. Genetically, hT-ALLs 
are a heterogeneous group, distinguished in subgroups characterized by chromosomal 
rearrangements and related gene expression profiling signatures (TALLMO, HOXA, 
TLX1, TLX3). In pediatric T-ALL patients ~65% present NOTCH1 mutations with 
consequent activation of the NOTCH1 pathway. MYC seems to have a critical role for 
tumor growth and maintenance, even if its overexpression is not sufficient to guide 
alone lymphomagenesis. In T-ALL, MYC overexpression is usually trigged by 
NOTCH1 activation, however there are some cases that present MYC upregulation 
independently from NOTCH1 mutations: MYC/TCR translocations (~1% T-ALLs), 
FBXW7 mutations (~5% T-ALLs), down-regulation/absence of PTEN, MYC 
translocation with unknown partner genes. Recently, it was shows how an activation of 
the Wnt/"-catenin pathway in T-cells trigged the development of T-ALL characterized 
by an overexpression of C-MYC, due to high percentages of both MYC secondary 
genomic rearrangements and loss of PTEN. This work underlines the presence of a 
subgroup of T-ALL independent from Notch1 activation but with a high expression of 
C-MYC. In this part of the work, we used a gene expression profiling approach to study 
T-ALL patients that have different C-MYC expression levels to define if C-MYC 
deregulation can have also a prognostic value. Moreover, we investigated the different 
events that triggered C-MYC upregulation (NOTCH1 activation, FBOX and PTEN 
mutations, MYC rearrangements) to understand the biological meaning of  different 
causes that result all in C-MYC over-expression. Finally, were able to find a strong 
signature insight the group of patients with high expression of C-MYC that can 
discriminate patients with- and without- C-MYC rearrangements. 
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T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive haematopoietic cancer 
resulting from an uncontrolled clonal proliferation of T-immature lymphoid cells that 
represents !15% of pediatric and !25% of adult T-ALLs [1]. Genetically, hT-ALLs 
represent a heterogeneous malignancy distinguished in main subgroups characterized by 
specific chromosomal rearrangements and related to distinct gene expression profiling 
signatures (TALLMO, HOXA, TLX1, TLX3) [2-4]. Independently from the subgroups, 
more than 50% of T-ALL patients carried NOTCH1 mutations (NOTCH1m) [5] with 
consequent constitutive NOTCH1 pathway activation and transcription of direct 
NOTCH1 target genes, suggesting an universal role of NOTCH1 in T-ALL 
pathogenesis. Several studies have already shown the central role played by NOTCH1 
activation in promoting T-ALL development; moreover, these  works identified C-MYC 
as a NOTCH1 directed target gene having a critical role in determining tumor growth 
and maintenance both in mouse- [6] and human- [7,8] NOTCH1-dependent T-ALL. 
MYC is involved in cell growth and proliferation in diverse solid and hematologic 
malignancies [9], but this oncogene can promote also apoptosis through the BIM and 
P53/P14ARF pathways [10,11]. However, the over-expression of C-MYC alone is not 
sufficient to determine T-ALL development and other events are required to initiate 
leukemogenesis [12,13]. The potential role of MYC activation in initiating T-ALL 
tumorigenesis was demonstrated both in transgenic zebrafish- [14,15] and mouse 
models [16-18], where the induced over-expression of C-MYC lead to T-ALL 
development with high penetrance and short latency. However, a recent work suggested 
that these animal models fail to reproduce the natural events that give rise to leukemia 
in human patients, as the accumulation of secondary hits is a slow process that is 
necessary for tumor development, according to a “multi-genomic alteration” model of 
hT-ALL pathogenesis [19]. Instead, transgenic animal models massively over-express 
C-MYC in specific target tissues, accelerating the leukemogenic process and moving 
away from human kinetics of oncogenesis.  In Chapter 1 of this thesis, we used the 
transgenic hMYC-ER zebrafish model that over-expressed human C-MYC under the 
zebrafish rag2 promoter [15]. Even if this model does not perfectly reflect the process 
of human leukemogenesis, it can be considered a very good model for studying the 
biology of T-ALL cases characterized by high C-MYC expression. In T-ALL human 
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patients, C-MYC over-expression is usually triggered by NOTCH1 activation. However, 
there are other events that can drive C-MYC up-regulation independently from 
NOTCH1
m; C-MYC translocations with T-cell receptor (~1% T-ALLs) [20] or unknown 
partner genes may directly cause an up-regulation of C-MYC, while FBXW7m (~5% 
TALLs) [21-23] and down-regulation/absence of functional PTEN/AKT activation 
(~15-20% TALLs) [24-27] stabilize MYC impairing its degradation [28]. A recent 
study showed how MYC expression both at the mRNA and protein level resulted highly 
variable in a cohort of 164 mixed adult and pediatric T-ALL patients [28]. Even if the 
majority of T-ALL patients show a high expression of C-MYC, the role/importance or 
prognostic value of this oncogene is still not clear, among other things due to the 
complexity and variability of oncogenic networks that can occur in T-ALLs. A paper 
related T-ALL cell lines glucocorticoid resistance to up-regulation of cellular 
metabolism and proliferation due also to C-MYC signaling pathway activation [29], 
however the prognostic significance of C-MYC over-expression in T-ALL is still not 
understood. In fact, C-MYC over-expression is usually related to NOTCH1m and 
activation of  the NOTCH1 pathway has been associated to improved response to 
treatment in three different cohort of T-ALL, but showing different outcome that seems 
to be therapy-dependent [30-32]. However, patients with C-MYC over-expression due to 
loss of PTEN in  the absence of NOTCH1m were associated with resistance to 
chemotherapy and poor long-term outcome [27]. Recently, the activation of the Wnt/"-
catenin pathway in T-cells has been shown to trigger the development of  NOTCH1 
independent T-ALL characterized by over-expression of C-MYC due to high incidence 
of MYC secondary genomic rearrangements and/or loss of PTEN [33]. This work 
underlines the presence of a subgroup of T-ALL independent from NOTCH1 activation 
but with a high expression of C-MYC that could be related to poor prognosis. C-MYC 
over-expression seems to have diverse values depending on different T-ALL contexts.  
In this part of the work, we focussed on T-ALL patients that have different C-MYC 
expression levels to define if this C-MYC deregulation is related to a specific gene 
expression profiling signature. Moreover, we investigated the different events that 
triggered C-MYC deregulation (NOTCH1 activation, FBXW7 mutations, MYC 
rearrangements) to understand the biological meaning of different causes that result all 
in C-MYC over-expression.  
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Human leukemia samples  
Bone marrow or Peripheral Blood aspirates were collected from pediatric patients with 
or T-ALL at diagnosis. All patients selected for this study were enrolled in the AIEOP 
ALL-2000 protocol. Patients’ parents or legal guardians did provide written informed 
consent for the use of patient material for biomedical research in accordance with the 
Declaration of Helsinki.  
RNA isolation, quality controls and quantification 
Mononucleated cells (MNC) were isolated via the Ficoll-Paque method (GE Healthcare 
companies, Buckinghamshire, United Kingdom), which is based on density gradient 
centrifugation. Total RNA from MNC derived from bone marrow (BM) or peripheral 
blood (PB) aspirates was extracted using Trizol (Invitrogen, Karlsruhe, Germany), 
according to manifactures’ instructions. To perform gene expression experiments, 
extremely high quality of total RNA is required. To assess the quality of RNA, Agilent 
Bioanalyzer Expert 2100 (Agilent Technologies, Waldbronn, Germany) was used. RNA 
concentration was determined using QBit 2.0 Fluorometer (Life Technology, Carlsbad, 
California, U.S.). NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies Inc, 
Wilmington, DE). 
 
Fluorescence in situ hybridization (FISH) 
Two break apart FISH assays were used to study CMYC rearrangements: the 
commercial LSI MYC dual color break apart rearrangement probe (Vysis, Abbott) and 
homebrew DNA clones mapping upstream (RP11-367L7) and downstream (RP11-
26E5) CMYC (http://www.chori.org/BACPAC). TCRB was studied with RP11-1220K2 
and RP11-556I13; TCRAD with RP11-242H9 and RP11-447G18. Double colour 
double fusion FISH assays were done to investigated cryptic translocations between 
CMYC and TCRB or TCRAD. 
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Gene expression profiling 
Only RNA samples that passed the high quality controls were diluted to 100ng in a total 
volume of 3µl DEPC treated water to perform gene expression experiments. In vitro 
transcription, hybridization and biotin labelling were performed according to GeneChip 
3’IVT Express kit protocol (Affymetrix, Santa Clara, CA). The Affymetrix GeneChip 
Scanner was used to measure all intensities of the signals of each probe set on the 
GeneChip and stores all signals in a .DAT file (Raw image). Integrated software 
converts all raw signals into numbers, which were stored in a .CEL file. All GEP 
profiles used in these experiments were assessed for their comparability and quality, 
using different quality controls: Scale Factor, number of present calls, internal probe 
calls, Poly-A controls and the ratio GAPDH/!-actin 3’/5’.  
 
Statistical analysis 
Microarray data (.CEL files) were analyzed using Command Expression Console 
(Affymetrix). R-Bioconductor (Version 2.15.3) was used to analyze the .CEL files data 
in an unsupervised and supervised manner. Unsupervised analysis (Class Discovery) is 
a learning algorithm that clusters unspecified specimens together based on similar gene 
expression patterns and is therefore highly unbiased. Supervised analysis (Class 
Comparison, Class Prediction) is a learning algorithm that uses already defined 
(labeled) data in order to identify a set of genes that characterize the pre-specified data. 
The .CEL files first were normalized using the justRMA algorithm. justRMA is an 
algorithm fulfilling 2 steps, namely background adjustment of all the probe sets present 
on the GeneChip and quantile normalization to make the values of all the GeneChips 
comparable. In order to find differently expressed probe sets we applied a Shrinkage t-
test on the normalized .CEL files [35]. We used a local false discovery rate (lfdr) as 
correction of the p-value; a ldfr < 0,05 was considered significant for genes differently 
expressed between 2 groups. Differently expressed probe sets derived from the 
Shrinkage t-test were used for clustering analysis. Hierarchical clustering analysis was 
used to clusterize the specimens in an unsupervised manner using Euclidean Distance 
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and Ward’s Method. Euclidean Distance and Ward’s Method compute the distance 
between two groups in a metric space.  
Gene Ontology and Protein-Protein Interacting Analyses 
Differently expressed genes dereived by Shrinkage T-test analysis were analyzed using 
Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 and 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) v9.05. STRING, 
based on text mining, was used in order to investigate potential gene/protein networks 
within in the list of differently expressed genes. Gene ontology was performed with 
DAVID.  
 
Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis (GSEA) is a method that can be used to identify groups 
of genes that share common biological functions or belong to the same gene pathways 
described in the public domain [36]. For each group of gene sets, GSEA calculates an 
enrichment score and evaluates statistical significance n the enrichment score (ES). The 
ES reflects the degree to which a gene set is over represented. For this stud we 
conducted GSEA analysis using the GSEA software [16] version 4.0 to identify gene 
sets in the public domain that share the expression pattern enriched in our current study. 
As recommended by GSEA guidelines, only gene sets with a false discovery rate (FDR) 
q-value lower than 0.05 were considered.  
Sanger Sequencing 
The screening of NOTCH1 and FBXW7 mutations was performed for 40 T-ALL 
specimens comprising patients of the two quartiles with high and low expression of C-
MYC (table1), and 4 additional cases of T-ALL carrying C-MYC translocation (table2). 
Briefly, DNA was extracted from the bone marrow (BM) or peripheral blood (PB) of 
each patient using the Puregene DNA isolation kit according to the manufacturer’s 
instructions (QIAGEN). 20 ng/µl of genomic DNA was used for PCR-amplified 
(primers reported in the Table3), using according to optimized protocols for each gene. 
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NOTCH1 and FBXW7 PCR products were purified using illustra™ ExoStar™ enzymes 
(VWR International Ltd, Lutterworth, England). All PCR products were quantified 
using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies Inc, 
Wilmington, DE). Sanger sequencing was performed on both strands using BigDye 
Terminator v1.1 Sequencing kit (Applied Biosystems, Weiterstadt, Germany) and 
analyzed on an automated fluorescence-based analyzer according to the manufacturer’s 
protocol.  
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C-MYC expression levels in a cohort of 78 T-ALL pediatric patients 
This work aimed to clarify the biological significance of C-MYC oncogene expression 
in T-ALL development. Data of gene expression profiling considering a cohort of 78 T-
ALL patients at diagnosis, revealed the presence of a broad range of variable expression 
levels of C-MYC among patients. The expression levels of C-MYC formed a continuum 
observing the entire cohort, but we could distinguish the presence of two opposite 
groups with “high” or “low” expression of C-MYC respectively (figure 1). We used a 
descriptive statistical method to define two opposite groups, calculating the quartiles 
based on C-MYC expression and we identified 20 patients with low (first quartile) and 
20 patients with high (fourth quartile) expression of C-MYC.  
 
Different gene expression profiling signatures between groups with Low and High C-
MYC expression  
To understand the different gene networks that move in relation to having high or low 
C-MYC expression, we performed a T-test on GEP data comparing the patients of the 
two opposite quartiles for C-MYC expression (Q1-Q4). Shrinkage T-test revealed the 
presence of 115 genes significantly differently expressed between Q1 and Q4 groups. 
Supervised analysis separated patients belonging to the Q1 and Q4 group, except for 4 
patients with high expression of C-MYC that clustered together with the patients of Q1 
(figure 2). However, genes that were differently expressed did not present high fold 
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changes (FCs) and explained the rather weak signature found between the two  groups. 
The distinction between patients with high and low C-MYC expression levels is not 
related to a strong gene expression signature, which is maybe due to the high variability 
of events that regulate C-MYC expression in T-ALL patients. Moreover, Gene Set 
Enrichment Analysis (GSEA) did not reveal a particular enrichment of known gene sets 
when comparing the two groups. There is only a tendency for the group with high C-
MYC expression to have an enrichment of the WNT and CXCR4 pathways, but the p-
value is not significant (figure 3). 
 
NOTCH1, FBXW7 mutation screening 
Different events directly or indirectly induce C-MYC over-expression: NOTCH1m 
frequently sustain up-regulation of C-MYC [7,8], causing constitutive activation of the 
NOTCH1 pathway; FBXW7m can favour both indirect C-MYC over-expression 
(impairing active NOTCH1 degradation) and C-MYC protein stabilization directly 
preventing its proteasomal degradation [21-23]. We decided to investigate the causes 
that could be held responsible for C-MYC deregulation among the patientss with high 
MYC expression in our patient cohort. We screened NOTCH1, FBXW7 mutations for 
each patient of the two quartiles with high or low expression of C-MYC. We analysed 
the regions frequently mutated in T-ALL for each of these genes: NOTCH1 for the HD 
and PEST domains (26, 27, 28, 34T and 34P exons) while FBXW7 was screened for 
mutations in exons 9 and 10. Moreover, to have an overview of effective NOTCH1 
activation, we monitored the expression levels of NOTCH1 direct target genes (HES1, 
DELTEX1 CR2 and PTCRA) using gene expression profiling data. (Table1). With this 
analysis we were able to identify 1 case (patient 36) with over-expression of C-MYC not 
related to NOTCH1, FBXW7 mutations. These data suggested that this patient could 
carry other events that could explain C-MYC over-expression, such as a C-MYC 
rearrangements. 
 
Rearrangements of C-MYC can cause the “high” expression of C-MYC  
FISH [37,38] analysis using specific probes for C-MYC was performed for the 7/20 
cases that presented low expression of C-MYC (Q1) and 13/20 cases with high 
! ! $()!
expression of C-MYC (Q4) (table 1). The aim of this analysis was to identify 
rearrangements of C-MYC that could explain the over-expression of this oncogene 
occurring in the presence or absence of NOTCH1 and FBXW7 mutations. C-MYC 
reciprocal translocations, i.e. an hybridization pattern characterized by 1 fusion signal 
and 2 separated green and orange signal occurred in 5 cases (figure 7) and involved 
TCRB or TCRAD in two samples. New as yet unidentified partner would be involved in 
the other 3 cases as cryptic rearrangements with TCRB or TCRAD were excluded. Inside 
the group with “high” C-MYC expression, we identified one patient (patient 36) with a 
C-MYC translocation (with an undefined partner gene).  
Different signature among T-ALL patients with high expression of C-MYC related to 
C-MYC rearrangements 
Recently, in a mouse model a subgroup of T-ALL was identified  that was shown to be 
triggered by the activation of the Wnt/"-cathenin pathway, an event that seemed to be 
related to the development of secondary C-MYC rearrangements and loss of PTEN [33]. 
This mouse model developed a NOTCH1 independent T-ALL leukemia that migh 
identify a subgroup with bad prognosis, in fact the loss of PTEN in the absence of 
NOTCH
m has been shown to be related to poor outcome [28]. To understand if also in 
human T-ALL there is a subgroup of patients with high MYC expression independent of 
NOTCH1 mutations or activation in general, we decided to increase our cohort of 
patient with high expression of C-MYC (Q4) with patients carrying C-MYC 
translocations. Using a gene expression profiling approach, we wanted to investigate the 
biological significance and possibly the prognostic impact of C-MYC over-expression 
due to distinct genomic aberrations (activation of NOTCH1, mutation of FBXW7, C-
MYC translocations). We increased the high C-MYC group with 1 pediatric and 3 adult 
cases carrying C-MYC rearrangements in the absence of NOTCHm and FBXW7m. FISH 
specific for C-MYC rearrangements had been performed for all patients and this 
technique allowed to detect and quantify also sub-clones carrying C-MYC 
rearrangements. All patients analyzed by GEP had the C-MYC rearrangement in the 
major clone. Analysis of C-MYC expression revealed that the 5 cases with MYC 
rearrangements had high expression of this oncogene (Figure 4). Shrinkage T-test 
revealed the presence of 174 genes differently expressed comparing C-MYC rearranged 
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vs. non C-MYC rearranged groups. We have to remember that the group without C-
MYC rearrangement is enriched for NOTCH1 and FBXW7 mutations. Supervised 
analysis showed how patients carrying C-MYC translocations in absence of NOTCH1m 
clustered together, separately from the patients without translocations (Figure 5). Only 
one patient without a C-MYC translocation clustered in the group with C-MYC 
rearrangements.  
To investigate the genes differently expressed between the two groups (C-MYC 
rearranged vs. non C-MYC rearranged) we performed gene ontology and protein-protein 
interaction analyses using DAVID and STRING software, respectively. Both DAVID 
and STRING analysis showed a significant enrichment for the NOTCH1 signaling 
pathway (p-value: 0.002) in the group without C-MYC rearrangements (Figure 6). This 
enrichment was confirmed also by Gene Set Enrichment analysis (GSEA).  
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In this chapter, we aimed to investigate the biological meaning of C-MYC aberrant 
expression in relation to T-ALL disease. Oncogenic MYC deregulation is a complex 
process involving multiple events (MYC rearrangements, NOTCH1 and FBXW7 
mutations) that complicate the understanding of C-MYC- mediated oncogenesis in T-
ALL. In a cohort of 78 pediatric T-ALL patients, we found different expression levels 
of C-MYC. Particularly, we identified two groups characterized by high and low 
expression levels of this oncogene. To deepen insight in the biological impact of C-
MYC deregulation, we performed gene expression profiling analysis comparing these 
two groups. However, this analysis failed to identify a strong signature that could 
distinguish the two groups in a perfect way. This result can be attributed to the 
undeniable heterogeneity that characterize the T-ALLs and major subgroups with C-
MYC deregulation; in fact a multiplicity of pathways and genetic alteration may control 
C-MYC transcription [34]. Moreover, we have to consider that also post-transcriptional 
control can play an important role in determining MYC protein levels and C-MYC 
transcription levels do not in all cases corresponds to protein levels [28].  
Interestingly, inside the group with high expression of C-MYC, different molecular 
mechanisms can determine C-MYC overexpression or MYC stabilization (MYC 
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rearrangements, NOTCH1 and FBXW7 mutations). Usually the over-expression of C-
MYC is related to activation of the NOTCH1 signalling pathway, an event related to 
improved response to treatment [30-32]. Analyzing NOTCH1 direct target genes 
expression, we were able to identify some patients with high expression of C-MYC not 
associated to NOTCH1 and FBXW7 mutations. One among these patients carried a C-
MYC rearrangement. A recent work on a mouse model identified the presence of a 
NOTCH-independent subgroup of T-ALL characterized by high expression of C-MYC 
that can be related to poor prognosis. This subgroup was related to Wnt/"-catenin 
pathway activation and was characterized by  a high incidence of C-MYC 
rearrangements and loss of PTEN. To explore the presence of this Wnt/"-catenin-
dependent T-ALL subgroup also in T-ALL patients with high expression of C-MYC, we 
amplified our cohort introducing four patients carrying C-MYC rearrangements in  the 
absence of NOTCH1m. Analysis of gene expression profiling revealed a strong signature 
between patients with- or without- C-MYC rearrangements. Interestingly, this strong 
signature was associated to the presence of NOTCH1 pathway activation in the group of 
patients without C-MYC rearrangements. Although we failed to find activation of the 
Wnt/"-catenin pathway inside the group with C-MYC translocations, with this study we 
were able to show that inside the group of T-ALL characterized by an higher expression 
of C-MYC overexpression, the subgroup of patients carrying C-MYC rearrangements 
presents a NOTCH1-independent leukemia compared to the group without C-MYC 
rearrangement that seems to be strongly related to NOTCH1 pathway activation. 
Further analysis need to be performed increasing the number of patients carrying C-
MYC rearrangements. Importantly, the screening of PTEN mutations is ongoing, to have 
a complete view of the major modulators of MYC deregulation at the protein level. 
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Dot plot showing the variable expression levels of C-MYC in a cohort of 78 T-ALL patients 
based on GEP data 
 
Figure 1: The expression value of the C-MYC probe set (202431_s_at) for each patient (single dot) is 
given in a log2 scale after normalizing all GEP data with the  justRMA algorithm. Using descriptive 
statistics the cohort  was divided in quartiles and identified two opposed groups characterized by low 
(blue square) or high (orange square) expression of C-MYC (Q1 and Q4 respectively). 
 
 
Heatmap showing supervised analysis for groups with high (blue) or low (orange) 
expression of C-MYC 
 
 
Figure 2: Hierarchical clustering based on a list of 115 probe sets obtained after Shrinkage T-test 
between groups with high (blue) and low (orange) C-MYC expression (lfdr<.05). 
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Gene Set Enrichment Analysis for the group with high expression of C-MYC 
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Figure 3. GSEA analyses showing the tendency for the group with HIGH expression of C-MYC to be 
enriched for the WNT and CXCR4 pathways. However, this enrichment is not sgnificative. 
 
 
 
All C-MYC rearranged cases presented a high expression of C-MYC oncogene 
 
 
 
 
Figure 4: Dot plot showing the expression levels of C-MYC for the 4 new cases with a C-MYC 
rearrangements. In red are indicated the 4 additional cases (patients 41, 42, 43, 44) with C-MYC 
rearrangements that were included for new analysis. 
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Heatmap shows supervised analysis for groups with- (blue) and without (orange) C-MYC 
rearrangements 
 
 
Figure 5: Hierarchical clustering based on a list of 174 probe sets obtained after Shrinkage T-test 
between groups with- (blue) and without (orange) C-MYC translocation (lfdr<.05).  
 
 
Protein-Protein Analysis with STRING 9.05 for the group with high expression of C-MYC in 
absence of C-MYC rearrangements 
 
 
Figure 6: Analysis with STRING version 9.05 on genes significantly up-regulated in the group without 
C-MYC rearrangements shows enrichment in the NOTCH pathway  (KEGG pathway) for the group 
without MYC translocations compared to the group where MYC is rearranged. 
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FISH assay with LSI CMYC break apart probe (Vysis-Abbott) 
 
Figure 7: Two nuclei with C-MYC rearrangement. One Fusion signal corresponds to the CMYC wild type 
allele, two separated green and orange signals indicate a balanced CMYC translocation. 
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Table 1. Patients belonging to the two groups with low (Q1) and high (Q4) expression of C-MYC 
.")*'&.! .&;! b$"4%/'&! 3/.+! 78*9! :8;<8=9! >?@! A<>?B! CD<>79!.%"%$.! "E=FG!.%"%$.!
$! S! $! ! +J,'! *J$%! *J(,! )J)'! 1=B1"=B! 1=B1"=B!
%! S! $! =12?34! )J%*! (J+*! (J-*! )J$'! RK! RK!
&! W! $! ! 'J+,! )J))! 'J%)! )J)'! 1=B1"=B! 1=B1"=B!
'! W! $! ! 'J$(! )J%'! &J&$! )J$&! RK! RK!
(! W! $! ! +J)'! (J+&! )J-'! )J$$! 1=B1"=B! 1=B1"=B!
)! S! $! ! (J%(! )J%$! 'J*)! )J(*! 1=B1"=B! 1=B1"=B!
*! W! $! ! (J)'! )J*+! )J$(! )J'(! 1=B1"=B! 1=B1"=B!
+! W! $! ! (J)'! *J$*! ,J%,! *J()! RK! RK!
,! W! $! =12?34! 'J,'! )J'-! (J-*! (J,)! 1=B1"=B! RK!
$-! W! $! ! (J'-! )J,'! 'J)$! )J&$! 1=B1"=B! 1=B1"=B!
$$! W! $! =12?34! )J$+! )J'(! ,J($! +J-(! 1=B1"=B! 1=B1"=B!
$%! W! $! ! *J*+! )J)-! *J,'! )J(&! 1=B1"=B! 1=B1"=B!
$&! W! $! =12?34! $$J'(! $-J''! $-J,-! *J-*! UMKLKEP! 1=B1"=B!
$'! W! $! =12?34! )J&'! )J*+! (J))! )J)&! 1=B1"=B! 1=B1"=B!
$(! W! $! =12?34! )J&-! )J-,! 'J('! )J(,! 1=B1"=B! 1=B1"=B!
$)! W! $! ! (J(&! )J('! *J)(! *J$&! RK! RK!
$*! W! $! ! )J--! )J+%! +J&+! +J--! 1=B1"=B! 1=B1"=B!
$+! W! $! ! *J+,! )J&$! *J*(! *J-*! 1=B1"=B! 1=B1"=B!
$,! W! $! ! ,J)&! *J&-! +J$(! +J)+! 1=B1"=B! 1=B1"=B!
%-! W! $! =12?34! *J**! *J-'! ,J&+! +J'$! 1=B1"=B! 1=B1"=B!
%$! W! '! =12?34! +J+)! *J%,! +J**! ,J(%! UMKLKEP! UMKLKEP!
%%! W! '! ! +J&+! $$J-)! $-J))! ,J)&! 1=B1"=B! 1=B1"=B!
%&! S! '! =12?34! )J'-! )J-&! *J-,! *J&(! 1=B1"=B! 1=B1"=B!
%'! W! '! ! +J),! ,J$&! ,J'*! *J-%! UMKLKEP! RK!
! ! $)&!
%(! S! '! =12?34! $-J,)! )J',! *J'$! ,J'%! UMKLKEP! RK!
%)! W! '! =12?34! $-J%'! )J,$! *J&-! +J,-! 1=B1"=B! 1=B1"=B!
%*! W! '! ! ,J-&! ,J-*! $-J)-! +J$$! 1=B1"=B! 1=B1"=B!
%+! S! '! =12?34! $-J+'! *J+'! *J)*! )J,%! 1=B1"=B! 1=B1"=B!
%,! W! '! =12?34! ,J&+! )J%%! $$J&*! +J))! UMKLKEP! ?67370>!
&-! W! '! =12?34! +J&-! )J)+! )J+-! )J'%! 1=B1"=B! RK!
&$! W! '! =12?34! $$J,*! $-J$+! ,J%+! ,J+%! UMKLKEP! 1=B1"=B!
&%! S! '! =12?34! (J)+! *J*$! $$J+&! *J++! UMKLKEP! RK!
&&! W! '! =12?34! ,J+(! +J%&! $-J)'! +J$(! 1=B1"=B! 1=B1"=B!
&'! W! '! ! *J-%! ,J$*! $$J&&! ,J('! UMKLKEP! 1=B1"=B!
&(! S! '! ! (J&,! )J%(! (J',! )J+'! 1=B1"=B! 1=B1"=B!
&)! W! '! translocated )J--! )J)$! (J('! )J('! RK! RK!
&*! S! '! =12?34! *J,&! ,J++! $-J,&! +J+(! 1=B1"=B! 1=B1"=B!
&+! W! '! ! *J(&! )J%+! +J-+! +J(,! 1=B1"=B! 1=B1"=B!
&,! W! '! =12?34! $$J%-! +J&$! $$J+(! $-J-)! 1=B1"=B! RK!
'-! S! '! ! $$J%*! $-J+,! $$J-&! )J)+! 1=B1"=B! 1=B1"=B!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! ! $)'!
 
Features of T-ALL patients carrying C-MYC rearrangements 
 
Table 2: FISH details of 5 (2 pediatric and 3 adult) patients with C-MYC translocations. All 5 patients 
presented C-MYC rearrangements in the major clone. The C-MYC translocation involved both TCR and 
unknown rearranged partner genes. List of abbreviations: wt: wild-type; ND: not defined. 
 
In Table 3 are listed the primers used for the screening of NOTCH1 and FBXW7 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE 
 
AGE Type-MYC FISH STATUS 
NOTCH1 
STATUS 
FBXW7 
STATUS 
36 11 NO TCR 
del(1)(p32)/SIL-TAL1 (86%) 
C-MYC-translocation (70%) 
DIED wt wt 
41 5 NO TCR 
C-MYC-translocation  
t(1;8)(q32;q24) 
del(4)(p15) 
ND ND ND 
42 56 NOTCR 
del(9)(p21)/CDKN2A-B bial (95%) 
C-MYC-translocation (62%) 
MYB/6q23 gain 
MTCP1/Xq28 gain (34%) 
trisomy 7 (37%) 
DIED wt wt 
43 44 TCR 
del(9)(p21)/CDKN2A-B bial (88.5%) 
del(1)(p32)/SIL-TAL1 (82%) 
TCRA/D-C-MYC (90%) 
LOSS: PTEN/10q23 (12%) 
GAIN:AF10/10p13 (86%) 
ALIVE wt wt 
44 25 TCR 
del(9)(p21)/CDKN2A-B bial (72%) 
del(6q15)/CAS8AP2 (69%) 
del(1)(p32)/SIL-TAL1 (74%) 
t(7;11)(q34;p15)/TCRB-LMO1 
(66%) 
TCRAD-C-MYC (62%) 
DIED wt wt 
Exons Primers Product Size 
for-5'_GCTGAGGGAGGACCTGAACTTGG_3'  NOTCH1 ex26 
rev-5'_CCTGAGCTGGAATGCTGCCTCTA_3' 
812bp  
for-5'_CATGGGCCTCAGTGTCCT_3' NOTCH1 ex27 
rev-5'_TAGCAACTGGCACAAACAGC_3' 
335bp 
for-5'_GAGAGTGGGTGAGGAGGC_3' NOTCH1 ex28 
rev-5'_GTGAGGATGCTCGGCCAG_3' 
346 bp 
for-5'_ACAGATGCAGCAGCAGAACC_3' NOTCH1 ex34P 
rev-5'_CCTGGGGCCAGATAAAACAGTACA_3' 
721 bp 
for-5'_GCTGGCCTTTGAGACTGG_3' NOTCH1 ex34T  
rev-5'_CTCCTGGGGCAGAATAGTGT_3' 
592 bp 
for-5'_TGATGGGATCATTTTATACGGATG_3' FBXW7 ex9  
rev-5'_GACAAAACGCTATGGCTTTCC_3' 
495 bp 
for-5'_CCCAACTTCCCATTCCCTTA _3' FBXW7 ex10  
rev-5'_TTTCTTCATGCCAATTTTAACG_3' 
583bp 
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MLLT10 gene, located at 10p13, is a known partner of MLL and PICALM in specific 
leukemic fusions generated from recurrent 11q23 and 11q14 chromosome 
translocations. Deep sequencing recently identified NAP1L1/12q21 as another MLLT10 
partner in T-ALL. In pediatric T-ALL we have identified two RNA processing genes, 
i.e., HNRNPH1/5q35 and DDX3X/Xp11.3 as new MLLT10 fusion partners. Gene 
expression profile signatures of the HNRNPH1- and DDX3X- MLLT10 fusions placed 
them in the HOXA subgroup. Remarkably they were highly similar only to PICALM-
MLLT10 positive cases. The present study showed MLLT10 promiscuity in pediatric T-
ALL and identified a specific MLLT10 signature within the HOXA subgroup. 
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New genomic technologies, including whole genome analysis and gene expression 
profiling (GEP) dramatically improved cytogenetic-molecular classification of T-cell 
Acute Lymphoblastic Leukemia (T-ALL) which affects about 15% of children with 
ALL.1 At least 6 main genetic categories, i.e. TAL/LMO, TLX1, TLX3, NKX2-1/NKX2-
2, MEF2C, and HOXA have been identified. The HOXA group includes cases with 
TCRB-HOXA, SET-NUP214, MLL-translocations, and PICALM-MLLT10.1,2 In a case 
of Early T-cell Precursor-ALL (ETP-ALL) the NAP1L1/12q21 gene, member of the 
nucleosome assembly protein family, was recently identified as another MLLT10 
partner.3 
Interestingly, PICALM-MLLT10, MLL-MLLT10, and NAP1L1-MLLT10 fusions all 
retained the OM-LZ domain at their C-terminal. 3-5 It exerts a leukemogenic effect by 
interacting with chromatin modifying proteins such as the H3K79 methyltransferase 
hDOT1L.6,7 
The present study focuses on two new MLLT10 fusion genes in pediatric T-ALL, 
placing them within the HOXA subgroup. 
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A Combined Interphase (CI) FISH test (Supplementary Table 1) was applied in 42 
pediatric T-ALL enrolled in the AIEOP ALL protocol (number NCT 00613457). 
Informed consent according to the Declaration of Helsinki was obtained from parents. 
To identify the new MLLT10 fusions we used a 5’-RACE-PCR (Invitrogen, Carlsbad, 
CA, USA) and thermoscript RT-PCR System (Invitrogen) according to the 
manufacturer’s instructions. Primers are listed in Supplementary Table 2. PCR products 
were subcloned into pGEM-T easy vector (Promega, Madison, WI, USA) and 
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sequenced with AB3500 Genetic analyzer (Applied Biosystem, Foster City, CA, USA). 
SNPs analysis was performed using Whole Genome Cytogenetic 2.7M array 
(Affymetrix, Santa Clara, CA, USA).  
Statistical Methods for Microarray Data (Affymetrix hgu 133 plus 2 arrays) were 
analyzed using the Bioconductor package for R (v2.14.1). Data were deposited at GEO 
repository (Series Accession Number GSE42765; http://www.ncbi.nlm.nih.gov/geo/). 
Heatmaps were created using Ward’s method and Euclidean distance. The heatmap for 
the unsupervised analysis was created using the probe sets with the highest variances 
(threshold 90%), while the heatmap for the supervised analysis was created with 
differentially expressed probe sets. Arrays were normalized using robust multiple-array 
average (RMA).8 Batch effects were removed using ComBat.9 Differentially expressed 
genes were identified by the shrinkage T-statistic.10 False positive findings were 
prevented by the local False Discovery Rate (lFDR). Probe sets with local FDR below 
0.05 were considered significant.11,12 
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CI-FISH identified MLLT10 rearrangements in 6/42 (14.3%) patients. Four of the total 
cohort (9.5%) showed the PICALM-MLLT10 fusion and two (4.8%) MLLT10 
translocations to unknown partner(s). Clinical, hematological, cytogenetic and 
molecular data of these two patients are shown in Table 1. MLLT10 FISH probe gave 
three signals in 55% of nuclei in case 1 and in 60% in case 2. In case 1 metaphase-FISH 
confirmed the split between the short and the long arms of one chromosome 10, 
resulting in the der(10)inv(10)(p12q25) seen at karyotype. The 10q breakpoint localized 
to band 25.3, in a ~12 kb region without genes (Supplementary Figure 1A). 
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The MLLT10 gene breakpoint was narrowed to between exons 14 and 15 in patient 1 
and between exons 1 and 3 in patient 2 (Supplementary Figure 1B and 1C). 5’ RACE-
PCR and sequencing showed an HNRNPH1-MLLT10 in-frame transcript in the first 
case and a DDX3X-MLLT10 fusion transcript in the second (Figure 1A and 1C). These 
results were confirmed by RT-PCR, cloning and sequencing. Subsequently a diagnostic 
double color double fusion test was developed in both cases (Figure 1B and 1D). The 
only common additional genetic lesion was a mutated NOTCH1 gene (Table 1). 
HNRNPH1 and DDX3X are involved in RNA processing. HNRNPH1 encodes for a 
member of the ubiquitous heterogeneous nuclear ribonucleoprotein subfamily 
(hnRNPs). It is an RNA binding protein that is involved in pre-mRNA processing, and 
mRNA metabolism and transport.13 A HNRNPH1 frameshift mutation was previously 
described in gastric cancer14 and a HNRNPH1 splice variant with protein truncation was 
identified in murine breast cancer cells.15 Interestingly, a variant HNRNPH1 protein, 
covalently modified by O-linked acetyl hexosamine (GlcnaC), was isolated in acute 
leukemia with 11q23 cytogenetic changes.16 
DDX3X is a member of the large family of RNA helicases with a DEAD box domain 
(Asp-Glu-Ala-Asp), that is involved in RNA transcription, splicing, mRNA transport, 
translation initiation and cell cycle regulation.17 DEAD box RNA helicases were 
implicated in diverse forms of leukemia. 18,19 Recently, mutations inside and outside the 
DEAD box domain were detected in around 3% of patients with Chronic Lymphocytic 
Leukemia.20 
Structural analysis of HNRNPH1-MLLT10 and DDX3X-MLLT10 fusions showed 
HNRNPH1 maintained three RNA recognition motifs while DDX3X lost the DEAD 
box domain, at the N-terminal. At the C-terminal, MLLT10 lost 2/3 NLS domains in 
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patient 1 but maintained all 3 in patient 2 (Figure 1A and 1C). As in other MLLT10 
fusions,3-5 both cases retained the OM-LZ domain, which is needed to induce AML in 
mice bearing PICALM-MLLT10 or MLL-MLLT10.6,7 Interestingly DOT1L inhibitors 
binding the OM-LZ domain were successful in controlling MLL-MLLT10 and PICALM-
MLLT10 murine leukemias.21  
Whether these rare MLLT10 partners are part of a functional complex or share a 
common regulation pathway remains to be investigated. The Net View Tools software 
(http://netview.tigem.it/netview_project/netview_tools.html)22 showed DDX3X was 
significantly co-expressed and directly linked (Mutual Information >0.1) to HNRNPH1, 
PICALM, and NAP1L1 (Supplementary Table 3).  
We applied GEP to determine whether HNRNPH1-MLLT10 and DDX3X-MLLT10 
shared leukemogenic properties with other MLLT10 recombinations within the HOXA 
category of T-ALL.23-24 In an unsupervised analysis of 11 T-ALL samples with the 
HOXA signature, the 6 cases with MLLT10 rearrangements (4 PICALM-MLLT10, 1 
HNRNPH1-MLLT10, and 1 DDX3X-MLLT10) clustered separately from the other 5 
cases (1 MLL-ENL, 1 MLL-AF6, 2 TCRB-HOXA, and 1 SET-NUP214) (Figure 1E). T-
test analysis revealed significant (lFDR<0.05) differences in expression of 280 probe 
sets (Supplementary Table 4). Supervised analysis with these probe sets confirmed two 
subgroups (Figure 1F). In the HOXA patients with MLLT10 rearrangements HHEX gene 
expression was higher (> 1.5 fold-change) than in those without. HHEX is highly 
expressed in normal hematopoietic stem cells and down-regulated during normal T cell 
development.25 HHEX over-expression was found in ETP (as seen in our case n. 1) and 
linked to up-regulation of MEF2C which directly binds the HHEX promoter.2 
Interestingly, HHEX is a member of the NK-like family of class II homeobox genes. In 
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the other sub-group of 5 patients without MLLT10 rearrangements Gene Set Enrichment 
Analysis (GSEA) showed enrichment of HOXA  class I homeobox genes and target 
genes (Supplementary Figure 2). Although these findings need to be confirmed in a 
larger series of T-ALL, present results suggest that MLLT10 recombinations underlie a 
specific signature, within the HOXA category of T-ALL.  
The present study provides insights into the biological pathways involved in MLLT10 
recombinations in pediatric T-ALL. Finding two new MLLT10 fusion genes, involving 
HNRNPH1 and DDX3X, highlights the role of the MLLT10 gene, and particularly of its 
OM-LZ domain in this type of leukemia.  
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Table 1. Clinical, immunophenotypic, hematologic, molecular and cytogenetic data.       
Patients 
Sex/
age 
Diagnosis 
WBC 
(x10
9
/L) 
CALM-
MLLT10 
MLL-
ENL 
MLL-
AF4 
SIL-
TAL1 
NOTCH1 FLT3 Karyotype CI-FISH SNPs 
MRD 
+33/+78 
Chemotherapy 
†
 
Follow-up 
(months) 
1                      
(UPN 
1036616)   
F/7 ETP-ALL 10,55 n.a. n.a. neg neg mut* neg 
46,XX,inv(10) 
(p12q25)[2] 
/46,XX[17] 
SPLIT:  
MLLT10/10p12  
(55%) 
LOSS: 
IKZF1/7p12  
(10%) 
normal  +/+ 
 High risk, no 
transplant  
donor 
33+ 
2                         
(UPN 
1023865) 
M/11 
Cortical 
T-ALL 
152,8 neg neg n.a. neg mut** neg failed 
SPLIT:  
MLLT10/10p12 
LOSS:  
PAX5,CDKN2A/B, 
JAK2/9p13-24 
GAIN:  
RP11-
501C14/17q21.31                        
LOSS  
9p24.3-p11.2: 
from 0 to 
47 508 608 bp 
GAIN  
17q21.32-
q25.3: 
from 45 273 
751 
to
78 786 769 bp  
+/-  Standard risk 73+ 
F=female; M=male; WBC= White Blood Cell; n.a.= data not available; neg.=negative; mut= mutated; MRD=Minimal Residual Disease; * c.4766_4767insAGCAGAACCGGAGCAGCTGCGCAACAGCTC; 
p.S1589_F1590insAEPEQLRNSS; ** c.G4793C; p.R1598P; NOTCH1 mutation numbers refer to CCDS 43905.1 and NP_060087.3; † AIEOP LLA 2000 (Supplementary reference 1)!
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Figure 1 
Panel A: Two HNRNPH1-MLLT10 splicing isoforms were identified in patient 1. 
Upper panel: direct sequencing showed an in-frame HNRNPH1-MLLT10 isoform 
joining nucleotide 1324 (HNRNPH1 exon 11) to nucleotide 2097 (MLLT10 exon 15). 
Bottom panel: cloning and sequencing showed nucleotide 6701 (HNRNPH1 intron 10) 
fused in-frame with nucleotide 2097 (MLLT10 exon 15). Hypothetical fusion protein 
was shown in which HNRNPH1 maintained all three RNA Recognition Motifs (RRM) 
at the N-terminal and MLLT10 lost 2/3 Nuclear Localization Signals (NLS). MLLT10 
mantained the critical OM-LZ domain at the C-terminal. Primer and sequence numbers 
refer to GenBank accession NC_000005.9, NM_005520.2, NP_005511.1 for 
HNRNPH1 and NM_004641.3, NP_004632.1 for MLLT10. 
Panel B: DCDF-FISH test: probes for MLLT10 (RP11-418C1 and RP11-249M6) in 
orange and for HNRNPH1 (CTD-3223H16 and RP11-410B18) in green, showed 1 
fusion signal on der(10) (arrow). 
Panel C: Two DDX3X-MLLT10 splicing isoforms were identified in patient 2. Upper 
panel: sequencing showed an in-frame DDX3X-MLLT10 isoform joining nucleotide 958 
(DDX3X exon 2) to nucleotide 510 (MLLT10 exon 3). Bottom panel: cloning and 
sequencing showed an in-frame isoform with nucleotide 900 (DDX3X exon 1) fused 
with nucleotide 590 (MLLT10 exon 4). The hypothetical fusion protein lost the DDX3X 
DEAD box domain at the N-terminal and maintained part of the Plant Homeo Domain 
(PHD), all three NLS and the OM-LZ domain at the C-terminal. Primer and sequence 
numbers refer to GenBank accession NM_001356.3, NP_001347.3 for DDX3X and 
NM_004641.3, NP_004632.1 for MLLT10. 
Panel D: DCDF-FISH with probes for DDX3X in green (RP11-1058N11, flanking 5’, 
! ! "#$!
and RP11-10K13, flanking 3’) and MLLT10 in red (RP11-418C1 and RP11-249M6), 
showed 1 fusion signal (arrow). 
Panel E: Unsupervised analysis of 11 T-ALL HOXA patients. In such unsupervised 
analysis patients bearing MLLT10 rearrangements and those without MLLT10 
rearrangements (1 MLL-ENL, 1 MLL-AF6, 2 TCRB-HOXA, and 1 SET-NUP214) are 
naturally clustered in two distinct groups. PICALM-MLLT10 patients are indicated in 
orange; patient 1 and patient 2 (HNRNPH1-MLLT10, DDX3X-MLLT10) in green and 
patients without MLLT10 rearrangements in blue. 
Panel F: Supervised analysis was created using the significative probe sets from the 
comparison of HOXA patients with MLLT10 rearrangements (4 with PICALM-MLLT10 
and the two new cases with HNRNPH1-MLLT10, DDX3X-MLLT10) vs patients without 
MLLT10 rearrangements (1 MLL-ENL, 1 MLL-AF6, 2 TCRB-HOXA, and 1 SET-
NUP214). Patients bearing MLLT10 recombinations are indicated in orange or green 
while patients without MLLT10 rearrangements are indicated in blue. 
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Supplementary Figure 1:  
Panel A: Schema of der(10)inv(10)(p12q25)t(5;10)(q35;q25) in patient 1: 
the10q disruption was located at 10q25.3. A region of about 12 kb without 
genes (NCBI build 37.3) was flanked by fosmid G248P87999G12 and by RP11-
411P18, which was translocated to chromosome 5. FISH located the 5q 
breakpoint at band 35.3 between NSD1 (CTC-549A4) and SQSTM1 (RP11-
! ! "#$!
379P7) which translocated to der(10) together with the 5q subtelomeric probe 
RP1-240G13. 
Panel B: Metaphase analysis of inv(10) in patient 1: the MLLT10 breakpoint 
was investigated with 6 fosmids: G248P86314F1, G248P8684D10, 
G248P87580B3, G248P89434C6, G248P88419G5, G248P89761F10, 
spanning the entire gene. Fosmids G248P89434C6 (MLLT10 exons 10-14, 
green) and G248P88419G5 (MLLT10 exons 15-23, red), gave split signals on 
der(10) (arrow). 
Panel C: MLLT10 break apart assay in patient 2 showed RP11-418C1 (red) 
gave a split signal indicating the breakpoint occurred within exons 1-3. 
!
!
!
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Supplementary Figure 2: Selected enriched gene sets from GSEA. 
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Figure showed positively enriched gene sets, containing genes upregulated in 
the “other HOXA” group (number 1) compared with that bearing MLLT10 
rearrangements (number 0). Left side: the first pathway was characterized by 
an upregulation of the HOXA5 targets genes; Right side: the second pathway 
was characterized by the upregulation of different HOXA genes (HOXA1, 
HOXA2, HOXA5, HOXA6, HOXA9, HOXA10). Green trace showed the 
enrichment score based on hits of genes (indicated by the band on the x axis) 
that are ordered depending on their level of correlation with one of the two 
phenotypes compared (in our case “other HOXA” vs “MLLT10 
rearrangements”). 
 
Supplementary Table 1: FISH probes  
CI-FISH (Supplementary reference 2) 
Gene/region Centromeric probe Spanning probe Telomeric probe 
SIL/TAL1/1p33 G248P80397F3   RP11-346M5 
LEF1/4q25   
G248P81593B3 G248P81094A7  
RP11-840M18 
  
TLX3/5q35 
RP11-182E4  
RP11-453D13 
  
RP11-117L6   
CTB-31E20  
RP11-266N12 
CASP8AP2/6q15   RP11-81C7   
GRIK2/6q16   RP1-258B3   
MYB/6q23   RP1-32B1   
IKZF1/7p12   CTC-736O2   
HOXA@/7p15 RP1-170O19   RP1-167F23 
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TCRB@/7q34 RP11-1220K2   RP11-556I13 
PAX5/9p13   RP11-243F8   
CDKN2A/B/9p21   
G248P82010F5 G248P82557D2  
RP11-149I2 
  
JAK2/9p24 RP11-39K24   RP11-125K10 
ABL1/9q34 RP11-57C19   RP11-83J21 
NUP214/9q34 RP11-143H20 RP11-544A12   
NOTCH1/9q34 RP11-83N9 RP11-413M3 RP11-251M1 
MLLT10/10p12 RP11-249M6   RP11-418C1 
PTEN/10q23   RP11-380G5   
LMO2/11p13 RP11-313G13   RP11-60G13 
WT1/11p13   RP1-74J1   
LMO1/11p15 RP11-782G4   RP11-1065L8 
NUP98/11p15 RP11-348A20   CTD-3234F16 
PICALM/11q14 RP11-90K17   RP11-12D16 
MLL/11q23 RP11-832A4 RP11-770J1 
RP11-861M13  
RP11-158I9 
ETV6/12p13 
RP11-418C2  
RP11-297N18 
  RP11-434C1 
NAP1L1/12q21 RP11-290L1   RP11-453D16 
TCRAD@/14q11 RP11-242H9   RP11-447G18 
BCL11B/14q32 RP11-74H1 RP11-431B1   
NF1/17q11 RP5-926B9   
RP5-1002G3  
RP11-501C14 
PTPN2/18p11   CTD-2280F20   
AML1/21q22   RP5-1107L6   
PHF6/Xq26   G248P80005E1   
MLLT10 narrowing 
Gene/region Centromeric probe Spanning probe Telomeric probe 
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MLLT10/10p12  G248P86314F1  
MLLT10/10p12  G248P8684D10  
MLLT10/10p12  G248P87580B3  
MLLT10/10p12 
(exons 10-14) 
 G248P89434C6  
MLLT10/10p12 
(exons 15-23) 
 G248P88419G5  
MLLT10/10p12  G248P89761F10  
10q narrowing 
Gene/region Centromeric probe Spanning probe Telomeric probe 
RET/10q11.21  RP11-351D16  
TET1/10q21.3  RP11-524O24  RP11-119F7 
TLX1/10q24.31 RP11-108L7  RP11-107I14 
ADD3/10q25.1 RP11-182C2  RP11-252O7 
TCF7L2/10q25.2  RP11-139K1  
3' CASP7, 
DCLRE1A/10q25.3 
 RP11-211N11  
3' NHLRC2/10q25.3  G248P81309A4 G248P81596B5  
flanking 3' 
NHLRC2/10q25.3 
 G248P82625E6 G248P84642G1  
ADRB1/10q25.3  G248P87999G12  
MIR2110/10q25.3  RP11-411P18  
FAM160B1/10q25.3   RP11-106M7  
ATRNL1/10q25.3  RP11-359H22  
GFRA1/10q25.3  RP11-96N16  
flanking 3’ 
EMX2/10q26.11 
 RP11-99L6  
5' CASC2/10q26.11  RP11-354M20  
BAG3/10q26.11 RP11-179H18  RP11-88I10 
WDR11/10q26.12 RP11-323P17  RP11-95I16 
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FGFR2/10q26.13  RP11-62L18  
DMBT1/10q26.13  RP11-481L19  
BNIP3/10q26.3  RP11-50E23  
GPR123/10q26.3 RP11-97M24  CTD-2557L14 
* In bold are indicated probes flanking 10p12 and 10q25 breakpoints in patient 1. 
Supplementary Table 2: Primers used in 5'-RACE and RT-PCR experiments !
Patients Primers used in 5'-RACE Sequences (5'->3') 
1 MLLT10ex21_3191R GGGTAGGGTTCTGGGACATT 
2 MLLT10ex11_1529R ATGACTGTTGGGAGTGAGAG 
Patients Primers used in nested PCR Sequences 
HNRNPH1ex5_586F GTGCAGTTTGCTTCACAGGA 
HNRNPH1ex6_794F CTGGCTTTGAGAGGATGAGG 
HNRNPH1ex8_965F TCCAGAGCACAACAGGACAC 
MLLT10ex16_2319R TGAGATGGTGCCTGACTGAG 
1 
MLLT10ex17_2419R TAGGTTGCGGCTATTGTCTC 
DDX3X_501F TAGGGTTTTAGCGGAGAGCAC 
DDX3X_514F GAGAGCACGGGAAGTGTAG 
2 
MLLT10ex4_620R CTCCATCCTTATGGGGACAA 
Primer numbers refer to Genbank accession: NM_005520.2 for HNRNPH1, 
NM_001356.3 for DDX3X and NM_004641.3 for MLLT10.!
Supplementary Table 3: Connected genes ranked by Mutual Information (MI). !
Probeset Id Gene Symbol MI MI 
Cons 
Probeset ID Gene Symbol 
201210_at DDX3X 0.142 0 201031_s_at HNRNPH1 
201210_at DDX3X 0.103 0 208753_s_at NAP1L1 
201210_at DDX3X 0.09 0 208754_s_at NAP1L1 
201210_at DDX3X 0.07 0 204528_s_at NAP1L1 
201210_at DDX3X 0.075 0 212511_at PICALM 
212514_x_at DDX3X 0.16 0 215236_s_at PICALM 
!
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Connections between DDX3X-HNRNPH1, DDX3X-PICALM and DDX3X-
NAP1L1 are significant (MI>0.1).  
(http://netview.tigem.it/netview_project/netview_tools.html). 
Supplementary Table 4: List of genes with significantly different expression (p 
<0.05) in the “other HOXA” and the “MLLT10 rearranged” groups, after t-test 
analysis on gene expression results. !
Probe Symbol Cytoband p-value FC 
232424_at PRDM16 1p36.23-p33 0.005259157 2.41 
244413_at CLECL1 12p13.31 9.59E-09 2.15 
213506_at F2RL1 5q13 0.001086216 1.90 
1557167_at HCG11 6p21 0.043036153 1.83 
1556261_a_at   0.000192345 1.76 
237458_at   0.033178575 1.69 
231747_at CYSLTR1 Xq13.2-q21.1 0.005259157 1.61 
240413_at PYHIN1 1q23.1 6.39E-05 1.59 
215933_s_at HHEX 10q23.33 0.001086216 1.58 
1569479_at ZNF718 4p16.3 0.023225169 1.57 
204689_at HHEX 10q23.33 0.001086216 1.55 
221045_s_at PER3 1p36.23 0.000192345 1.52 
233903_s_at ARHGEF26 3q25.2 0.000393532 1.51 
238127_at FLJ41484 13q34 0.023225169 1.50 
227889_at LPCAT2 16q12.2 0.023225169 1.50 
232686_at SIGLECP3 19q13.3 0.033178575 1.48 
229822_at   0.001086216 1.47 
206120_at CD33 19q13.3 0.000192345 1.44 
1562067_at   0.002392781 1.44 
209108_at TSPAN6 Xq22 0.011065268 1.42 
37966_at PARVB 22q13.2-q13.33 0.023225169 1.42 
228538_at ZNF662 3p22.1 0.001086216 1.40 
212686_at PPM1H 12q14.1 0.023225169 1.40 
241696_at CNTLN 9p22.2 0.000413972 1.39 
204638_at ACP5 19p13.3-p13.2 0.000192345 1.38 
202449_s_at RXRA 9q34.3 0.002392781 1.38 
243113_at   0.033178575 1.37 
1563226_at SLC38A10 17q25.3 0.023225169 1.37 
215695_s_at GYG2 Xp22.3 0.012520058 1.36 
215813_s_at PTGS1 9q32-q33.3 0.013232319 1.36 
225255_at MRPL35 2p11.2 0.019228939 1.35 
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205418_at FES 15q26.1 0.003034408 1.35 
205222_at EHHADH 3q26.3-q28 4.47E-05 1.35 
237497_at   0.005259157 1.34 
223487_x_at GNB4 3q26.33 0.008376883 1.34 
57082_at LDLRAP1 1p36-p35 0.008376883 1.34 
240661_at LOC284475 1p13.1 0.023225169 1.31 
1561899_at CLECL1 12p13.31 0.012520058 1.31 
239062_at LOC100131096 17q25.3 0.000393532 1.31 
203128_at SPTLC2 14q24.3 0.014162154 1.31 
210964_s_at GYG2 Xp22.3 0.038059584 1.30 
233467_s_at TSPAN32 11p15.5 1.18E-07 1.29 
1558105_a_at   0.043036153 1.28 
221879_at CALML4 15q23 0.033178575 1.27 
1566040_at   0.043036153 1.27 
214235_at CYP3A5 7q21.1 0.012520058 1.27 
227999_at PWWP2B 10q26.3 0.012520058 1.26 
233428_at   0.013232319 1.26 
1569401_at CLEC12A 12p13.2 0.019228939 1.25 
39318_at TCL1A 14q32.1 0.013232319 1.25 
242966_x_at   6.39E-05 1.24 
1556116_s_at TNPO1 5q13.2 0.038059584 1.24 
234645_at   0.023225169 1.24 
223467_at RASD1 17p11.2 0.033178575 1.24 
205505_at GCNT1 9q13 0.000545837 1.24 
220558_x_at TSPAN32 11p15.5 0.002696521 1.23 
224708_at KIAA2013 1p36.22 0.003034408 1.22 
223995_at SLC12A9 7q22 0.014162154 1.22 
228066_at C17orf96 17q12 0.012520058 1.22 
204394_at SLC43A1 11p11.2-p11.1 0.001906421 1.21 
211582_x_at LST1 6p21.3 0.023225169 1.21 
236501_at SALL4 20q13.2 0.008376883 1.20 
214181_x_at LST1 6p21.3 0.023225169 1.20 
241466_at   0.023225169 1.19 
232309_at LOC202181 5q35.3 0.023225169 1.19 
204336_s_at RGS19 20q13.33 0.023225169 1.18 
229686_at P2RY8 Xp22.33 0.002852378 1.18 
227344_at IKZF1 7p13-p11.1 0.003034408 1.17 
236454_at RNF212 4p16.3 0.001086216 1.17 
201954_at ARPC1B 7q22.1 0.005259157 1.15 
220600_at C3orf75 3p21.31 0.033178575 1.15 
208736_at ARPC3 12q24.11 4.47E-05 1.14 
201143_s_at EIF2S1 14q23.3 0.019228939 1.13 
201651_s_at PACSIN2 22q13.2-q13.33 0.043036153 1.11 
221267_s_at FAM108A1 19p13.3 0.001906421 1.10 
217839_at TFG 3q12.2 0.033178575 -1.08 
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224630_at ERLEC1 2p16.2 0.043036153 -1.08 
221493_at TSPYL1 6q22.1 0.038059584 -1.09 
203279_at EDEM1 3p26.1 0.000192345 -1.11 
217858_s_at ARMCX3 Xq21.33-q22.2 0.023225169 -1.11 
201738_at EIF1B 3p22.1 0.013232319 -1.11 
218497_s_at RNASEH1 2p25 0.001086216 -1.12 
227141_at TYW3 1p31.1 0.043036153 -1.12 
209067_s_at HNRPDL 4q21.22 1.18E-07 -1.12 
203261_at DCTN6 8p12-p11 0.023225169 -1.12 
218740_s_at CDK5RAP3 17q21.32 0.023225169 -1.12 
203484_at SEC61G 7p11.2 0.033178575 -1.12 
210178_x_at SRSF10 1p36.11 0.011065268 -1.12 
223766_at LOC100133130 10q11.22 0.003034408 -1.14 
230659_at EDEM1 3p26.1 0.002392781 -1.14 
207079_s_at MED6 14q24.2 0.001086216 -1.14 
226285_at CAPRIN1 11p13 0.033178575 -1.14 
218582_at MARCH5 10q23.32-q23.33 0.012520058 -1.14 
213447_at   0.003034408 -1.14 
222307_at LOC282997 10q25.2 0.012520058 -1.14 
217825_s_at UBE2J1 6q15 0.000192345 -1.14 
218178_s_at CHMP1B 18p11.21 0.033178575 -1.14 
201057_s_at GOLGB1 3q13 0.012520058 -1.14 
225811_at C11orf58 11p15.1 0.043036153 -1.14 
228349_at KIAA1958 9q32 0.013232319 -1.15 
227640_s_at   0.023225169 -1.15 
213594_x_at SRSF10 1p36.11 3.94E-05 -1.15 
202583_s_at RANBP9 6p23 0.000393532 -1.15 
202557_at HSPA13 21q11 0.019228939 -1.16 
223486_at GTPBP8 3q13.2 0.023225169 -1.16 
222435_s_at UBE2J1 6q15 0.011065268 -1.16 
1554678_s_at HNRPDL 4q21.22 0.000192345 -1.16 
235566_at TMF1 3p21-p12 0.011065268 -1.16 
225284_at DNAJC3 13q32.1 0.023225169 -1.17 
1555832_s_at KLF6 10p15 0.014162154 -1.17 
202798_at SEC24B 4q25 0.023225169 -1.17 
205068_s_at ARHGAP26 5q31 0.008376883 -1.18 
204299_at SRSF10 1p36.11 3.39E-06 -1.18 
219335_at ARMCX5 Xq22.1-q22.3 0.023225169 -1.18 
209712_at SLC35D1 1p32-p31 0.012520058 -1.18 
223117_s_at USP47 11p15.3 0.033178575 -1.18 
210285_x_at WTAP 6q25-q27 0.000413972 -1.18 
39729_at PRDX2 19p13.2 0.023225169 -1.18 
235112_at   0.014162154 -1.18 
224606_at KLF6 10p15 1.08E-06 -1.18 
1553686_at C18orf25 18q21.1 0.023225169 -1.18 
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213372_at PAQR3 4q21.21 3.94E-05 -1.19 
202842_s_at DNAJB9 14q24.2-q24.3 0.011065268 -1.19 
213074_at PHIP 6q14 0.043036153 -1.19 
212542_s_at PHIP 6q14 0.033178575 -1.20 
214289_at PSMB1 6q27 0.012520058 -1.20 
239562_at MTHFD2L 4q13.3 0.013232319 -1.20 
223602_at USP30 12q24.11 0.023225169 -1.20 
235526_at   0.014162154 -1.20 
1560029_a_at C11orf57 11q23.1 0.013232319 -1.20 
231269_at ASCC3 6q16 0.006117516 -1.20 
206181_at SLAMF1 1q23.3 0.033178575 -1.20 
238946_at   0.011065268 -1.20 
238114_at PCMTD1 8q11.23 0.012520058 -1.21 
232126_at COQ2 4q21.23 0.023225169 -1.21 
235103_at MAN2A1 5q21-q22 8.44E-06 -1.21 
228857_at GNL1 6p21.3 0.001906421 -1.21 
200732_s_at PTP4A1 6q12 0.008376883 -1.21 
228330_at ZUFSP 6q22.1 0.023225169 -1.21 
213212_x_at   0.013232319 -1.21 
227160_s_at C20orf7 20p12.1 0.002852378 -1.21 
1555562_a_at ZCCHC7 9p13.2 0.038059584 -1.21 
201799_s_at OSBP 11q12-q13 0.000545837 -1.22 
218696_at EIF2AK3 2p12 0.011065268 -1.22 
203097_s_at RAPGEF2 4q32.1 0.008376883 -1.22 
1554661_s_at CNST 1q44 0.036210511 -1.22 
218013_x_at DCTN4 5q31-q32 0.013232319 -1.22 
1555274_a_at EPT1 2p23.3 0.000545837 -1.22 
227018_at DPP8 15q22 8.44E-06 -1.22 
222519_s_at IFT57 3q13.13 0.023225169 -1.23 
204526_s_at TBC1D8 2q11.2 3.94E-05 -1.23 
200898_s_at MGEA5 10q24.1-q24.3 0.023225169 -1.23 
233952_s_at ZNF295 21q22.3 0.023225169 -1.23 
228789_at MTMR6 13q12 0.008376883 -1.23 
244828_x_at NAF1 4q32.2 0.001958125 -1.23 
201775_s_at KIAA0494 1pter-p22.1 0.023225169 -1.23 
1553749_at FAM76B 11q21 0.005259157 -1.23 
1565651_at ARF1 1q42 0.008376883 -1.24 
202722_s_at GFPT1 2p13 0.023225169 -1.24 
204334_at KLF7 2q32 0.008376883 -1.24 
203017_s_at SSX2IP 1p22.3 4.47E-05 -1.24 
210048_at NAPG 18p11.22 0.019228939 -1.24 
1559862_at COPA 1q23-q25 0.013232319 -1.25 
222303_at   1.28E-09 -1.25 
1561965_at SNRPB2 20p12.1 0.001906421 -1.25 
1553133_at C9orf72 9p21.2 0.001906421 -1.25 
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223846_at AZI2 3p24.1 0.023225169 -1.25 
229790_at TERF2 16q22.1 0.000413972 -1.25 
225539_at ZNF295 21q22.3 0.023225169 -1.25 
219631_at LRP12 8q22.2 0.000393532 -1.25 
239124_at   0.001086216 -1.26 
244360_at FBXL17 5q21.3 6.39E-05 -1.26 
242325_at YWHAH 22q12.3 0.000192345 -1.26 
240432_x_at KLF7 2q32 0.023225169 -1.26 
235369_at C14orf28 14q21.2 0.023225169 -1.27 
1556144_at DHX30 3p21.31 0.023225169 -1.27 
1559023_a_at KIAA0494 1pter-p22.1 0.012520058 -1.27 
1555448_at MUDENG 14q22.3 0.011065268 -1.27 
212225_at EIF1 17q21.2 0.000545837 -1.27 
233138_at C18orf1 18p11.21 0.023225169 -1.27 
227767_at CSNK1G3 5q23 0.002575538 -1.27 
228370_at   0.001086216 -1.28 
232483_at MED17 11q14 0.000192345 -1.28 
242776_at ZCCHC6 9q21 0.000413972 -1.28 
231833_at RBM33 7q36.3 0.023225169 -1.28 
231793_s_at CAMK2D 4q26 0.023225169 -1.28 
243982_at KLHL28 14q21.2 0.013232319 -1.28 
237495_at MPP7 10p12.1 0.033178575 -1.28 
1569450_at CAPZA2 7q31.2-q31.3 0.011065268 -1.29 
242073_at   0.012520058 -1.29 
231953_at BPTF 17q24.3 0.038059584 -1.29 
201776_s_at KIAA0494 1pter-p22.1 0.005259157 -1.29 
233035_at   0.033178575 -1.29 
202766_s_at FBN1 15q21.1 0.008376883 -1.30 
1554038_at LARP1B 4q28.2 0.001086216 -1.30 
239862_at   0.013232319 -1.30 
227384_s_at   0.023225169 -1.31 
202558_s_at HSPA13 21q11 0.005259157 -1.31 
230764_at   0.033178575 -1.33 
243649_at FBXO7 22q12-q13 0.012520058 -1.33 
213292_s_at SNX13 7p21.1 0.001086216 -1.33 
221211_s_at C21orf7 21q22.3 0.023225169 -1.33 
231042_s_at   0.003034408 -1.34 
233480_at TMEM43 3p25.1 0.023225169 -1.34 
242999_at ARHGEF7 13q34 0.033178575 -1.34 
240513_at EIF3M 11p13 0.012520058 -1.34 
1568665_at RNF103 2p11.2 8.44E-06 -1.35 
1568627_at SMEK2 2p16.1 0.033178575 -1.35 
213093_at PRKCA 17q22-q23.2 0.005259157 -1.36 
202375_at SEC24D 4q26 0.023225169 -1.36 
239540_at   1.08E-06 -1.36 
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239200_at   0.023225169 -1.37 
242756_at   0.001086216 -1.37 
226750_at LARP1B 4q28.2 1.28E-09 -1.37 
225019_at CAMK2D 4q26 0.023225169 -1.37 
1554339_a_at COG3 13q14.13 0.019228939 -1.38 
1554785_at CCDC82 11q21 0.023225169 -1.38 
200731_s_at PTP4A1 6q12 0.008376883 -1.39 
227755_at   0.000192345 -1.39 
207850_at CXCL3 4q21 0.008376883 -1.40 
228555_at CAMK2D 4q26 0.023225169 -1.40 
1555279_at ARMC8 3q22.3 0.023225169 -1.41 
222167_at   0.012520058 -1.41 
226393_at CYP2U1 4q25 3.39E-06 -1.41 
232615_at   0.008376883 -1.41 
244700_at SEC61B 9q22.32-q31.3 6.39E-05 -1.41 
207068_at ZFP37 9q32 0.011065268 -1.42 
240485_at   8.44E-06 -1.42 
224994_at CAMK2D 4q26 0.000192345 -1.43 
216121_at   0.023225169 -1.43 
202083_s_at SEC14L1 17q25.2 0.008376883 -1.44 
239415_at MAP9 4q32.1 0.005259157 -1.44 
215351_at RTCD1 1p21.2 0.013232319 -1.45 
1554290_at HERC3 4q21 0.023225169 -1.45 
215209_at SEC24D 4q26 0.023225169 -1.47 
219532_at ELOVL4 6q14 0.013232319 -1.47 
1560846_at   0.023225169 -1.49 
212254_s_at DST 6p12.1 0.043036153 -1.49 
1555281_x_at ARMC8 3q22.3 8.44E-06 -1.49 
1568609_s_at   0.000545837 -1.49 
60084_at CYLD 16q12.1 0.023225169 -1.50 
226120_at TTC8 14q31.3 0.000393532 -1.50 
239005_at FLJ39739 1q21.1 0.000192345 -1.51 
212602_at WDFY3 4q21.23 0.001086216 -1.53 
202381_at ADAM9 8p11.22 0.008376883 -1.54 
220576_at PGAP1 2q33.1 6.39E-05 -1.55 
222142_at CYLD 16q12.1 0.012520058 -1.56 
229139_at JPH1 8q21 0.008376883 -1.57 
212606_at WDFY3 4q21.23 0.002696521 -1.57 
232304_at PELI1 2p13.3 0.002575538 -1.60 
236260_at LOC100287598 16p13.2 1.08E-06 -1.60 
1556911_at   6.39E-05 -1.60 
208015_at SMAD1 4q31 0.001086216 -1.61 
212526_at SPG20 13q13.3 0.011065268 -1.61 
207738_s_at NCKAP1 2q32 0.023225169 -1.61 
241801_at PGAP1 2q33.1 8.44E-06 -1.62 
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207705_s_at NINL 20p11.22-p11.1 0.008376883 -1.62 
204201_s_at PTPN13 4q21.3 0.012520058 -1.63 
212263_at QKI 6q26 0.014162154 -1.65 
216693_x_at HDGFRP3 15q25.2 0.011065268 -1.70 
237491_at   9.59E-09 -1.70 
232098_at DST 6p12.1 8.44E-06 -1.72 
235391_at FAM92A1 8q22.1 0.012520058 -1.74 
235451_at SMAD5 5q31 0.023225169 -1.76 
213469_at PGAP1 2q33.1 0.012520058 -1.76 
209526_s_at HDGFRP3 15q25.2 0.005259157 -1.79 
239725_at PGAP1 2q33.1 1.16E-11 -1.80 
218847_at IGF2BP2 3q27.2 4.47E-05 -1.81 
228266_s_at HDGFRP3 15q25.2 0.011065268 -1.84 
217963_s_at NGFRAP1 Xq22.2 0.033178575 -1.86 
202351_at ITGAV 2q31-q32 0.011065268 -1.91 
207781_s_at ZNF711 Xq21.1 0.012520058 -1.94 
242457_at   0.023225169 -1.98 
201579_at FAT1 4q35 6.39E-05 -2.05 
228423_at MAP9 4q32.1 1.18E-07 -2.06 
220145_at MAP9 4q32.1 0.000545837 -2.07 
210517_s_at AKAP12 6q24-q25 0.013232319 -2.18 
228988_at ZNF711 Xq21.1 1.56E-06 -2.18 
209524_at HDGFRP3 15q25.2 0.008376883 -2.21 
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Acute Lymphoblastic Leukemia (ALL) is an aggressive malignancy of lymphopoietic 
cells characterized by a clonal proliferation of blast cells originated from lymphoid 
precursors arrested at early stages of differentiation. ALL is the most common cancer 
and the most successfully treated malignancy in children, with long-term survival rates 
reaching over 80% as result of risk-directed treatment and intensifies cure protocols. 
Although advances in genomic and molecular analysis have improved the ability to 
stratify patients in risk groups that receive appropriate treatment, still a quarter of 
children experience relapse and have poor outcomes, failing to achieve a complete 
remission. Relapse in ALL is characterized by disease recurrence at extramedullary 
sites, such as the Central Nervous System. At diagnosis <2% of ALL patients present 
CNS disease, but at relapse >30% have infiltration at this site. Reaching leukemic cells 
in the so-called “sanctuary-sites”, such as the CNS, require specific therapies that can be 
invasive (i.e: cranial irradiation) and related to several deleterious effects. Modern 
diagnostic techniques improved the ability to categorize risk, allowing clinicians to 
optimize therapy including that directed to the CNS. Moreover, numerous efforts have 
been made to reduce or avoid the use of cranial irradiation. The need to use cranial 
irradiation in the cure of patient with CNS disease is still debated, in fact some studies 
propose to avoid this treatment. However, cranial irradiation is still recommended for 2-
20% of ALL at high risk of CNS relapse, such as patients with CNS infiltration at 
diagnosis or presenting T-immunophenotype with high WBC count. This overview 
shows the importance to understand molecular mechanisms that allow or predispose 
blast cells to infiltrate the CNS in order to improve the CNS-directed treatment. 
With this work we aimed to deep insight into molecular mechanisms that allow T-ALL 
cells to infiltrate the CNS. Particularly, to gain in this aim we used a whole 
transcriptome analysis approach (gene expression profiling) starting from animal 
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models to arrive to T-ALL patients. We studied T-cell Acute Lymphoblastic Leukemia 
(T-ALL) as the incidence of CNS infiltration is higher in T-ALL compared to B-ALL. 
We identify for the first time the presence of CNS infiltration in two zebrafish models 
that develop T-ALL (hMYC-ER and hlk). These two zf lines are genetically different 
and could represent different subgroup of human T-ALL; hMYC-ER model overexpress 
the human C-MYC as a larger number of T-ALL patients, while hlk line carries an 
unknow mutation. Interesting, the type of CNS invasion in these models was very 
similar to CNS infiltration found in pediatric patients at time to dead in 1970s. In fact, 
we found different degree of infiltration at the meningeal level, often correlated to optic 
nerve involvement. These data underline the ability of these zf models to mimic the 
human CNS disease. This discovery is very important, not only for the study of 
mechanisms that predispose T-ALL cell to enter in the CNS, but also to perform 
pharmacological test in a high-throughput manner. Another important aspect was the 
presence of a different trend of CNS infiltration that was characteristic for each zf line: 
hMYC-ER zf line presented higher levels of CNS infiltration compare to hlk model. 
GEP analysis allowed us to identify two different molecular networks active in hMYC-
ER and hlk cancer, suggesting the idea that T-ALL cells could use different mechanisms 
to infiltrate the CNS. Particularly, we found a positive correlation between the degree of 
CNS infiltration and the expression levels of the chemokine receptor cxcr4. This result 
suggests that higher expression levels of cxcr4 increase the ability of T-ALL cells to 
infiltrate the CNS. Interesting, in zebrafish the transcription of cxcr4 was also related to 
high expression levels of C-MYC oncogene.  
At this point we decided to validate the results found in zebrafish using another animal 
model closer to human patients: we used murine models xenografted with primary T-
ALL cells coming from pediatric patients. We demonstrated that also in xenografted 
mice, human T-ALL cells could mimic the phenomenon of CNS infiltration. 
Importantly, we found another useful model to study the phenomenon of CNS. 
Moreover, mice xenografted with different patients presented variable degree of CNS 
infiltration, suggesting a different predisposition of T-ALL cells to invade the CNS 
environment. Results found in murine model were very similar to previous ones obtain 
in zebrafish. At this point we decided to investigate also in xenografted model the 
! ! "##!
CXCR4 as one possible molecular mechanism that predispose T-ALL cells to invade the 
CNS. Preliminary results seem to validate the relation between higher CXCR4 
expression levels and the increased ability of blast cells to invade the CNS. Other 
analyses on a larger cohort of xenoengrafted mice are ongoing. Once confirmed the 
importance of this chemokine receptor in regulating the phenomenon of CNS invasion, 
we could start to test specific inhibitor for CXCR4, such as ADM3100, in murine model 
xenografted with T-ALL cells that we know to infiltrate the CNS.  
We do not limit the study of CNS infiltration to animal models, but we preceded this 
work performing a whole transcriptome analysis on human pediatric T-ALL patients 
with- and without- CNS infiltration at diagnosis. The study of CNS infiltration directly 
in human patient is not easy, as little material is available for research and it is not 
possible to study cells directly extracted from the cerebrospinal fluid. GEP analysis 
failed to find a strong signature that could distinguish patients with- and without CNS 
involvement. Moreover, in T-ALL human patients we were not able to find the 
correlation between higher expression levels of CXCR4 and the CNS infiltration, as 
almost all CNS- patients highly expressed the CXCR4. The passage from animal model 
to human patients is not so linear. First, the biological process we are observing in 
patients and animal models is not exactly the same, in fact, animal models present an 
extreme infiltration that might happen in human if disease is not treated and that could 
partially change the gene expression profiling of blast cells. Second, it is possible that a 
group of patients is underestimated for CNS disease and is classified among CNS- 
cases; that increases the complexity to study this phenomenon in human patients. Third, 
different mechanisms could be used by T-ALL cells to infiltrate the CNS; in fact, we 
proposed the CXCR4/CXCL12 axis as one possible mechanisms or a predisposing 
factor to enter in the CNS, but not as the absolute mechanisms that can discriminate 
between CNS+ and CNS- cases. Further studies are necessary to better understand the 
role of CXCR4 in human patients, maybe studying also the activation of this chemokine 
receptor in T-ALL cells. 
Another aspect we investigated inside the human pediatric T-ALL group was related to 
C-MYC expression levels. Previously, we have seen that hMYC-ER line is also a 
zebrafish model that can mimic human T-ALL overexpressing C-MYC. The prognostic 
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significance of C-MYC activation is not still understood. Analysis of C-MYC expression 
on a cohort of T-ALL patients revealed different expression level of C-MYC oncogene; 
particularly it is possible identify a group with high- and low- expression of C-MYC. 
However, GEP analysis failed to found a signature that can distinguish these groups. 
Once again we are in front of this problem; human T-ALL is a complex disease in 
which multiple events can occur to contribute and give rise to leukemogenesis process. 
In fact, many factors can contribute to C-MYC deregulation (NOTCH1, FBXW7, PTEN 
mutations and C-MYC rearrangements). To give a prognostic significance to C-MYC 
deregulation, it is probably necessary to investigate not only the deregulation of the 
single gene but contextualize its expression in different T-ALL contexts. To understand 
the biological meaning to have C-MYC upregulated by different causes, we compared 
patients with C-MYC rearrangement in absence of NOTCH1
m
 and patients without C-
MYC rearrangement but possible NOTCH1, FBXW7, PTEN mutations. A strong 
signature separated cases with-and without C-MYC rearrangement. Of note, the 
subgroup of patients carrying C-MYC rearrangements presents a NOTCH1-independent 
leukemia compared to the group without C-MYC rearrangement that seems to be 
strongly related to NOTCH1 pathway activation. 
In this thesis work we tested the ability of GEP analysis in distinguish signatures also 
inside specific T-ALL subgroups, such us in the subgroup of T-ALL patients with high 
expression of C-MYC. This power of GEP was already tested in another study, where 
we were able to identified a specific signature for patients carrying MLLT10 
rearrangements, inside the HOXA subgroup in pediatric T-ALL. 
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